Depression and anxiety in HIV infected individuals attending HIV treatment facilities at various sites in South Africa: occurrence and related factors. A descriptive-analytic study by Thom, Rita
 DEPRESSION AND ANXIETY IN HIV INFECTED 
INDIVIDUALS ATTENDING HIV TREATMENT 
FACILITIES AT VARIOUS SITES IN SOUTH AFRICA: 
OCCURRENCE AND RELATED FACTORS. A 
DESCRIPTIVE-ANALYTIC STUDY 
 
 
 
 
Rita Gillian Marie Thom 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A thesis submitted to the Faculty of Health Sciences, University of 
the Witwatersrand, in fulfilment of the requirements for the degree 
of  
Doctor of Philosophy 
 
 
 
Johannesburg, 2008 
 ii 
Declaration 
 
 
I, Rita Gillian Marie Thom, declare that this thesis is my own work. It is being submitted 
for the degree of Doctor of Philosophy in the University of the Witwatersrand, 
Johannesburg. It has not been submitted before for any degree or examination at this or any 
other University 
 
 
Signature 
 
Place:  
On the   day of     2008 
 iii 
Dedication 
 
This thesis is dedicated to all South Africans affected by the HIV epidemic
 iv 
Publications and presentations emanating from this thesis 
 
 
Poster presentation at 7th International AIDS Impact Conference, Cape Town. April 2005: 
Mental Disorders in HIV-infected individuals – notes from a focus group discussion with 
staff at an HIV-treatment centre. 
 
Oral presentation at University of Toronto Department of Psychiatry Grand Ward Round 
on 19 May 2006: Facing Mental Health Challenges in South Africa. 
 
Poster presentation at American Psychiatric Association Congress, Toronto. 20th to 25th 
May 2006: Mental Disorders in HIV-infected individuals attending selected HIV-treatment 
sites in South Africa. 
 
Oral presentation at the University of the Witwatersrand Faculty of Health Sciences 
Research Day, 23rd August 2006: Mental disorders in HIV-infected individuals in HIV-
treatment facilities 
 
 v 
Abstract 
 
International literature, most of which originates from First-world countries where HIV 
predominantly affects socially marginalised minority populations, has well-described the 
burden of mental disorder, particularly depressive and anxiety disorders in HIV-infected 
individuals. The few studies conducted in developing countries show contradictory results. 
This study aimed to describe the occurrence of mental disorders; particularly depressive 
and anxiety disorders, in a population of HIV-infected individuals attending HIV-treatment 
sites in Gauteng and Mpumalanga in South Africa from November 2004 to November 
2005.  
 
A cross-sectional descriptive-analytic study, it included a clinical diagnostic interview and 
a semi-structured interview to explore postulated risk and protective factors, including 
demographic, clinical and psychosocial variables, for depressive and anxiety disorders in 
HIV-infected individuals. Three hundred and two (302) individuals were interviewed at the 
Perinatal HIV Research Unit’s associated Wellness clinics and at the Chris Hani 
Baragwanath Hospital’s Nthabiseng HIV clinic. 
 
Just over thirty percent of participants had a current mental disorder and the lifetime 
prevalence of mental disorder was 40%. Almost 17% of participants had a current 
depressive disorder and almost 16% had a lifetime depressive disorder. The occurrence of 
major depressive disorder, current and lifetime, was 3.64% and 10.26% respectively. Sixty 
percent of participants with lifetime major depressive disorder had their first onset after 
diagnosis of HIV status. The occurrence of current and lifetime anxiety disorder was 
almost 4%. 
 vi 
Substance use disorders were common, affecting 7.6% of the participants at time of 
interview. Lifetime prevalence of substance use disorders was 18.9%, suggesting that 
knowledge of HIV status or other interventions may have resulted in this significant 
decrease. 
 
Identified significant risk factors for depressive disorder included a history of a lifetime 
depressive disorder, moderate or severe psychosocial stress and feelings of isolation. Being 
in a support group was found to be a protective factor against depressive disorder.  
 
While the results in this study are conservative compared to those of other similar South 
African studies in HIV-infected individuals, there was a statistically significantly increased 
occurrence of depressive and anxiety disorders (combined) compared to general population 
prevalence studies of these disorders in South Africa. Ways of improving access to mental 
healthcare for HIV-infected individuals and the general population, are discussed 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background 
South Africa is an emerging economy in a state of significant transition; from a country 
isolated by apartheid, to one taking its place on the global playing field. The HIV epidemic 
in South Africa is one of the biggest challenges facing post-Apartheid South Africa. It 
impacts at social, political and personal levels. The lack of sufficient trained healthcare 
professionals and the financial burden of managing over 5 million people infected with 
Human Immunodeficiency Virus (HIV), now and into the future (UNAIDS/WHO, 
2006b:Annexure 2), have created an enormous challenge for the country, and health 
services in particular, to address. However, this challenge offers opportunities, as it has 
created an imperative need to develop our health system to provide the best care possible.  
 
South Africa is a middle-income country with a history that resulted in socio-economic 
class divisions, predominantly along racial lines. While the new democracy has seen the 
emergence of a more racially integrated middle class, most people in South Africa still live 
in racially segregated neighbourhoods. The majority of people in South Africa are poor and 
live in townships, informal settlements and rural areas.  
 
Although HIV in South Africa was initially diagnosed among homosexual males, it is now 
predominantly found in heterosexual individuals. It has spread throughout the country and 
affects people at all levels of society. However, the epidemic has mostly affected poor, 
predominantly black African, communities. These have emerged from a period of political 
struggle, violence, unrest and economic disruption into a new dispensation, only to be 
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faced with the ravages of the HIV epidemic. This epidemic is changing the face of society, 
causing a loss of active, working young adults, a burgeoning population of orphaned or 
otherwise affected children and potentially serious impacts on the economy. 
 
At a personal level, HIV impacts on individuals, families and communities, which exist 
within particular contexts shaped by the socio-political environment. HIV is an infectious 
disease, for which there is currently no cure. Its predominant mode of transmission is 
through sexual contact, both heterosexual and homosexual (a fact that brings significant 
prejudice to the fore). At an individual level, psychosocial and physical factors interact. 
Besides its systemic effects, HIV affects the brain, through direct central nervous system 
(CNS) infection with HIV and other opportunistic infections (An & Scaravilli, 1997). The 
psychosocial impact of the disease in South Africa generally occurs in the context of 
poverty and disadvantage. Until the recent roll-out of antiretroviral treatment, a diagnosis 
of HIV in South Africa was a death sentence. Despite the current optimism resulting from 
the recent availability of antiretroviral medications, people continue to die daily and the 
reality of long-term/life-long treatment of this incurable disorder in large numbers of 
people in the country has not yet been fully realised.   
 
HIV infection is a condition where the mental health of the infected individual cannot be 
ignored. International research shows significant mental disorder in people with HIV 
(Ciesla & Roberts, 2001; Israelski, Prentiss & Lubega, 2007). While Highly Active Anti-
Retroviral Treatment (HAART) has saved many from imminent death, and has changed 
HIV infection into a chronic “manageable” disease, international literature indicates that 
significant mental disorder and suffering persists (Green & Smith, 2004) in people living 
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with HIV, and ongoing intervention by mental health professionals is still needed. Despite 
a limited amount of research in this area, this is also likely in developing countries. 
 
Health services in South Africa are planned and implemented according to the premise that 
most people will access healthcare through the district health care service (Owen, 1995). 
Primary healthcare services in South Africa currently deal with a significant workload 
(Day & Gray, 2006). A shortage of human resources is a serious problem and working 
conditions are very difficult in many areas. It is not surprising that mental healthcare is 
sidelined in such a situation, when mental illness is not seen to contribute directly to 
mortality, considerable stigma surrounds mental illness, and its management is believed to 
be labour-intensive, requiring more time of health workers than physical healthcare does.  
 
Mental health services in South Africa are also inadequate and inequitably distributed 
(Thom, 2004). In 1994 the country inherited a vertical, primarily custodial, mental health 
system. The challenge has been to develop a community-based mental health service with 
initial access to mental healthcare through primary healthcare services (primary mental 
healthcare) and with provision of the “least restrictive care possible” according to the 
Mental Health Care Act, No 17 of 2002 (South Africa, 2002). In addition, as well as acute 
and other specialized inpatient services, more specialized secondary-level community 
mental health services are needed to support primary mental healthcare services and to 
coordinate the management of the large numbers of people with serious and chronic mental 
illness who will no longer be institutionalized for life, and to be a referral resource for 
primary healthcare services. While the more developed provinces such as Gauteng, 
Western Cape and KwaZulu-Natal have established secondary-level community mental 
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health services, less developed provinces rely on primary healthcare services with a limited 
amount of specialist outreach from inpatient psychiatric facilities.  
 
1.2 Motivation for the study/description of the problem 
While international literature on mental disorders in HIV-infected individuals, in particular 
depression and anxiety, in developed countries abounds, the information on the situation in 
developing countries is limited. With Sub-Saharan Africa forming the current epicentre of 
the epidemic ((UNAIDS/WHO, 2006a:2), accurate estimations of the burden of mental 
disorder in HIV infected individuals are needed. This research project aims to highlight the 
need for mental health services for people with HIV, in terms of both the quantity and the 
type of services and to suggest the most cost-effective models for such service-provision. 
An exploration of factors which may increase the risk of mental disorder, particularly 
depressive and anxiety disorders, or protect an individual from such conditions would 
facilitate early identification and intervention and development of preventive interventions 
to improve mental health in HIV-infected individuals. 
 
1.3 The study context 
 
This study was conducted in Wellness clinics linked to the Perinatal HIV Research Unit 
and in the Nthabiseng HIV clinic at Chris Hani Baragwanath Hospital (CHB), Soweto. The 
Perinatal HIV Research Unit (PHRU) was initially established as a research unit in 1996 
(Perinatal HIV Research Unit, 2005) to study the impact of HIV and potential interventions 
in pregnant women and their offspring. Its range of activities was subsequently extended to 
include prevention of mother to child transmission, voluntary counselling and testing. 
These are available to everyone. Also included are management of HIV infection in a wide 
range of people regardless of age or sexual orientation, clinical trials of antiretroviral 
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medication, wellness clinics, TB treatment, HIV vaccine testing and preventive work to 
keep people HIV negative.  
 
The PHRU headquarters are based at the Chris Hani Baragwanath Hospital in Soweto, 
Johannesburg. The PHRU established its first “Wellness” clinic at the Chris Hani 
Baragwanath Hospital PHRU site in 2003, before the roll-out of anti-retroviral treatment in 
the public sector. Additional sites have been established at Weiler’s Farm (in a local 
authority clinic in an informal settlement south of Johannesburg) at Tintswalo Hospital, 
Acornhoek in Mpumalanga province (in partnership with the Rural AIDS Development 
and Action Research (RADAR) programme, and in the Mopani Health District in Limpopo 
province. These wellness clinics provide a package of services to people from the time of 
diagnosis of HIV-status. This includes family planning, education on HIV infection, 
treatment of sexually transmitted infections, TB treatment, nutritional advice, and immune 
status monitoring. Psychosocial support is provided by HIVSA, a partnering non-
governmental organisation, which runs support groups and provides some individual 
counselling. The clinics generally manage people in the early stages of infection, who are 
asymptomatic. The aim is to keep these individuals as well as possible for as long as 
possible. Once a patient becomes immune-compromised or develops AIDS-defining 
illnesses, and antiretroviral treatment becomes necessary, the person is referred to a 
suitable treatment point. Before the government roll-out of anti-retroviral treatment, a 
minority of people could access treatment in the private sector (those who had medical aid 
insurance or could afford private treatment). The only other access to treatment was 
through clinical trials. In the early stages, many of these trials used monotherapy, with 
resultant resistance and implications for treatment later on.  
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Since the government roll-out was initiated, between April 2004 and April 2005, the 
Nthabiseng HIV clinic at Chris Hani Baragwanath Hospital has been providing anti-
retroviral treatment and, more recently, some of the community health centres in Soweto 
have also started providing comprehensive HIV/AIDS care, including Anti-Retroviral 
Treatment (ART). Patients attending PHRU or Weiler’s Farm wellness clinics at the time 
of this study could be referred to these sites for antiretroviral (ARV) treatment. The ARV 
roll-out in Mpumalanga province was not as far advanced as in Gauteng and, at the time of 
data collection, ARV treatment was still available only through clinical trials being 
conducted at the Wellness clinic site.  
 
The Nthabiseng HIV clinic at CHB has been managing people with HIV infection since the 
early years of the epidemic. Inpatient and outpatient units at the hospital are the primary 
referral sources for this clinic, one of the ART sites in Gauteng Province. Thus patients 
attending this clinic are generally symptomatic. Newly referred patients are initially 
assessed and staged. Patients requiring ARV treatment are worked up medically and 
counselled before initiation of treatment.  
 
Overall, the patients attending the wellness clinic at PHRU, Chris Hani Baragwanath 
(CHB) Hospital, are healthier than those attending the HIV clinic at CHB. However, this is 
not the case at Weiler’s Farm and Tintswalo, where access to health services is limited. 
 
The data for this study were collected from November 2004 to November 2005. The roll-
out of HAART in South Africa began in earnest during this one-year period. This provided 
a unique opportunity for describing psychopathology pre-HAART and for further studies 
to track the process as it unfolds. The primary purpose was to identify those at risk of 
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mental disorder and those needing psychiatric treatment and determine how that treatment 
could be provided.  
 
1.4 Purpose of study 
The aim of the study was to try to find answers to the following questions:  
1. Are mental disorders, especially depression and anxiety, common in HIV-infected 
individuals and are they more common than in the general population in South 
Africa? 
2. Are there particular risk factors associated with the development of these mental 
disorders (especially depression and anxiety)? 
3. Are there any mitigating factors that could protect the HIV-infected individual from 
developing a mental disorder, particularly depression or anxiety? 
 
1.5 Specific objectives 
Primary objectives 
These were: 
1. To determine the occurrence of mental disorders in general, and depressive and 
anxiety disorders in particular, in HIV-infected individuals attending selected HIV-
treatment facilities in South Africa;  
2. To compare the occurrence with similar and existing studies of the prevalence of 
mental disorders, in particular depressive and anxiety disorders, in the general 
population in South Africa; 
3. To explore factors that may predispose to, or mitigate against the development of 
mental disorders (in particular depressive and anxiety disorders) in HIV-infected 
individuals. 
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Secondary objective 
The secondary objective was to use the information obtained from this study to make 
recommendations on appropriate models of care for depressed HIV-infected individuals.  
 
1.6 Outline of study 
 
This thesis describes current international thinking in the field of depression and anxiety 
related to HIV-infection. It highlights postulated risk and protective factors and outlines 
the importance of these disorders in terms of their impact on HIV-infected individuals. The 
literature review focuses particularly on research conducted in Sub-Saharan Africa. The 
findings of this research project are discussed in the context of existing knowledge and 
recommendations are made for further research and for interventions to address the burden 
of depressive and anxiety disorders in HIV-infected individuals.  
 
The intention of this study is to inform an area of HIV-research that has until now not been 
explored to any great extent in South Africa in order to provide healthcare professionals 
working in HIV-treatment facilities with more in-depth knowledge of the mental health 
needs of HIV-seropositive individuals, thereby enabling them to provide more holistic care 
for their patients. It is hoped that some of the systemic issues around integrating mental 
healthcare into general healthcare services will also be addressed. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Introduction 
This chapter reviews the literature on depressive and anxiety disorders in HIV-infected 
individuals, with particular reference to the context of the HIV epidemic in Sub-Saharan 
Africa. Relevant literature regarding prevalence of these disorders, their impact, and 
possible risk and protective factors is also reviewed.  
 
2.2 The HIV pandemic 
2.2.1 The global HIV epidemic 
Acquired Immune Deficiency Syndrome (AIDS) is a relatively new and unique disease. It 
was first described in America, in 1981, after a number of young, previously healthy men 
with homosexual orientation developed pneumocystis carinii pneumonia (PCP) and 
subsequently died. All had developed severe immunodeficiency which led to the 
development of opportunistic infection with PCP. Soon afterwards, in central Africa, 
healthcare workers noted a new fatal disease causing severe weight loss and diarrhoea, 
which came to be called “Slims Disease”. This was also due to immune-deficiency and it 
was present in heterosexual people. More and more people began to develop this illness 
and other conditions associated with immune-deficiency. In September 1983 scientists 
isolated the human immunodeficiency virus (HIV) and found this to be the cause of this 
new disease, which they called AIDS (Broder & Gallo, 1984). 
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Some 25 years later, millions of people have become infected world-wide and AIDS has 
become the world’s most serious public health problem. Sub-Saharan Africa (including 
South Africa) has one of the most severe HIV/AIDS epidemics in the world.  
 
Current global statistics show that an estimated 39.5 million people were living with 
HIV/AIDS in 2006, of which 37.2 million were adults, and 17.7 million were women. It is 
estimated that a total of 4.3 million people were newly infected, and 2.9 million people 
died of AIDS in 2006 (UNAIDS/WHO, 2006a:1).  
 
The profile of HIV infected people in the developed world continues to represent 
predominantly marginalised groups in society. These include the original population; men 
who have sex with men (MSM), as well as ethnic minorities, migrants from the developing 
world, refugees, the homeless (and often mentally ill) and the poor (Green, et al., 2004).  
 
The profile of HIV-infected people in the developing world is much broader. All social 
strata are affected, although HIV predominantly affects the poor and disadvantaged (who 
are the majority in these societies). In particular, it affects women on the basis of their 
biological vulnerability and their social and economic disempowerment in the developing 
world (Evian, 2000: Chapter 2). 
 
During the past two years, the number of people living with HIV increased in every region 
of the world. The most striking increases occurred in East and Central Asia and in Eastern 
Europe. Globally, and in every region, more adult women (15 years or older) than ever 
before are now living with HIV (UNAIDS/WHO, 2006a:1). Sub-Saharan Africa continues 
to bear the brunt of the global epidemic. An estimated 24.7 million people in Sub-Saharan 
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Africa were living with HIV at the end of 2006: 63% of the total global infected 
population. Approximately 2.8 million additional people were infected with HIV during 
that year (UNAIDS/WHO, 2006a:2). About 2.1 million people in Southern Africa are 
estimated to have died of AIDS in 2006. To date, more than twelve million children in 
Africa have been orphaned by AIDS (UNAIDS/WHO, 2006b: Chapter 4). Globally, one 
third (32%) of all people with HIV live in Southern Africa, and 34% of all deaths due to 
AIDS in 2006 occurred there (UNAIDS/WHO, 2006a:3-5). 
 
With the advent of highly active anti-retroviral therapy (HAART), the outcome of HIV 
diseases in the developed world has changed. Mortality has decreased, and HIV infection 
has become a chronic “manageable” disease. There is, however, considerable morbidity 
and, as HAART does not rid the body of infection, it is necessary to remain on HAART 
indefinitely to maintain full viral suppression. The long-term outcome is complicated by 
side-effects from medication and treatment-resistance (Panther & Libman, 2005). 
 
2.2.2 The HIV epidemic in Africa 
The extent of the AIDS crisis is only now becoming clear in many African countries, as 
increasing numbers of people with HIV are becoming ill. In the absence of massively 
expanded prevention, treatment and care efforts, the AIDS death toll in sub-Saharan Africa 
is expected to continue to rise. Indications are that the impact of the AIDS epidemic on 
these societies will be felt most strongly in the course of the next ten years and beyond. Its 
social and economic consequences are already widely felt, not only in the health sector but 
also in education, industry, agriculture, transport, human resources and the economy in 
general, and it threatens to undermine the gains in development that were underway before 
the epidemic. 
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Prevalence is the number of individuals in a population that are affected by a particular 
disease at a point in time. It is influenced by the number of new cases as well as by the 
number of deaths. If the time that a person is infected and survives is increased, this will 
increase the prevalence. Therefore if more people with HIV survive longer due to HAART, 
the prevalence of the disease will not necessarily decrease, unless the number of new 
infections is also significantly reduced 
 
Overall, rates of new HIV infections in Sub-Saharan Africa appear to have peaked in the 
late 1990s, and HIV prevalence seems to be levelling off, albeit at an extremely high level. 
Stabilization of HIV prevalence occurs when the rate of new HIV infections is equalled by 
the AIDS death rate among the infected population. This means that a country with a stable 
but very high prevalence must be suffering a very high number of AIDS deaths each year. 
Owing to general population growth, although prevalence remains stable, the actual 
number of Africans living with HIV is rising.  
 
Both HIV prevalence rates and the numbers of people dying from AIDS vary greatly 
between African countries and large variations exist between the patterns of the AIDS 
epidemic in different countries in Africa. In some places the HIV prevalence is still 
growing, while in others it appears to have stabilized, or even declined (probably due in 
part to effective prevention campaigns). Others countries face a growing danger of 
explosive increase (Pembrey, Kanabus & Fredriksson-Bass, 2007). 
 
Antiretroviral drugs (ARVs), which significantly delay the progression of HIV to AIDS 
and allow people living with HIV to live relatively normal, healthy lives, have been 
available in wealthier parts of the world since about 1996. Distributing these drugs requires 
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money, a well-structured health system and a sufficient supply of healthcare workers. Most 
developing countries have struggled to cope with the increasing numbers of people 
requiring treatment. Fewer than one in five of the millions of Africans in need of the 
treatment are receiving it. Many millions are not even receiving treatment for opportunistic 
infections that affect individuals whose immune systems have been weakened by HIV 
infection. Nonetheless, the overall situation is slowly improving; the number of people 
receiving ARVs in Africa doubled in 2005 alone (UNAIDS/WHO, 2006b: Chapter 7).  
 
International support has helped in this, with numerous governments and international 
organizations encouraging progress. In 2003 the World Health Organisation (WHO) 
initiated the “3 by 5” programme, which aimed to have three million people in developing 
countries receiving ARVs by the end of 2005. While this target was not reached, a number 
of African nations made substantial progress under the scheme. A substantial number of 
people needing ART initiated treatment in Sub-Saharan Africa in 2006, and by the end of 
December 2006, it was estimated that more than 1.3 million people were receiving 
treatment (representing about 28% of the treatment need) (WHO, 2007). The latest 
international target, “All by 2010”, is aiming at universal access to treatment by 2010 
(WHO, 2006). Under this programme, it is hoped, considerable progress will be made in 
Africa’s fight against AIDS.  
 
The major challenges to successfully dealing with the AIDS epidemic are poor healthcare 
infrastructures, a shortage of healthcare professionals, and the need to ensure the ongoing 
supply of sufficient quantities of medications. This is critically important because once an 
individual starts to take ART it must be taken lifelong. Because the risk of resistance is so 
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high with sub-threshold blood levels of ARV drugs, an interruption in the supply of ARVs 
to a health service can have very serious consequences. 
 
2.2.3 The HIV epidemic in South Africa 
The first case of AIDS was identified in South Africa in 1982. The first infections occurred 
amongst men who had sex with men (MSM), but it rapidly became a predominantly 
heterosexual disease. The most rapid increase in South Africa’s HIV prevalence took place 
between 1993 and 2000, during which time the country was focusing on major political 
changes. While the attention of South Africans, and the world’s media, was focused on the 
political and social changes occurring in the country, HIV was rapidly becoming more 
widespread (Pembrey, 2007). 
 
Antenatal seroprevalence has been monitored nationally since 1990, when it was found 
that 0.8% of pregnant women were HIV-positive (National Department of Health, 2000). 
In 2005 the antenatal seroprevalence was 30.2% (National Department of Health, 2006). 
The Nelson Mandela HSRC 2005 national household survey of HIV seroprevalence 
(Shisana, Rehle & Simbayi, 2005) estimated the overall national seroprevalence to be 
10.8%. Women between the ages of 15 and 49 years were found to have the highest 
prevalence (29.5%). It was also noted that the incidence of new HIV infections in the 15 to 
24 years age group was eight times higher in females than in males (6.5% vs. 0.8%).  
 
South Africa is currently experiencing one of the most severe AIDS epidemics in the 
world. By the end of 2005, approximately five and a half million people were living with 
HIV in South Africa and almost 1 000 AIDS deaths were occurring every day 
(UNAIDS/WHO, 2006b: Annexure 2). 
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It is thought that almost half of all deaths in South Africa, and 71% of deaths among those 
aged between 15 and 49, are caused by AIDS (Dorrington, Johnson & Bradshaw, 2006). 
As well as the death and suffering that HIV has caused at individual and community levels, 
South Africa’s AIDS epidemic has also had a substantial impact on the country’s overall 
social and economic progress: 
· Average life expectancy in South Africa is now 54 years – without AIDS, it is 
estimated that it would be 64. Over half of 15 year olds currently are not expected 
to reach the age of 60 (Centre for Actuarial Research, 2006).  
· Between 1990 and 2003, a period during which HIV prevalence in South Africa 
increased dramatically, the country fell 35 places in the Human Development 
Index, a global directory that ranks countries according to how developed they are 
(UNAIDS/WHO, 2006b:Chapter 4). 
· Hospitals are struggling to cope with the number of HIV-related patients requiring 
care. In 2006 a leading researcher estimated that HIV-positive patients would soon 
account for 60-70% of medical expenditure in South African hospitals (Inter Press 
Service News Agency, 2006). 
· Schools have fewer teachers because of the AIDS epidemic. In 2006 it was 
estimated that 21% of teachers in South Africa were living with HIV 
(UNAIDS/WHO, 2006b: Chapter 4). 
Antiretroviral treatment became available in the public sector in March 2004, and by 
March 2005 at least one service point for AIDS related care and treatment had been 
established in all of the 53 districts in the country (Pembrey, et al., 2007). Recent statistics 
indicate that by the end of 2006, some 200 000 people (28% of those in need of it) were on 
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anti-retroviral treatment in South Africa, almost half of them receiving treatment through 
the private sector or non-governmental organisations (NGOs) (WHO, 2007; Johnson & 
McLeod, 2007).  
 
2.3 Psychosocial factors in HIV infection 
Because of the severity of the disorder, HIV has an impact on any individual who receives 
a positive diagnosis. The ramifications of a positive diagnosis are many for any individual. 
It is a serious, life-threatening disorder. Elizabeth Kubler-Ross (1969) and others (Byock, 
1996) described the stages that people go through when facing death or bereavement. As 
part of this process, individuals may experience depressive and anxiety symptoms. The 
considerable stigma surrounding HIV infection because of the mode of transmission makes 
it difficult for infected individuals to obtain support in their time of need. It challenges 
intimate relationships with issues of fidelity and trust that lie at the heart of such 
relationships. The consequences may be loss of relationships and even, domestic violence. 
Within the family, partners and children may be infected and many people within one 
family may die. This results in further losses in terms of childcare, employment, income 
and often, of the home, for the remaining members of the family. Because sexuality and 
death are such taboo subjects in most cultures, it may be difficult for individuals and 
families to address the issues with openness and honesty. This may result in complicated 
bereavement, anger, distrust and sadness.  
 
Therefore, most individuals diagnosed as HIV-infected could be expected to experience 
psychological distress. There is no doubt that part of comprehensive HIV treatment should 
include the provision of emotional or psychological support to all those who are infected. 
However, differentiation between an expectable and transient reaction in the face of 
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adversity and a mental disorder requiring an additional psychological or psychiatric 
intervention is also necessary. 
 
There has been much speculation on the role that mental disorders play in the spread of 
HIV. It is suggested that people with mental disorders may be more at risk of acquiring the 
disease as a result of risky sexual behaviour. Evidence from the United States of America 
indicates that people with severe mental illnesses are at greater risk because of their 
particular vulnerability (Cournos & McKinnon, 1997). Recent evidence from South Africa 
shows that depressive and anxiety disorders play a role in the development of risky sexual 
behaviour (Smit, Myer & Middelkoop, 2006), possibly as a result of lack of concern for the 
future, or even suicidal ideation. These issues are not within the scope of this thesis, and 
the primary focus will be on the consequences of HIV infection in terms of depressive and 
anxiety disorders.  
 
2.4 Depressive disorders in HIV-infected individuals 
2.4.1 Introduction 
Depression may range from transient feelings of depression as a reaction to life events 
along a spectrum to a serious life-threatening illness. There are no clear-cut distinctions 
along this spectrum and to determine the presence of a depressive disorder, psychiatric 
classification systems depend upon the accumulation of signs and symptoms, as well as 
intensity, duration and impact of symptoms on functioning.  
 
2.4.1.1 Depressive symptoms vs. depressive illness 
Differentiation between feelings of depression/depressive symptoms and a depressive 
illness is important but is not always clear, particularly in the presence of a medical illness, 
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where physical symptoms can confound the diagnosis. However, it is clear that depressive 
symptoms are common in people who are infected with HIV, as they are in other serious 
medical conditions (Rodin & Voshart, 1986; Israelski, et al., 2007). These symptoms may 
be a result of biological factors, as well as psychosocial factors that reflect the meaning 
that a serious medical illness has to a particular individual. Ultimately, differentiation 
between depressive symptoms and a depressive disorder may not be very important, 
although the treating clinician must be aware of both. Determining the appropriate type of 
intervention needed is more important. In some cases, it may be sufficient for the clinician 
to listen and support; in others, psychotherapy may be the treatment of choice, whereas 
antidepressant medication, admission to hospital, or even electro-convulsive therapy (and a 
combination of psychosocial interventions) may be necessary in cases of a serious 
depressive illness. 
 
2.4.1.2 Interpreting results of prevalence studies of depressive disorders in HIV-infected 
individuals 
Many prevalence studies use screening tools and rating scales (often in the form of self-
report questionnaires), because they are quick and easy to administer. However, caution 
needs to be exercised when interpreting the results of studies that use these instead of 
diagnostic instruments, as they are likely to overestimate the prevalence of disorders.  
 
2.4.1.3 Depressive disorders in the general population 
Over the past fifty years prevalence rates of mental disorders across a range of countries 
have been studied many times. Studies conducted in the 1970s and 1980s emphasised the 
uniformity of the prevalence of serious mental disorders across countries and cultures 
(Harding, De Arango & Baltazar, 1980). This was found to be particularly true for serious 
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disorders such as schizophrenia, although it was also noted that the presentation and 
outcome of schizophrenia differed across countries and cultures. It has since been 
determined that (unipolar) depressive disorders are the commonest mental disorders1 
across the globe and that their prevalence has increased over the years (Lopez, Mathers & 
Ezzati, 2006). Whether this increase is due to an increase in reporting or whether there is a 
genuine increase is uncertain. However, the recent World Mental Health (WMH) survey of 
common mental disorders (which excluded psychotic disorders and disorders of cognitive 
impairment) in a range of countries (Demyttenaere, Bruffaerts & Posada-Villa, 2004) has 
highlighted an important fact: the current prevalence of mental disorders, including 
depression, varies widely across countries. The disorders included in this study were: 
mood, anxiety, substance use and impulse control disorders, and they were classified as 
serious, moderate or mild in terms of severity. The prevalence of any disorder in the study 
in Shanghai was 4.3%, while in the United States of America it was 26.3%. The prevalence 
in Nigeria (the only African site included) was 4.7%. Prevalence rates in Europe varied 
considerably by country, as did other sites in the Americas. On average, the rates in Asia, 
the Middle East and Africa were the lowest, Europe had intermediate rates and the 
Americas’ rates were the highest. The prevalence of mood disorders reflected the same 
patterns. This study also pointed out that access to treatment is not necessarily determined 
by severity of disorder, and that this may be dependent on other factors, including social 
class and healthcare system. 
 
One key issue likely to be raised concerning this apparent disparity in prevalence levels of 
mood and anxiety disorders across the globe is the role of cultural and linguistic issues in 
diagnosis and how accurate diagnostic tools developed in Western countries are in 
                                            
1 Unipolar depressive disorders are the third most common cause of disability in high income countries, and 
the seventh most common cause of disability in low and middle income countries. 
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detecting these disorders. Recent ethnographic research in Uganda has confirmed that a 
syndrome equivalent to the DSM diagnosis of major depressive disorder is described by 
local inhabitants in that country (Wilk & Bolton, 2002). However, the ways in which 
different populations express mental disorders may differ, and diagnostic instruments may 
not always be sensitive to the different idioms used to describe such phenomena. This 
continues to pose a major challenge in the field of psychiatric epidemiology.  
 
2.4.1.4 Depressive disorders in medically ill populations (including those with HIV 
infection) 
That depression is common in medically ill populations has been established by numerous 
research studies (Koenig, Cohen & Blazer, 1993). Studies have shown that up to one third 
(33%) of medical inpatients report mild or moderate depressive symptoms and one fourth 
(25%) may suffer from a depressive syndrome (Rodin, et al., 1986). However, much 
confusion exists regarding the actual prevalence of depressive disorders in the context of a 
medical illness. This is partly because physical symptoms of the medical illness may 
overlap with neuro-vegetative features of a depressive disorder and, thus, confound 
diagnosis, leading to an overestimation of the prevalence of depressive disorders in this 
population. On the other hand, presentation of symptoms that are not considered core 
features of depressive illness (for example, unexplained or excessive pain or somatisation) 
may result in under-diagnosis. Research findings in this area are difficult to interpret and 
do not provide firm evidence, as a result of differing methodologies, definitions of 
“caseness”, selection bias, the heterogeneity of populations studied (different medical 
illnesses), the absence of control groups, the subjective nature of reporting symptoms of 
depression, and the transient nature of depressive symptoms.  
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Koenig, George and Peterson (1997) demonstrated some of these difficulties when they 
examined and compared rates of depression, correlates, and course of symptoms in 
medically ill hospitalized elderly people through use of different diagnostic schemes 
[inclusive – including all symptoms meeting criteria for a major depressive episode, 
etiologic – excluding disorders due to a general medical condition, substitutive – 
substitution of other psychological or cognitive symptoms for physical symptoms – 
combinations of these approaches were also tested]. They found that the prevalence of 
major depression in a medically ill in-patient population (over the age of 60 years) varied 
from 10% to 21%, depending on diagnostic scheme and, similarly, minor depression varied 
from 14% to 25%.  
 
The diagnostic strategy that best distinguished a severe and persistent major depression 
was the exclusive-etiologic approach (elimination of anorexia and fatigue from the list of 
DSM criteria for major depressive disorder; elimination of a depressive disorder that is 
clearly due to a general medical condition [an organic mood disorder]). However, this 
strategy missed 49% of patients with major depression identified by the inclusive 
approach, almost 60% of whom continued to experience persistent symptoms of depression 
many weeks after discharge. It was thus concluded that diagnostic strategy affects rates of 
major and minor depression, with about a twofold difference between the extremes. 
Therefore, diagnostic strategy should be chosen on the basis of the specific goals and 
purposes of the examiner. While the exclusive-etiologic approach identifies the most 
severe and persistent depressions, the inclusive approach is the most sensitive and reliable 
one and is an intermediate predictor of persistent depression.  
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Ultimately, it may be difficult to distinguish primary from secondary depressive disorders, 
but research shows that treatment of both with antidepressant medication is helpful (Rodin, 
et al., 1986). It is, however, important to identify a mood disorder secondary to a general 
medical condition, where treatment of the medical condition will result in improvement in 
the depressive disorder. Discriminating symptoms found to be useful in diagnosing a 
depressive disorder in the presence of medical illness include: suicidal feelings, sense of 
failure, and feeling of being punished, diminished social interest, crying, indecision and 
dissatisfaction.  
Other diagnoses with depressive symptoms to consider in the context of a medical illness 
include adjustment disorder with depressed mood, dysthymic disorder and dementia. 
Suicidal behaviour and refusal of medical treatment is also common in the presence of 
serious medical illnesses. There are numerous issues to consider in this situation, but one 
should always consider the possibility of the presence of a treatable depressive disorder.  
 
Therefore, depression is common in the medically ill as an affective experience, a 
symptomatic complaint or a clinical syndrome. It may occur in association with or as part 
of the individual response to the physical and psychological calamity of illness. The 
concept of depression as a “psychobiological final common pathway” (Akiskal & 
McKinney, 1975) is particularly relevant in this population. The primary challenge is to 
detect a treatable psychiatric disorder and understand the personal meaning of illness for 
each individual.  
 
2.4.2 Prevalence of depressive disorders in HIV-infected individuals 
Much of the discussion above has relevance when considering depressive disorders in 
HIV-infected individuals. There are numerous confounding factors in making a diagnosis 
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of depressive disorder in an HIV-infected individual, including psychological reactions to 
the illness, physical symptoms common to both HIV disease and depressive disorder, and 
common symptoms in HIV dementia and depressive disorders. 
 
2.4.2.1 International prevalence studies of depressive disorders in HIV-infected 
individuals 
These studies can be divided into those conducted from 1982 to 1996, the period before 
highly-active anti-retroviral treatment (HAART) became available, and from 1997 to 2007, 
the period of wide availability of HAART in the developed world. In this context, before 
1997, HIV infection was a fatal disease; it was a new disease, occurring predominantly in 
already highly-stigmatised individuals in the developed world. 
 
Studies from 1982 to 1996 
It is important to note that most studies during this period were conducted in clinic settings 
(HIV-treatment sites) or advertised for participants as a recruitment strategy (Williams, 
Rabkin & Remien, 1991). Some used screening instruments and rating scales (Brown, 
Rundell & McMains, 1992), not clinical diagnostic assessments, and therefore reported 
only on depressive symptoms or drew inferences about the rates of depressive disorders 
(Kelly, Murphy & Bahr, 1993a). 
 
Most of the research during this period was conducted in the United States of America, 
followed by Europe (including the United Kingdom). Most of the studies show a high 
prevalence of depressive symptoms (Williams, et al., 1991) and, in some cases, depressive 
disorders in HIV-infected individuals (Atkinson & Patterson, 1992). However, in studies 
that compared HIV-seropositive individuals with matched HIV-seronegative controls, most 
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showed that there was a high lifetime prevalence of depressive disorders in both the 
affected individuals and the controls (Rosenberger, Bornstein & Nasrallah, 1993). The 
conclusion drawn from these findings was that HIV infection was occurring in groups of 
individuals already at high risk of depressive disorders ([MSM], and intravenous drug 
users [IDUs]). A study of 75 haemophiliac men (Dew, Ragni & Nimorwicz, 1990), some 
of whom had been infected through blood transfusion, showed higher depression, anxiety 
and anger scores in those who were HIV-seropositive than in those who were HIV-
seronegative. The individuals more likely to have problems were those who had a past 
history of psychological or psychiatric difficulties. This was a small sample, with even 
smaller sub-samples and no diagnostic interviews were done (the symptom-90 checklist 
was used), so caution needs to be exercised in drawing conclusions from this study. 
 
During this period very limited studies were conducted in the developing world. One, by 
Belec, Martin and Vohito (1989) in the Central African Republic, in 1989, on hospitalised 
HIV-infected patients found no evidence of depressive disorder. It is however, noteworthy 
that these were patients in the terminal stages of HIV-infection. As this was a hospitalised 
sample of ill patients, it is not comparable with the research population of studies in the 
developed world at the time, which predominantly comprised outpatients receiving 
primary care services for HIV-infection. 
 
Between 1994 and 1996 the results of the World Health Organisation’s multi-national 
study on prevalence of neuropsychiatric disorders were published (Maj, Janssen & Starace, 
1991; Sebit, 1995; Maj, 1996). This was the first multi-national study conducted in all the 
areas of high HIV-prevalence at the time (1990 to 1991). The study sites included sites in 
North America (Los Angeles, USA), two sites in Africa (Nairobi, Kenya) and (Kinshasa, 
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Zaire), Asia (Bangkok, Thailand), South America (Sao Paulo, Brazil) and Europe (Munich, 
Germany). Study populations at each site represented at-risk groups for HIV in that 
particular country. Thus, the research populations in the two African sites consisted of 
heterosexual subjects; the North American, South American and European sites, consisted 
of MSM and minority groups and in Munich, a disproportionate number of haemophiliacs. 
The Bangkok site group consisted predominantly of injection drug users (IDUs). Results 
published in 1994 and 1996 reported on five sites (excluding the USA site).  
Subjects were recruited from primary care facilities at all sites, and HIV-negative controls 
were included for comparison purposes. The structured Composite International Diagnostic 
Interview (CIDI), which uses algorithms for psychiatric diagnosis according to the 
International Classification of Diseases, 10th Revision (ICD-10), was used. (Results were 
also reported for DSM111-R disorders). Subjects were also rated according to the 
Montgomery-Asberg Depression Scale (MADRS) in terms of severity of depressive 
symptomatology. The interviews were conducted by qualified psychiatrists, who had been 
trained in administration of this structured interview with good inter-centre and intra-centre 
reliability (Maj, Janssen & Satz, 1991). 
 
The findings reported current and lifetime prevalence of a depressive episode. It is worth 
noting that the prevalence of current and lifetime depressive disorders in HIV-negative 
controls varied considerably between centres (from 0% in Munich, Kenya and Kinshasa to 
7.8% in Sao Paulo, Brazil), indicating, as in the WMH study (Demyttenaere, et al., 2004), 
that the prevalence of depressive disorders in the populations studied varied across the 
globe. Prevalence rates of a current depressive episode in symptomatic HIV+ subjects 
ranged from 4% in Munich to 21% in Bangkok. While all sites demonstrated a higher 
prevalence of current depressive disorder in HIV+ subjects than in HIV- subjects, the only 
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sites showing a statistically significant difference between symptomatic HIV+ and HIV- 
subjects were Bangkok and Sao Paulo. Across all sites the mean global score on the 
MADRS was statistically significantly higher in symptomatic seropositive individuals than 
in seronegative controls. The overall prevalence of lifetime mental disorders was not 
significantly increased in HIV-seropositive individuals (asymptomatic or symptomatic), 
compared to HIV-seronegative controls.  
 
This was the first study of depressive disorders in HIV-infected outpatients in Africa. The 
only conclusion drawn regarding the African centres was that the symptomatic stages of 
HIV infection were associated with an increased prevalence of depressive symptoms. How 
much of the depressive symptomatology could be explained by transient psychological 
reactions to the diagnosis is not clear. Participants were tested for HIV-status as part of the 
study, and in these cases interviews were conducted only one month after post-test 
counseling had been completed. Therefore some of their depressive symptomatology may 
have been part of an adjustment reaction to the diagnosis of HIV infection.  
 
This study therefore did not confirm a statistically significant increase in the prevalence of 
depressive disorders in HIV-infected individuals (except in Bangkok) compared to HIV-
negative controls, but the extent of depressive symptomatology was statistically 
significantly increased in HIV-infected individuals. It also demonstrated the same 
variability in prevalence of depressive disorders across the globe. 
 
International research since 1997 
Many of the studies conducted in the United States of America and Europe since 1997 
have continued to show a high prevalence of depressive disorders in HIV-infected 
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individuals and to display many of the methodological difficulties outlined above. The 
demographics of the disease have changed, in that more women and some heterosexual 
men are now becoming infected (Catalan, Meadows & Douzenis, 2000; Morrison, Pettito 
& Ten Have, 2002). HIV-infection, however, occurs more commonly in marginalised 
communities who have inadequate access to social resources; including healthcare 
(African-Americans, Hispanics/Latinos, refugees, the mentally ill, the homeless and the 
poor) (Green, et al., 2004). Many of these groups already have an increased risk of 
depressive disorders due to socio-economic factors, so it is again difficult to tease out 
depressive disorders that are specific to HIV-infection itself. 
 
One of the most cited studies in the field of HIV depression research is the meta-analysis 
conducted by Ciesla, et al. (2001). In their review, they outlined how studies determining 
the prevalence of major depressive disorder in HIV-infected individuals showed varying 
results and noted that the findings were inconclusive. This, they suggested, was largely due 
to small sample sizes and methodological difficulties. In order to obtain a sufficiently large 
sample, 10 studies were selected for meta-analysis. Those which they included all had an 
HIV-negative control group. All determined Major Depressive Disorder (MDD) by means 
of a diagnostic interview (not self-report or rating scales) using DSM-111 or 1V criteria 
and assessed current (1-6 months) rates of MDD and/or dysthymic disorder. If a study was 
longitudinal, data from the first assessment was used and study subjects were not recruited 
through the mental health system (which would have biased results). The study subjects 
included MSM, heterosexual men and women and injection drug users.  
 
Three separate statistical analytical techniques were used and all three meta-analytic 
techniques showed a highly significant relationship between MDD and HIV-positive 
 Literature Review 
 28 
status. The frequency of MDD was nearly twice as high in HIV-positive subjects as in 
HIV-negative comparison subjects. There was no association with sexual orientation or 
disease stage in infected individuals. The risk of depression was apparent in both 
symptomatic and asymptomatic HIV-positive individuals. It is noteworthy that, in six of 
the studies the study population was MSM, in one study the population was IDUs, and 
only two had study populations of men and women. These studies were all done in 
developed countries, except for the one conducted by Maj et al. (1991). 
No compelling evidence of increased risk of dysthymic disorder was found. (Fewer studies 
have been conducted on this disorder, which has a lower prevalence and is a less severe 
condition. Moreover, it can be even more difficult to differentiate between HIV disease and 
dysthymic disorder.)  
 
This meta-analysis was conducted rigorously, using a number of differing statistical 
methods in a large sample, and it provides the strongest evidence thus far, that HIV-
positive individuals, compared to HIV-negative individuals in the same population, are at 
an elevated risk of developing major depressive disorder. The authors noted that 
determining attribution of symptoms to depression or HIV disease requires considerable 
clinical skill.  
 
Another oft-cited study was that by Morrison et al. (2002). This reported on rates of 
depressive and anxiety disorders in women with HIV in the U.S.A. The Structured Clinical 
Interview for DSM-1V was used to assess depressive and anxiety disorder diagnoses. 
Symptoms of depression and anxiety were evaluated according to the Hamilton Depression 
and Anxiety rating scales. The rate of current major depressive disorder was four times 
higher (19.4%) in HIV-seropositive women than in HIV-seronegative women (4.8%). 
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Mean depressive symptom scores on the HAM-D also were significantly higher in the 
HIV-infected women than in comparison subjects (mean = 8.7 compared to mean = 3.3). 
Some of the limitations of the study include the recruitment process, confounding physical 
symptoms and the fact that the study site was in rural Florida in the United States, so its 
findings are not necessarily generalisable. On the other hand, the strengths of the study 
include the comprehensive nature of the assessment process using structured and 
standardized psychiatric instruments and consensus diagnoses, as well as the exclusion of 
subjects with substance use disorders, which can be a major confounding factor in research 
in this field.  
 
2.4.2.2 Prevalence of depressive disorders in HIV-infected individuals in Sub-Saharan 
Africa, including South Africa 
Research on prevalence rates of depression in HIV-infected individuals in Africa and 
South Africa is limited: besides the study by Belec et al. (1989) and the WHO study 
mentioned above, only a handful of research studies have been published.  
 
An interesting study was conducted by Carson, Sandler and Owino (1998), who examined 
a population of working adults in Western Kenya. This was a cross-sectional study, with 
subjects and raters both blind to HIV status, to assess psychiatric morbidity associated with 
HIV. Subjects were recruited from an occupational health clinic for statutory annual health 
checks of workers in the food industry. Psychiatric interviews and neuropsychological tests 
were conducted. Of 230 subjects, 34% were HIV-positive. Women had a higher infection 
rate than men, and those who worked as bargirls or were divorced, widowed, or separated 
were particularly at risk of HIV infection. The study reported only psychiatric symptoms as 
assessed by the Clinical Interview Schedule (CIS), which reported symptoms of depression 
 Literature Review 
 30 
in 12% of HIV-positive individuals and 8% in HIV-negative individuals (not statistically 
significant), and a manifest abnormality of “being depressed” in one HIV positive 
individual, and no manifest abnormality of “being depressed” in any HIV negative 
individuals (statistically significant with a Fisher’s exact test p-value = 0.02). “Slowness” 
and “lack of spontaneity” were other manifest abnormalities noted in HIV positive 
individuals and not in HIV negative individuals. These could indicate early cognitive 
impairment or depression. There were no substantial differences in psychiatric morbidity 
or neuropsychological functioning between the HIV-positive and HIV-negative subjects. 
Some problems related to the study were: the small number of participants; a significant 
refusal rate regarding entering the study, of individuals at high risk of HIV-infection; the 
loss of a large number of blood specimens; various other logistical difficulties. The 
methodology of this study differed from previous research in that participants were 
asymptomatic (working, and therefore healthier overall than many other study populations) 
and unaware of their HIV status, and interviewers were also blinded to the subjects’ HIV 
status, so this study was perhaps better able to provide information on the biological effects 
of HIV without the variables of psychosocial reactions to knowledge of HIV status.  
Studies of the prevalence of Depressive disorders in HIV in sub-Saharan Africa are noted 
in the table below. 
Table 2.1 Studies of prevalence of Depressive disorders in HIV-infected 
individuals in sub-Saharan Africa 
Researcher Country Year 
published 
Methodology Results 
Sebit (1995)* Zaire 
(DRC) and 
Kenya 
1995 Diagnostic 
interview 
(CIDI)  
HIV-negative 
controls 
No statistically significant 
increase in depressive 
disorders; generally low 
prevalence of depressive 
disorder 
Sebit, Tombe 
and Siziya 
(2003) 
Zimbabwe 2003 Diagnostic 
interview 
(MINI) 
HIV-negative 
controls 
71.3% of HIV-positive 
individuals had a psychiatric 
disorder vs. 44.3% in HIV-
negative individuals (no 
separate information on 
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depressive disorder) 
Stranix-
Chibanda, 
Chibanda 
and 
Chingono 
(2005) 
Zimbabwe 2005 Screening 
instrument 
(Shona SSQ) 
HIV-negative 
controls 
17% of all women attending a 
VCT clinic had psychological 
morbidity. No statistically 
significant difference between 
those who were HIV-positive 
and those who were HIV-
negative 
Kahazura, 
Bunnell and 
Moss (2006) 
Uganda 2006 Screening 
instrument 
(CES-D) No 
control group 
47% of 1 017 HIV-infected 
individuals had a CES-D 
score > 23 (significant 
depression). 
*This study was part of the WHO study described by Maj et al. (1991) earlier and describes the results for the 
two African centres 
 
These studies appear to show the same inconsistent findings overall between HIV-positive 
and HIV-negative individuals. The same methodological difficulties abound. However, in 
contrast to the WHO study (Sebit, 1995), the others show a significant prevalence of 
mental disorder, in both infected and uninfected individuals in Africa. This may be a 
reflection of the burden of depressive disorders on the continent. This is important, 
considering the lack of access to treatment, which was highlighted in the WMH study 
(Demyttenaere, et al., 2004). Therefore, if countries respond to the need for treatment of 
mental disorders in the context of HIV, this may result in increasing access to mental 
health treatment for the general population overall.  
 
It is also worth noting that the prevalence of depressive disorders in both HIV-positive and 
HIV-negative individuals is higher in these studies than that found in the African site 
(Nigeria) in the World Mental Health survey (Demyttenaere, et al., 2004). It is unclear 
whether these differences can be wholly accounted for by methodological differences, or 
whether the prevalence of depressive disorders varies considerably in different places in 
Africa; for example, community prevalence studies of common mental disorder in Uganda, 
conducted in 1979 and 2004, showed high prevalence rates (Orley & Wing, 1979; Bolton, 
Wilk & Ndogoni, 2004), as have similar studies conducted in South Africa (see below).  
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Studies of prevalence of depressive disorders in HIV in South Africa are noted in Table 2. 
These studies all show high prevalence rates of depressive disorders in the study 
populations. The numbers of patients in these studies were low (between 90 and 130). In 
addition, all these samples were from hospital infectious diseases clinics treating people 
with HIV infection, before the availability of HAART in the public sector, and were likely 
to be weighted with people in the later stages of the infection. It is also not known how 
long the participants had been aware of their HIV status and whether recent diagnosis of 
HIV status influenced reporting of depressive symptomatology. Also, none of these studies 
used HIV-seronegative controls to compare prevalence rates.  
Table 2.2 Studies of prevalence of Depressive disorders in HIV-infected 
individuals in South Africa  
Researcher Year 
published 
Methodology Results: prevalence 
of MDE 
Bganya 
(1999) 
(Gauteng) 
1999 
(MMed) 
Screening (Beck Depression 
Inventory) + unstructured clinical 
interview 
38%  
Els, Boshoff 
and Scott 
(1999) (Free 
State) 
1999 Mini International Neuropsychiatric 
Interview (MINI) 
35% 
Olley, 
Gxamza and 
Seedat 
(2003) 
(Western 
Cape) 
2003 MINI (baseline of cohort; within 6 
months of HIV-diagnosis) 
34.9%  
Olley, Seedat 
and Stein 
(2006) 
(Western 
Cape) 
2006 MINI (6-month follow-up of cohort) 26% 
 
The Nelson Mandela/Human Sciences Research Council (HSRC) HIV Household Survey 
(2005) (Shisana, et al., 2005) noted that mental health in people living with HIV/AIDS was 
an unexplored area. The survey included some screening questions probing the mental 
health of respondents who knew their HIV status. It was found that 41% of those who were 
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HIV-positive felt sad, empty and depressed, while these feelings were present in 29.6% of 
HIV-negative respondents. Overall, the rates of sleeping, eating and anxiety problems were 
higher in HIV-positive respondents. While these results were not prevalence rates of 
depressive or anxiety disorders, they suggest that these are likely to be quite high. Studies 
of prevalence of mental disorders in more general populations in South Africa are listed in 
the table below. 
 
Table 2.3 Studies of prevalence of mental disorders in general populations in 
South Africa 
Study name Year Site Methodology Result 
Thom et al. 
(Thom, Zwi 
& Reinach, 
1993) 
1993 Urban Primary 
Care clinic 
SRQ + PSE 10% (anxiety and 
depression) 
Rumble et al. 
(Rumble, 
Swartz & 
Parry, 1996)  
1996 Rural community 
in Western Cape 
SRQ + PSE 27.1% (most anxiety and 
depression 
Bhagwanjee 
et al. 
(Bhagwanjee, 
Parekh & 
Paruk, 1998) 
1998 Rural community 
in KwaZulu-Natal 
SRQ + clinical 
interview 
23.9% (anxiety and 
depression) 
Pillay et al. 
(Pillay & 
Kriel, 2006) 
2006 District-level 
services – hospital 
and CHC 
Screening 
instrument 
21% depression 
SASH Study 
(Stein et al, 
2007) 
2007 Country wide 
community 
prevalence study 
CIDI (12-
month and 
lifetime) 
4.5% 12- month (mood 
disorders) 
9.8% lifetime (mood 
disorders) 
 
The studies conducted in rural community settings found very high levels of both 
depression and anxiety (reported together). The study by Thom et al. was conducted in a 
primary care setting and results pertain to that population and not to the general population. 
The study by Pillay et al reported on women only, and covers a selected sample of women 
attending clinical psychology services in an urban district health service in KwaZulu-Natal. 
Because the participants were in mental health referral centres, rates of depression and 
 Literature Review 
 34 
anxiety were likely to be higher than in the general population or in primary care settings. 
A recent survey linked to the World Mental Health Survey, the SASH study (South 
African Stress and Health Survey) (Williams, Herman & Kessler, 2004), aimed to produce 
community prevalence figures for mental disorders in South Africa. The focus of this study 
was on consequences of apartheid violence, torture and trauma. The SASH study used the 
CIDI as its diagnostic tool. The findings of this study were released in October 2007, in a 
policy brief of the South African Medical Research Council (MRC). The 12-month 
prevalence rate for mood disorders was 4.5% and the lifetime prevalence rate was 9.8% 
(Stein, Seedat & Herman, 2007). No separate findings were noted for people in relation to 
their HIV-status.  
 
These studies show a great variability in prevalence rates. The SASH study was conducted 
across the country with representative samples from all provinces. It provides the most 
recent evidence of prevalence rates of mental disorders in the general population in South 
Africa. The findings from South African studies of HIV-infected individuals (in clinic 
settings) appear to show an increased prevalence of depressive disorder (26% to 38%) in 
these populations compared to the prevalence in the general population in this most recent 
study (4.5%).  
 
2.4.3 Possible risk factors for depressive disorder in HIV infected individuals 
2.4.3.1 Biological factors 
Recent research into the pathophysiology of depressive disorder suggests a complex 
interaction between genetic factors (Levinson, 2006), early adversity (Pollak, 2005) and 
psychosocial stressors (Akiskal, 1985; Caspi, Sugden & Moffitt, 2003), which results in 
functional (and possibly structural) changes in the areas of the brain responsible for mood 
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regulation and emotions. Neuroimaging studies of depressed patients have shown several 
abnormalities of regional cerebral blood flow and glucose metabolism (a surrogate of 
neuronal function) in various brain regions, including the limbic cortex, the prefrontal 
cortex, the anterior cingulate cortex, the hippocampus and the amygdala) (Kalia, 2005). 
Recent research has also demonstrated the complex interaction between the central nervous 
system, endocrinological and immunological systems in the genesis, maintenance and 
resolution of depressive disorder (Leonard, 2001). It has also been suggested that 
antidepressants play a role in recovery from depressive illness through neurotropic and 
neuroplastic effects (structural remodelling) (Lanfumey & Hamon, 2005) on the brain. 
Genetic factors (for example, those which regulate the production of brain-derived 
neurotropic factor (BDNF) are also involved (Hashimoto, Shimizu & Iyo, 2004) and may 
explain the variability in response to antidepressant medication. It is suggested that 
vulnerability to, or recovery from depressive illness is mediated through the balance 
between neurotoxins and neurotropic factors (Kalia, 2005).  
 
Age and gender are thought to play a role in increasing the risk for depressive disorders. 
Older age is associated with an increasing risk, while female gender is associated with an 
almost two-fold increase in risk. Whether this is a result of biological or social factors or a 
combination of both is not clear (Kaplan, Sadock & Grebb, 1997:522). 
 
HIV infection leads to a range of antiviral responses in the body, including the production 
of virus specific antibody, but the major response is in cell-mediated immunity (Cann, 
2007). Because the virus infects and damages these very cells in the body, this leads to 
dysregulation of many aspects of immune response, including defective antibody and T-
cell responses to new antigens and decreased natural killer (NK) cell responses (Mavilio, 
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Benjamin & Daucher, 2003). During the antiviral response, and as a result of damage to 
cells involved in cell-mediated immunity, toxic substances are released, which damage 
immune cells both systemically and within the central nervous system. While the CD4 
count is the standard clinical marker of disease progression in HIV-infection, there are 
effects on other cells within the psychoneuroendocrinological and 
psychoneuroimmunological systems that are not usually measured in the clinical setting. 
However, in research settings, these effects have been detected even when CD4+ cell 
numbers are normal, but become more marked as CD4+ cell numbers decline. 
 
It is now known that HIV is commonly found in the Central Nervous System and that the 
virus has a direct effect on CNS structures (An & Scaravilli, 1997). It has been shown that 
pro-inflammatory cytokines, free radicals and other neurotoxins released from glial cells 
play a role in damaging neurons and ultimately resulting in neuronal death (Merrill & 
Chen, 1991). 
 
Without the support of glial cells, and with the release of neurotoxins, neurons are 
damaged or destroyed. HIV is thought to invade the subcortical areas and can destroy the 
basal ganglia, thalamus and temperolimbic structures. While these changes have been 
directly linked to HIV-associated cognitive/motor complex disorders (HIV-associated 
dementia complex and Minor Cognitive Motor Disorder), it is also thought that damage in 
these areas can result in new-onset depression (Martin, Tummala & Fernandez, 2002) as 
well as mania or psychosis. 
 
Because of the effects of HIV infection discussed above, there has been considerable study 
of the association between depressive disorder and clinical indicators of HIV infection.  
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Stage of illness and association with depressive disorder 
Many studies show an association between current HIV symptoms and the presence of 
depressive disorder (Catalan, Klimes & Day, 1992; Maj, 1996). Most do not confirm a 
relationship between depressive disorder and HIV disease stage (Ciesla, et al., 2001). 
However, some have shown an association between the earlier stages of infection and 
depressive disorders (Els, et al., 1999; Olley, et al., 2003). This may be related more to the 
time from diagnosis when a study is done than to the HIV infection itself, since it is known 
that the immediate period after diagnosis is a period of high risk for psychological distress. 
An interesting finding by Lyketsos, Hoover and Guccione (1996) in a prospective follow-
up study was that a significant rise in depressive symptoms occurred in the 18 months prior 
to the onset of clinical AIDS, but this finding has not been replicated. 
 
CD4 count and association with depressive disorder 
Research on the association between CD4 count and depressive disorder has focussed 
largely on the impact of depressive disorder on CD4 count as a factor in disease 
progression (Ickovics, Hamburger & Vlahov, 2001; Ironson, O’Cleirigh & Fletcher, 2005). 
Most studies showing an association between depressive disorder and a decrease in CD4 
count or other immune-status markers have been prospective cohort studies which found 
that the deterioration of immune status is a consequence of depressive disorder, and not 
that a low CD4 count is a cause of depressive disorder. Two studies in Africa have 
explored this association. Both were cross-sectional studies, and were therefore subject to 
limitations. The study by Moosa, Jeenah and Vorster (2005), in South Africa, found no 
association between CD4 count and depressive symptomatology on the Beck Depression 
Inventory (with a cut-off score of 10 or more being indicative of possible depressive 
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disorder). On the other hand, the study by Kahazura et al. (2006) did find a statistically 
significant association between CD4 counts less than 100 cells/ml and the presence of a 
probable depressive disorder (cut-off on the Centre for Epidemiological Studies – 
Depression Scale of 23 or more). However, due to its cross-sectional design, this study was 
still not able to conclude whether a low CD4 count is a cause or a consequence of 
depressive disorder. 
Other biological causes of depressive disorders in HIV-infected individuals 
Besides the direct effects of HIV CNS infection, other opportunistic infections and 
conditions, substance use disorders, as well as medication used in the treatment of HIV 
infection (HAART), opportunistic infections, co-infections and associated conditions may 
also produce depressive disorders (secondary to a general medical condition or substance). 
Of these, the conditions most commonly associated with depressive disorders are: 
substance use disorders; toxoplasmosis; herpes zoster and varicella virus infections; 
hepatitis C co-infection, as well as its treatment with Interferon-gamma (Jones, Ferrando & 
Talal, 2004); some of the antiretrovirals used in treatment (zidovudine, efavirenz) 
(Halman, Bialer & Worth, 2002); CNS malignancies (Stolar, Catalano & Hakala, 2005). 
 
The impact of anti-retroviral medication on depressive disorders 
As noted above, some antiretroviral medications have been implicated in the development 
of neuropsychiatric syndromes, including depressive disorders. However, longitudinal 
follow-up studies on the relationship between HAART and depressive disorders found that 
HAART appears to decrease depressive disorders overall (Judd, Cockram & Komiti, 2000; 
Low-Beer, Chan & Yip, 2000; Rabkin, Ferrando & Lin, 2000; Alciati, Starace & 
Scaramelli, 2001; Starace, Bartoli & Aloisi, 2002; Chan, Orlando & Joyce, 2003). There 
also appears to be a reverse effect, with evidence that individuals with depressive disorders 
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have inferior virologic and clinical responses to HAART and, once treated for depression, 
this response improves (Pence, Miller & Gaynes, 2007). 
 
2.4.3.2 Past psychiatric history and family psychiatric history 
Several studies describing prevalence and risk factors of depressive disorder in HIV 
infected individuals have found that a previous personal history of depressive disorder 
(Dew, et al., 1990; Perry, Jacobsberg & Fishman, 1990; Brown, et al., 1992; Catalan, et al., 
1992; Rosenberger, et al., 1993; Rabkin, Ferrando & Jacobsberg, 1997), substance abuse or 
dependence (Brown, et al., 1992), or a family history of mental disorders (Dew, et al., 
1990) increases the risk of developing a depressive disorder in the context of HIV 
infection. Whether this reflects a biological predisposition or vulnerability is unclear, but it 
does suggest that the host response to a severe psychosocial stressor (knowledge of HIV 
infection) is compromised by earlier events, and that genetic and biological factors listed 
above play a role in this.  
 
2.4.3.3 Personality characteristics 
It has also been shown that low self esteem (Catalan, et al., 1992), poor sense of mastery 
(Dew, et al., 1990), avoidant or disengaged personality styles, insecure or anxious 
attachment and levels of perceived stress increase the likelihood of an HIV-infected 
individual’s developing a depressive disorder. Whether these characteristics are 
biologically or environmentally determined, or not, they are characteristics that predate the 
onset of HIV-infection, and appear to increase vulnerability to depressive disorders in the 
context of HIV infection.  
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The issue of perceived stress is important, as HIV infection is associated with greatly 
increased levels of stressful life events. Koopman, Gore-Felton and Marouf (2000) 
examined the relationships of coping, attachment style and perceived social support, to 
perceived stress within a sample of HIV-positive people. Participants were 147 HIV-
positive persons (80 men and 67 women). Multiple regression analysis was used to 
examine the relationships of total score on the Perceived Stress (PS) Scale with 
demographic variables, AIDS status, three coping styles, three attachment styles and 
perceived quality of general social support. PS was significantly associated with less 
income, greater use of behavioural and emotional disengagement in coping with 
HIV/AIDS and less secure and more anxious attachment styles. These results indicate that 
HIV-positive people who experience the greatest stress in their daily lives are those with 
lower incomes who disengage behaviourally/emotionally in coping with their illness, and 
those who approach their interpersonal relationships in a less secure and more anxious 
style. Thus, it is important to consider the psychological meaning of stressful events to a 
particular individual. 
 
2.4.3.4 Psychosocial factors in the development of depressive disorders in HIV-infected 
individuals 
Most research on the role of psychosocial factors in depressive disorders relates to the 
study of the impact of stress on individuals. Literature covering the impact of stressful life 
events and other environmental stressors in the development or precipitation of a 
depressive illness is extensive (Kaplan, et al., 1997:522). The conclusion is that stressful 
life events play a role in the genesis of depressive disorders. One of the striking findings of 
more recent research is that stress, particularly cumulative stress, induces endocrine, 
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immunological and neurochemical changes in the brain (Leonard, 2001; Dantzer & Kelley, 
2007, Gunnar & Ouevedo, 2007).  
 
Infection with HIV results in an individual having to deal with a number of serious 
psychological issues, including: the impact of the illness on body image; self-esteem; sense 
of identity; capacity to maintain social, family and marital relationships; facing one’s own 
death and the deaths of loved ones. The early months after diagnosis of HIV infection are 
associated with increased levels of psychological distress, which appears to lessen with 
time (Lyketsos, Hoover & Guccione, 1996b). However, some individuals remain at risk of 
developing mental disorders, particularly depressive disorders, both at the time of 
diagnosis and during all the stages of HIV infection.  
 
Psychosocial factors found to be associated with an increased prevalence of depressive 
disorders in HIV-infected individuals include: lack of social support, stressful life events 
(both general events and HIV-related stressors, both past and recent), low income and 
unemployment, female gender and disability (Dew, et al., 1990; Perry, 1994; McClure, 
Catz & Prejean, 1996; Rabkin, et al., 1997; Simoni & Ng, 2000; Mello & Malbergier, 
2004). Social support is the most commonly mentioned variable in these studies. Of note in 
South Africa is the research conducted by Olley et al. (Olley, Seedat & Nei, 20040. Female 
gender, negative life events and disability were the factors found to predict major 
depression in these studies. [Female gender and negative life events have also been 
associated with depressive disorders in uninfected samples as well (Piccinelli & Wilkinson, 
2000).] This study also noted that the impact of negative life events, rather than the number 
of such events, predicted major depression, bearing out a previous point that it is not only 
the amount of stress, but the way that stress is perceived by the individual that is important.  
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Information on the impact of stigma and discrimination around HIV in South Africa is 
limited and contradictory, with some authors suggesting that considerable stigma exists 
and impacts on the mental health of HIV-infected individuals (Simbayi, Kalichman & 
Strebel, 2007), while others emphasise the changes in society’s response and the 
importance of avoiding stereotyping of responses when the reality of the overwhelming 
numbers of people affected by the epidemic means that more and more people are called to 
care (Jewkes, 2006).  
2.4.3.5 Possible protective factors in HIV-infected individuals that could prevent 
development of depressive disorders 
An aspect that has received little attention relates to the factors associated with resilience in 
patients with HIV infection and those which may protect them from depressive disorders 
and/or disease progression. Much of the literature on stressful and negative life events and 
perceived stress suggests that less vulnerable individuals are less likely to develop 
depressive disorders, and that psychological diatheses moderate the impacts of life events. 
 
Simoni and Cooperman (2000), in their study of women living with HIV/AIDS in New 
York City, found that while there were considerable severe stressors (both past and 
present) in this group, participants also reported considerable strengths, including high 
levels of spirituality, mastery and HIV-related social support. Multivariate analyses 
indicated that these resources were generally associated with less depressive 
symptomatology.  
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The impact of disclosure on mental health has also not been explored to any great extent in 
South Africa; nor has the impact of pre- and post-test counselling in protecting individuals 
from mental disorder been explored. 
 
2.4.4 The impact of depressive disorders on HIV-infected individuals 
2.4.4.1 Depressive disorder and disease progression 
Research into the impact of stress and depressive disorders on physical health indicates a 
close relationship between psychological factors, neurological pathways and the immune 
and endocrine systems (Kiecolt-Glaser & Glaser, 1991; Kemeny, Solomon & Morley, 
1992). In terms of HIV infection, considerable research exploring the impact of stress, 
depression and anxiety on HIV-illness progression has been done (Coates, Stall & 
Ekstrand, 1989; Leserman, Jackson & Petito, 1999; Farinpour, Miller & Satz, 2003). In 
addition, in recent years there has been a focus on the impact of anti-retroviral medication 
on psychiatric symptomatology (see Section 2.4.3.1) and the impact of mental disorders on 
treatment response to HAART (Pence, et al., 2007). All of this research appears to indicate 
a close and reciprocal relationship between internal factors and systems, both biological 
(the brain, endocrine and immune systems) and psychological (coping mechanisms, 
personality structure and internal brain circuitry affected by early life events, which may 
predispose or protect against later depressive illness) and external stressful life events. 
Each individual has various homeostatic mechanisms which interact, with the ultimate aim 
of survival, and psychiatric disorders as well as HIV infection can be both cause and effect 
of disruptions in these homeostatic mechanisms.  
 
Both stress and depressive disorders appear to impact on disease progression, either 
directly through effects on the immune system (Mayne, Vittinghoff & Chesney, 1996; 
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Ickovics, et al., 2001; Ironson, et al., 2005), or indirectly through poor adherence to 
medication (Cook, Cohen & Burke, 2002). The studies in this area generally indicate an 
association between depression and disease progression. However, the mechanisms by 
which this association is mediated are not clear. There seems to be evidence for mediation 
through CD4 cell count (Ickovics, et al., 2001; Ironson, et al., 2005), but it is also 
suggested in some studies that most of these effects are mediated through other cell-lines; 
in particular, CD8 cells and Natural Killer cells (Evans, Ten Have & Douglas, 2002; 
Creuss, Douglas & Petitto, 2005). Studies of both psychotropic and psychotherapeutic 
treatments for depressive disorders have also shown a beneficial effect on disease state 
immune markers (Antoni, 2003; Burke, Cook & Grey, 2004).  
 
2.4.4.2 Impact of depressive disorders on adherence 
Another reason advanced for motivating for the need to identify and treat depressive 
disorders is the suggested impact of depressive disorders on adherence. It has been 
proposed that depressive disorders result in decreased adherence as a result of poor 
motivation, poor organisational capacity, diminished energy, and on the basis of suicidal 
ideation or behaviour. Several studies have examined this issue.  
 
Two studies published in 2002 do not mention depressive disorders as factors in non-
adherence. In a cross-sectional study of a sample of HIV-seropositive patients in Hong 
Kong, Molassiotis, Nahas-Lopez and Chung (2002) identified predictors of adherence as 
high self-efficacy, low tension-anxiety scores and low intensity of nausea and vomiting. 
Murphy, Greenwell and Hoffman (2002) found very poor rates of adherence in a group of 
HIV symptomatic or AIDS diagnosed women with young children. The major factors 
associated with non-adherence were alcohol use, perceived stress, having a partner and age 
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of youngest child, poor self-efficacy to stay with treatment, and poor outcome expectancies 
regarding the benefits of following the treatment regimen. Neither of these studies 
specifically mentioned depressive disorder as a possible factor, and whether this was 
actually investigated is unclear.  
 
A prospective cohort study by Cook et al. (2002) followed HIV-seropositive women from 
1996 to 1998 and examined the longitudinal effects of depressive symptoms and mental 
health quality of life on utilization of HAART among HIV+ women. High levels of 
depressive symptoms and poor mental health quality of life were found, and they 
significantly reduced the probability of HAART utilization. Receiving mental health 
services significantly increased the probability of using HAART. HIV+ women 
characterized as being in poor mental health were less likely to use HAART, whereas those 
receiving treatment for mental health difficulties were more likely to use it.  
 
Tucker, Burnam and Sherbourne (2003) used data drawn from the HIV Cost and Services 
Utilization Study, and showed that HIV-seropositive patients with depression, generalised 
anxiety disorder and panic disorder were more likely to be non-adherent than those without 
a psychiatric disorder. Non-adherence was also associated with use of cocaine, marijuana, 
amphetamines or sedatives in the previous month. Compared with patients who did not 
drink, those who were moderate, heavy or frequent heavy drinkers were more likely to be 
non-adherent. These associations could not be explained by demographic, clinical or 
treatment factors. 19% of the 1910 study subjects screened positive with the CIDI-screen 
for a probable psychiatric disorder, 14% reported heavy drinking in the past month, and 
28% reported other substance use (illicit) or abuse.  
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Turner, Laine and Cosler (2003), in a retrospective cohort study, using a pharmacy-based 
measure of adherence and DSM diagnoses, showed that antiretroviral adherence is worse 
in women than in men, and that depression can influence medication adherence. The study 
also found that treatment for depression improved adherence in those with depression. 
 
On balance, the evidence seems to show an association between depressive disorders and 
poor adherence. However, other psychiatric illness (anxiety disorders) and active substance 
abuse also play a role (Ickovics & Meade, 2002). The literature also shows that treating 
depressive disorders has a significantly improves treatment adherence in HIV-infected 
individuals.  
2.4.4.3 Suicidal behaviour in HIV-infected individuals 
Another reason for actively diagnosing and treating depressive disorders in HIV-infected 
individuals is the high rate of suicidal behaviour in such individuals (Cote, Biggar & 
Dannenberg, 1992; Starace 1995), which is similar to that in other chronically medically ill 
patients (Hughes & Kleespies, 2001). Kelly, Raphael and Judd (1998b) also found 
increased levels of suicidal ideation in symptomatic HIV-positive men and highlighted the 
role that multiple psychosocial factors associated with suicidal ideation and attempted 
suicide play in this population. A 2001 Komiti et al. review (Komiti, Judd & Grech, 2001) 
noted that most studies had considerable methodological problems (the problems inherent 
in assessing suicidal ideation and completed suicide, particularly in retrospective studies), 
and that longitudinal studies of a wider range of affected groups were needed. No 
information is available on suicide related to the HIV-infected in Sub-Saharan Africa 
although it is needed to improve care to this group.  
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Other factors besides depressive disorders play a role in producing suicidal behaviour; in 
particular, substance abuse. To control for the impact of substance use disorders, Roy 
(2003) studied a series of 149 HIV-seropositive substance-dependent patients, to identify 
other risk factors. Almost half the group had attempted suicide. Significantly more female 
than male patients attempted suicide, had a family history of suicidal behaviour, reported 
childhood trauma, scored significantly higher for neuroticism, had experienced 
significantly more comorbidity with depression, and had received antidepressant 
medication. This study indicated that past, as well as more recent risk factors were 
involved in producing suicidal behaviour. The challenge for the clinician is to intervene, 
particularly with recent and current risk factors. High risk periods for suicidal behaviour in 
the course of HIV infection have been identified as the months immediately following 
diagnosis and periods of evident disease progression. 
 
2.5 Anxiety disorders 
2.5.1 Introduction 
Anxiety disorders in HIV-infected individuals have received far less attention in the 
literature than depressive disorders, possibly because anxiety symptoms are regarded as 
expectable normal reactions to the stress of being HIV-infected. Furthermore, anxiety is 
often part of a complex symptom picture that frequently includes mood disorders and 
substance use disorders. This co-morbidity makes diagnosis of “pure” anxiety disorders 
difficult. There are also many general medical factors and substance related factors that 
may cause anxiety disorders. Other viral opportunistic infections, medication side-effects, 
vitamin deficiency states and substance-related withdrawal states are common causes of 
anxiety disorders secondary to general medical conditions.  
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2.5.2 Methodological issues 
The same issues regarding anxiety symptomatology vs. disorder, as in depressive 
disorders, are evident and create methodological difficulties. In addition, the nature of 
anxiety disorders is continually under review. Confusion surrounds differentiation of trait 
anxiety (a personality characteristic) from state anxiety (a disorder). There is considerable 
overlap between symptoms of generalised anxiety disorder and depressive disorders, as 
well as in genetic loading for both disorders, and it has been suggested that these may be 
the same disorder expressed with slightly different phenomenologies (Breslau, 1985). On 
the other hand, anxiety disorders as a group may be disparate, with different genetic 
underpinnings and psychosocial correlates (Stein, 2006). 
This is reflected in methodological issues. Current diagnostic psychiatric systems tend to 
use a stepwise approach to diagnosis; thus before a diagnosis of a generalised anxiety 
disorder is made, a depressive disorder would generally be excluded (anxiety symptoms 
affect as many as 90% of all depressed patients), as would a substance-related disorder or a 
disorder due to a general medical condition (according to DSM1V-TR criteria).  
 
“Stress” is a common term used to describe a number of different events or mental states. 
These include the normal stress of living, “abnormal” stressful/negative life events or 
traumatic events, and individuals’ reactions to stress/difficulties in their lives. Recent 
literature on stress and coping has highlighted the difference between perceived and 
objective stress, suggesting that individuals may react differently to the same stressful 
event, depending on their individual histories (including genetic factors, personality factors 
and early experience of adversity). There are also anxiety disorders that are classified as 
acute stress disorders and post-traumatic stress disorder (PTSD).  
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Post-Traumatic Stress Disorder is of interest to many researchers in the field of HIV 
psychiatry. It has been postulated that it is common in HIV-infected populations, both as a 
result of learning of one’s HIV-status and because individuals may be infected through 
rape and assault, which in themselves are traumatic. A significant amount of controversy 
exists in the literature regarding post-traumatic stress disorder as a diagnosis, and there has 
been considerable research on its biological, personality and psycho-social correlates. 
Concern has been expressed over possible over-diagnosis of this disorder for the purposes 
of insurance claims. This has led to caution in terms of defining traumatic events that could 
result in PTSD. The controversy has extended to debate on whether a diagnosis of HIV is 
in itself a traumatic event.  
2.5.2.1 Interpreting research findings on anxiety disorders in HIV-infected individuals 
The same issues regarding screening instruments, diagnostic interviews and rating scales 
discussed in the section on depressive disorders pertains to the diagnosis of anxiety 
disorders. The CIDI, MINI, SCAN and SCID are all diagnostic instruments that can be 
used to diagnose anxiety disorders. There are screening instruments and rating scales for 
specific anxiety disorders such generalised anxiety disorder, post-traumatic stress disorder, 
obsessive compulsive disorder and panic disorder. It is important to use these instruments 
for the correct purposes and to interpret research findings with an awareness of what 
exactly is being reported depending on the instruments that are used in the research.  
 
Common screening instruments used in anxiety disorders research include general 
questionnaires like the General Health Questionnaire (GHQ), the Self-Reporting 
Questionnaire (SRQ) and the Symptom-90 checklist. In addition, screening instruments for 
specific anxiety disorders have been developed. The PTSD-checklist – civilian version has 
been commonly used in studies of PTSD in HIV-infected individuals. Researchers report a 
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high correlation between the cut-off (44) on this checklist and DSM-diagnostic criteria for 
this disorder (Dobie, Kivlahan & Maynard, 2002). 
 
Rating scales which are primarily used for rating the severity of a disorder and tracking 
changes over time, are also commonly used in studies to determine the levels of anxiety 
symptomatology. The Hamilton Anxiety Rating Scale for Generalised Anxiety Disorder  is 
one such tool.  
 
2.5.3.2 Anxiety disorders in the general population 
The WMH study (Demyttenaere, et al., 2004) again showed a wide range of prevalence 
rates of anxiety disorders across countries and continents. The prevalence rates of anxiety 
disorders (all disorders) diagnosed with the CIDI-12-month instrument ranged from 2.4% 
in Shanghai to 18.2% in the United States of America. The site in Africa (Nigeria) reported 
a 12-month prevalence of 3.3% for all anxiety disorders.  
Recent prevalence studies on PTSD in the United States are noted in the table below. 
 
Table 2.4 Studies of prevalence of Post-Traumatic Stress Disorder in the United 
States of America 
Authors Country Methodology Prevalence 
Koopman, Gore-Felton and Azimi 
(2002) 
USA no control group; screening tools 
ASD 
PTSD 
 
31.3%  
40% 
Martinez, Israelski and Walker 
(2002) 
USA No control group; screening tool 
PTSD 
 
42% 
Israelski et al. (2007) USA primary care; no control group; 
screening tool 
PTSD 
ASD 
 
 
34% 
43% 
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These studies report very high prevalence of Acute Stress Disorder and Post Traumatic 
Stress Disorder. The studies all used self-report screening instruments, the Stanford Acute 
Stress Reaction Questionnaire and the PTSD Checklist-Civilian Version. Although 
researchers argue that these are valid instruments correlating well with the DSM diagnoses, 
results should be treated with caution, particularly in countries where the scale has not 
been validated in terms of factors and cut-off score. The studies noted above lacked HIV-
seronegative control groups, so it is not possible to comment on the prevalence rates 
reported in these studies.  
 
2.5.3.3 Anxiety disorders in medically ill populations 
The differential diagnosis of anxiety symptoms in medically ill populations includes 
disorders secondary to a general medical condition, substance-induced anxiety disorder, 
adjustment disorder with anxious mood, generalised anxiety disorder, panic disorder, 
specific and social phobias, obsessive compulsive disorder and post-traumatic stress 
disorder. Anxiety symptoms and anxiety disorder have been estimated to occur in 5% to 
20% of medical inpatients and 4% to 14% of medical outpatients (Skodol, 1999). These 
estimates do not distinguish between anxiety symptoms and anxiety disorders, nor between 
the various causes of anxiety in the medically ill.  
 
2.5.3 The prevalence of anxiety disorders in HIV-infected individuals 
Prevalence data on anxiety disorders in this population are limited and often of 
questionable value. Studies often do not separate anxiety disorders from other mental 
disorders, but merely report on high rates of “mental disorder” or “depression and 
anxiety”. As with depressive disorders, there are many methodological problems (small 
samples, selected groups, measuring and reporting of symptoms and not syndromes). Study 
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design may limit the usefulness of information as, for example, retrospective cross-
sectional studies often do not address the issue of whether anxiety preceded or followed 
HIV infection. There is, therefore, a very wide range of reported rates of anxiety disorders 
(5% to 40%) in HIV-infected individuals (McDaniel & Blalock, 2000). 
 
2.5.3.1 International prevalence studies of anxiety disorders in HIV-infected individuals 
Early studies in the developed world showed that lifetime prevalence rates of anxiety 
disorders in HIV-seropositive and matched HIV-seronegative controls were similarly high, 
suggesting that individuals at risk for HIV infection were also at risk for anxiety disorders. 
The only statistically significant difference in prevalence rates between HIV-seropositive 
individuals and HIV-seronegative controls in these studies is in adjustment disorder with 
anxious mood in the study by Dew, Becker and Sanchez (1997).  
 
The table below outlines studies that have used diagnostic instruments and control groups 
to make (current) anxiety disorder diagnoses. 
Table 2.5 International studies of the prevalence of anxiety disorders in HIV-
infected individuals 
AUTHOR Country  Methodology Prevalence 
   HIV+ HIV-  
Williams et al. 
(1991) 
USA control group; SCID (total anxiety 
disorders) 
2% 0% (ECA: 
4.7%) 
Brown et al. (1992) USA control group (ECA); SCID (total anxiety 
disorders) 
12.9% 4.8% 
Rosenberger et al. 
(1993) 
USA control group: SCID (total anxiety 
disorders) 
10% 10% 
Dew et al. (1997) Prospective cohort study; control group; SCID 
Baseline data USA GAD lifetime prevalence 15% 8.8% 
 
Baseline data USA GAD current prevalence 2.4%  1.9% 
 
Baseline data USA Adjustment disorder with anxious mood: 23.4%  11.3% 
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Rabkin et al. 
(1997) 
USA control group: SCID (total anxiety 
disorders) 
14% 8% 
Bing, Burnam and 
Longshorgshore 
(2001) 
USA HIV Cost and SUS; CIDI screen (12-month 
version) 
GAD 
Panic Attack 
 
 
15.8% 
10.5% 
 
Morrison et al. 
(2002) 
USA control group: SCID 10.8%  6.5% 
 
The most recent controlled study with rigorous methodology was conducted by Morrison 
et al. (2002). The findings were that 10.8% of HIV-positive women had an anxiety 
disorder (diagnosed with the SCID), whereas 6.5% of HIV-negative women had such an 
anxiety disorder. This difference was not statistically significant. However, levels of 
anxiety symptoms were higher in HIV-positive women than in HIV-negative women 
(using the Hamilton Anxiety Rating Scale) and the difference was statistically significant. 
The most common anxiety disorder in HIV-positive women was social phobia and in HIV-
negative women it was generalised anxiety disorder. Again, it was not noted how long the 
participants had been aware of their HIV-status, and whether this had an impact on anxiety 
symptoms.  
 
2.5.3.2 Prevalence studies in Africa and South Africa 
Studies conducted in Africa are even more limited than in the developed world. Some 
results of research conducted at sites in Africa are listed in the table below. 
 
Table 2.6 Studies of the prevalence of anxiety disorders in HIV-infected 
individuals in sub-Saharan Africa 
Prevalence AUTHOR Country 
of study 
Methodology 
HIV+ve HIV-ve  
Maj et al. (1994) Multi-
national 
control group: CIDI 1-2% 1-2% 
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Carson et al. (1998) Kenya control group: CIS 
worry symptoms (no anxiety disorders) 
13% 12% 
Els et al. (1999) South 
Africa 
no control group; MINI 
Panic disorder 
Agoraphobia 
Social phobia 
GAD 
PTSD 
 
37% 
9% 
15%  
21% 
6% 
 
Olley, Zeier and Seedat 
(2005) 
South 
Africa  
no control group; MINI 
PTSD (Baseline) 
 
14.8% 
 
Olley et al. (2006) South 
Africa 
cohort study; MINI at 6 month follow-
up 
PTSD 
 
 
20% 
 
 
Only the Carson et al. and Maj et al. studies used HIV-seronegative controls, and these 
reported low rates of anxiety disorder in both groups and no difference between HIV-
seropositive and HIV-seronegative individuals. The studies in South Africa show much 
higher prevalence rates for all the anxiety disorders reported but none of these studies had 
control subjects. Comparison of the reported rates of PTSD in the American and South 
African studies shows that rates in the American studies are higher. The American studies 
used a screening tool, whereas the South African ones used a diagnostic instrument. 
Whether this explains the difference in rates or reflects a true variation in rates of PTSD is 
unclear. Studies in both countries need to be conducted using the same diagnostic 
instrument and using control groups, to compare with general population prevalence rates.  
 
Some studies of the prevalence of anxiety disorders in the general population in South 
Africa have already been discussed in the section on depressive disorders (see the table 
below). The recent SASH study showed a 12-month prevalence rate of 8.1% and lifetime 
prevalence rate of 15.8% for anxiety disorders in South Africa. Of interest in this study is 
that, despite high rates of exposure to psychological trauma in the study sample, the rates 
of PTSD were found to be low.  
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Table 2.7:  Studies of the prevalence of anxiety disorders in general population in 
South Africa 
Study name Year Site Methodology Result 
Thom et al. 
(1993)  
1993 Urban Primary 
Care clinic 
SRQ + PSE 2% (anxiety disorders) 
Rumble et al. 
(1996) 
1996 Rural community 
in Western Cape 
SRQ + PSE 27.1% (most anxiety and 
depression 
Bhagwanjee 
et al. (1998) 
1998 Rural community 
in KwaZulu-Natal 
SRQ + clinical 
interview 
23.9% (anxiety and 
depression) 
Pillay et al. 
(2006) 
2006 District level 
mental health 
services – hospital 
and CHC 
Screening 
instrument 
10% anxiety 
SASH Study. 
Stein et al 
(2007) 
2007 Country-wide 
community 
prevalence study 
CIDI (12-month 
and lifetime 
prevalence) 
8.1% 12-month 
15.8% lifetime 
 
 
Summary 
International studies of anxiety disorders in HIV-infected individuals show great variability 
and while there is some evidence of an increased prevalence of anxiety disorders in these 
individuals, compared to individuals in the general population, the variability in prevalence 
rates across countries and differing methodologies make it difficult to conclusively state 
that this is the case. The same conclusion applies to studies conducted in African and South 
African settings. While there is considerable variability in prevalence rates of anxiety 
disorders in the general population, it appears from the most recent study (Stein, et al. 
2007), that anxiety disorders are common. The prevalence of anxiety disorders in HIV-
infected individuals in studies conducted in South Africa is also high, but there does not 
appear to be a statistically significantly higher prevalence in this population compared to 
the general population.  
 
Therefore, the conclusion from this review must be that while anxiety disorders are 
common in HIV-infected individuals and should be a focus of attention, current evidence 
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does not show that they are more common than anxiety disorders in matched HIV-
seronegative controls or in similar medically ill populations.  
 
2.5.4 Risk factors for anxiety disorders in HIV-infected individuals 
As with depressive disorders, in the recent past, considerable research has been carried out 
on the psychobiology of anxiety disorders. Investigations into genetic factors, 
psychoneuroendocrinological responses, brain development and plasticity are attempting to 
elucidate factors responsible for the development of anxiety disorders. The outcomes of 
these investigations again suggest that the development of anxiety disorders involves a 
complex mix of genetics, early brain development, early adversity, and current 
psychosocial stressors. Stein (2006) suggests that anxiety disorders can be conceptualised 
in terms of a “false alarm”, mediated by specific neurocircuitry, with a particular 
evolutionary origin for specific anxiety disorders, and that Serotonin-Specific Reuptake 
Inhibitors (SSRIs) and Cognitive Behaviour Therapy (CBT) appear to normalise “false 
alarms”, possibly by inducing brain changes. 
 
Westermann, Sirois and Shultz (2006) explored the interaction between brain development 
and cognitive development in terms of the role that experience (environmental influences) 
and innate maturational factors play in development. A number of authors have explored 
the issue of trait anxiety and Pollak (2005) suggests that trait anxiety is related to adversity 
in early development, and that these experiences effect structural brain changes. Van Eck, 
Berkhof and Nicolson (1996) studied salivary cortisol levels and explored the effects of 
perceived stress, traits, mood states and stressful daily events on these levels. The findings 
were that distress reflected by mood states was associated with higher cortisol levels and 
stressful daily events increased cortisol secretion. Perceived stress, anxiety and depression 
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did not increase reactivity, but there was reduced habituation to recurrent events in subjects 
scoring high on these traits. The conclusion reached was that mood appears to play a 
mediating role in the relationship between stressful events and cortisol secretion. Schlotz, 
Schulz and Hellhammer (2006), in recent work using salivary cortisol levels, showed that 
subjects scoring high on trait anxiety seem to process stress-relevant information in a way 
that amplifies the association between performance pressure and cortisol levels. These 
studies suggest that longstanding traits of anxiety develop as the brain develops and they 
are accompanied by biological changes. These long-term changes may make individuals 
more vulnerable to stress and the development of anxiety disorders later in life.  
 
Many authors have commented on the role of stress in the genesis of anxiety disorders, 
explaining how stress is necessary for survival, but that repeated stress increases the risk of 
physical and mental health problems especially during periods of rapid brain development. 
Gunnar and Ouevedo (2007) also outlined the critical role of social regulation and the 
importance of individual differences.  
 
Research into Post Traumatic Stress Disorders highlights that not all people who 
experience traumatic events develop PTSD ( Keane, Marshall & Taft, 2006). There is a 
striking individual variation in emotional and neurobiological responses. Cognitive 
appraisal and coping factors may explain differences in neuroendocrinological stress 
response and development of this disorder (Olff, Langeland & Gersons, 2005). 
 
Suggested risk factors for PTSD in HIV include: more physical symptoms, more pre-HIV 
trauma, less perceived social support, more perceived stigma, and more negative life 
events. Katz & Nevid (2005) found three individual predictors for PTSD in HIV infected 
 Literature Review 
 58 
individuals: total impact of negative life events; total stigma score; total number of 
physical symptoms. Stigma was found to be the strongest individual predictor. Social 
support in this study failed to moderate relationships between PTSD symptoms and HIV 
symptoms and negative life events.  
 
Kelly et al. (1998a) explored the issue of PTSD as a response to HIV infection: in a small 
sample of MSM, 30% met criteria for PTSD in response to the diagnosis of HIV. PTSD 
was associated with other mental disorders, especially first onset major depression after 
diagnosis of HIV status and was significantly associated with a past history of PTSD 
before HIV, other pre-HIV mental disorders and neuroticism traits. While the authors 
suggest that a PTSD response to HIV diagnosis or any other life-threatening illness has 
clinical validity, the small sample size and the confounding variables in this study are 
problematic. The strongest predictor of PTSD post-HIV diagnosis was a past history of 
PTSD, which may suggest that particular individuals are more at risk of developing the 
same pattern of illness when faced with a new stressor, and not necessarily that the stressor 
per se is of sufficient severity to produce PTSD. While this is in keeping with the current 
understanding of PTSD, it is precisely this approach that has caused the controversy in 
psychiatric circles regarding PTSD.  
 
2.5.5 The impact of anxiety disorders in HIV-infected individuals 
What impact anxiety disorders have on HIV-infected individuals and whether there is an 
impact in terms of disease progression, adherence to treatment, suicide and/or quality of 
life needs clarification.  
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Leserman, Whetten and Lowe (2005) explored the impact of recent stressful events, trauma 
and PTSD on biological markers as well as physical functioning and healthcare utilisation 
in HIV-seropositive individuals in the “Coping with HIV/AIDS in the South-East study – 
CHASE Study”. Results of 611 interviews showed that patients with more lifetime trauma, 
stressful events and PTSD symptoms reported more bodily pain and poorer functioning. 
Trauma and PTSD symptoms predicted an increase in healthcare utilisation, but this was 
not explained by CD4 count or viral load.  
 
2.5.5.1 Impact on disease progression 
The impact of stress on disease progression has already been discussed in the section on 
depression and disease progression. Research into the impact of anxiety disorders on 
progression is limited and the findings do not confirm a direct association between specific 
anxiety disorders and disease progression. Perry, Fishman and Jacobsberg (1992) found no 
association between emotional distress and biological markers of progression. One study, 
by Kimerling, Calhoun and Forehand (1999), found a high prevalence of traumatic 
stressors and PTSD in their small sample of HIV-seropositive women. In this study, 
traumatic stressors were significantly associated with lower CD4 to CD8 ratios at 1-year 
follow-up and those with PTSD symptoms as well had an even lower CD4/CD8 ratio. 
 
2.5.5.2 Impact on adherence 
A number of studies have shown an association between specific anxiety disorders and 
adherence and, therefore, an indirect effect on disease progression (Tucker, et al., 2003). In 
addition to the study by Tucker et al. (2003), Boarts, Sledjeski and Bogart (2006) found 
that PTSD had a negative impact on adherence, and Delahunty, Bogart and Figler (2004) 
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found an association of PTSD with worse adherence but also found lower morning salivary 
cortisol levels and higher CD4 counts.  
 
2.5.5.3 Impact on suicidal behaviour 
The impact of psychiatric disorders in general on suicidal behaviour in HIV-infected 
individuals has been discussed in the section on Depression. Although anxiety disorders 
have been associated with an increased prevalence of suicidal behaviour, it is difficult to 
separate these disorders from mood and substance use disorders in the affected individuals 
and it would appear that the latter two diagnoses have a particularly strong association with 
suicidal behaviour in this group.  
 
2.5.6 Impact of mental disorders on quality of life 
In terms of the impact of depressive or anxiety disorders on quality of life in HIV-infected 
individuals, the evidence is not specific for these disorders, but it is nevertheless likely that 
it is significant. Hays, Cunningham and Sherbourne (2000) reported on findings of the HIV 
Cost and Services Utilisation Study, which found that emotional well-being was 
significantly worse in HIV-infected individuals than in the general population and in other 
chronic disease populations (except for depression). There was no difference across the 
stages of the disease, but HIV-related symptoms were strongly associated with poor 
physical and mental health.  
 
2.6 Conclusion 
From the studies reviewed, it appears that depressive disorders in HIV-infected individuals 
internationally and in South Africa are a significant problem and that HIV-infection (or 
knowledge of HIV status) probably does increase the risk of developing a depressive 
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disorder, although the risk is probably similar to the risk in other chronically medically ill 
individuals. Whether or not there is actually an increased risk in HIV-infected, compared 
to non-HIV-infected individuals, the burden of depressive disorder is high in this group of 
individuals, and warrants treatment. Important risk factors for depressive disorders in HIV-
infected individuals, which have been identified in the literature, include: the individual’s 
clinical condition, their past psychiatric history, other co-morbid mental disorders such as 
substance abuse, the level of psychosocial stress to which they are exposed, a lack of social 
support and the individual’s particular coping style. There has been little research in terms 
of protective factors, but it has been suggested that personality characteristics, levels of 
spirituality and good social support may be important protective factors. The impact of 
depressive disorders on disease progression, adherence and suicidal behaviour is 
highlighted as an important reason why these disorders should be identified and treated. 
 
Evidence from prevalence studies of anxiety disorders is variable; few rigorously 
conducted studies have been conducted, and these do not show a significant difference 
between HIV-seropositive and HIV-seronegative individuals, although there appears to be 
a significant difference in levels of anxiety symptoms. The results are confounded by 
differing approaches to diagnosis and the considerable overlap of symptoms of anxiety 
disorders and depressive disorders. As with depressive disorder, the variability of the 
prevalence of anxiety disorders in both infected and uninfected populations across 
continents and countries is noted. The literature on risk factors for anxiety disorders in 
HIV-infected individuals emphasises the impact of psychosocial stress and the interaction 
of stress (both early in life and in adulthood) on neurobiological pathways that predispose 
the individual to anxiety disorders. The research on protective factors is extremely limited 
and is often linked with depressive disorders. A review of the literature indicates that the 
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impact of anxiety disorders on HIV-infected individuals is considerable in terms of 
adherence (and thus indirectly on disease progression), suicidal behaviour and quality of 
life. 
 
Therefore, depressive and anxiety disorders are common in HIV-infected populations. 
There is a wide variability in prevalence rates, some of which may be a reflection of 
methodological differences, or the variability in prevalence rates in general in community 
studies and primary care populations across the globe. While evidence exists that these 
disorders are at least as common in HIV-infected individuals as in people with other 
chronic diseases, it has not been proved that people with HIV-infection suffer greater 
emotional distress than people with other chronic illnesses.  
 
The information on prevalence, risk and protective factors in HIV-infected individuals in 
South Africa is limited. The aim of the current study was to explore some of these areas.
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CHAPTER 3 
 
METHODOLOGY  
 
3.1 Study design 
This was a cross-sectional, descriptive-analytic study.  
 
3.1.1 Study population 
The study population was as follows: 
1. All HIV-seropositive individuals attending HIV-wellness clinics run under the 
auspices of the Perinatal HIV research unit of the University of the Witwatersrand 
at the following sites: 
a. Chris Hani Baragwanath Hospital, in Soweto, Johannesburg, Gauteng 
b. Weiler’s Farm, an informal settlement south of Johannesburg, Gauteng 
c. Tintswalo Hospital in Limpopo Province. (During the study period, this area 
was incorporated into Mpumalanga Province). 
2. All patients attending the Nthabiseng HIV-clinic at Chris Hani Baragwanath 
Hospital. When the study started, the clinic included a general clinic on a 
Wednesday, where patients who were newly referred to the clinic, and those who 
did not yet qualify for anti-retroviral treatment, were seen. Patients receiving anti-
retroviral treatment were seen on all other days of the week once the anti-retroviral 
treatment roll-out was initiated (April 2005).  
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3.1.2 Inclusion criteria 
· All HIV-seropositive individuals over the age of 18 years attending the various 
clinics.  
· Willingness to be screened and interviewed.  
 
3.1.3 Exclusion criteria 
Any patient reluctant to participate in the study was excluded. An unforeseen exclusion 
criterion was that the potential participant was a prisoner. A number of prisoners attend the 
HIV clinic at Chris Hani Baragwanath Hospital for treatment. Prisoners can be included in 
research studies only with the consent of the head of Correctional Services. If a certain 
randomisation number had been allocated to a prisoner on a particular day, it was ‘skipped 
out’ and an additional randomisation number was used. The same strategy was used in the 
rare case that a particular individual selected by the randomisation strategy was not willing 
to participate.  
 
3.1.4  Sampling and Randomisation 
A randomisation strategy was used to select participants in the study on each day of interviews. On 
each clinic day, patients were given a number according to their place in the queue (this is a normal 
routine at the clinics). Random numbers were computer-generated and potential participants were 
selected using these numbers. The total number of numbers for each day was estimated based on 
knowledge of the daily patient load at each clinic. The number of patients attending each of the 
sites daily varied according to the site. During the year of data collection, the number of patients 
attending PHRU Wellness clinic at Chris Hani Baragwanath Hospital was limited to a maximum of 
thirty patients a day. The clinics at Weiler’s Farm and Tintswalo saw fewer patients (about 10 to 20 
per day). The numbers of patients attending the HIV clinic at the hospital ranged from 40 to 80 per 
day. Randomisation sheets were produced by the statistical department at the Peri-Natal HIV 
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Research unit, taking into account the varying daily attendance at each site. Therefore, for a busy 
day at Nthabiseng Clinic, random numbers were generated from a list of 1 to 60. On a 
quiet day in Tintswalo, random numbers were generated from a list of 1 to 10. 
 
 
3.2 Measurements 
3.2.1 Interview for obtaining demographic information and exploring risk and 
protective factors 
A semi-structured interview was conducted with all participants to explore factors that may 
have been associated with the presence of a mental disorder in general or a more specific 
depressive or anxiety disorder. Some factors postulated as protecting individuals from 
these disorders were also explored. The following factors were considered: 
· Demographic variables: age, gender, level of education, employment status, 
relationship status, household situation (financial status) 
· Clinical indicators of HIV disease stage: WHO Clinical Stage, CD4 count, presence 
of other medical conditions 
· Treatment with anti-retroviral medication 
· Duration of knowledge of HIV status 
· The amount and quality of voluntary counseling and testing 
· Utilisation of support groups 
· Impact of disclosure 
· Impact of stigma/discrimination 
· Feelings of isolation 
· Religious faith as a coping mechanism 
· Significant losses/bereavement 
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· Other significant psycho-social stressors 
· Past history of psychiatric disorder 
· Past or present substance use disorder 
The role of personality and coping style were not explored, as this would have lengthened 
the interview considerably. 
 
3.2.2 Screening for psychiatric disorder 
Patients recruited for the study were screened, using the overview from the Structured 
Clinical Interview for DSM (SCID) non-patient, primary care version (First, Gibbon & 
Spitzer, 2002). This tool includes a screen for psychosis, but lacks a screen for cognitive 
disorders associated with HIV, so in addition, the International HIV Dementia Scale 
(IHDS) was used to screen for possible cognitive impairment.  
3.2.3 Diagnostic interview 
The research version of the SCID, non-patient, primary care version, with psychotic screen 
(First, Gibbon & Spitzer, 2002) was then used to interview participants who screened 
positive for a possible mental disorder. The interviews were conducted in English. Where 
the study subject was not fluent in English, the research assistant translated during the 
interview. 
 
3.2.4 Rating of severity of disorder 
All patients identified as suffering from a current depressive disorder were rated using the 
Montgomery-Asberg Depression Rating Scale (MADRS) to describe the severity of the 
depressive disorder (Montgomery & Asberg, 1979). The MADRS is a more preferable 
measure of depression than the Hamilton Depression Rating Scale in people with co-
morbid physical illnesses, as it depends less on somatic symptoms of depression, which 
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could be confounding factors in this context (Khan, Broadhead & Kolts, 2004). All patients 
identified as suffering from a generalised anxiety disorder were rated using the Hamilton 
Anxiety Rating Scale (HAM-A) to describe the severity of the anxiety disorder (Bruss, 
Gruenberg & Goldstein, 1994). 
 
3.2.5 Staging of HIV infection 
Information regarding the staging of HIV-infection for every participant was obtained from 
the clinical file by the investigator, as was any relevant information regarding physical 
illnesses, laboratory investigations and medication that the subject was receiving. The 
staging was at the time of the interview, based on information in the file as well as the 
current history of the individual’s condition obtained from the participant.  
 
3.3 Statistical considerations 
The expected occurrence of depressive and anxiety disorders in this population ranges 
between 10% and 40% (from international literature). The conservative approach to 
determining the sample size was to consider an expected outcome of 40%. In order to 
detect an occurrence of 40% (with an accuracy of 7%), at the 95% confidence level, a 
sample of 180 was necessary (Elashoff, 2003). In addition, various variables (see section 
2.4) were explored in terms of their relation to depression and anxiety. No more than 12 
variables were expected to enter into a multivariate analysis. Hence, the suggested sample 
size of 10 to 15 subjects for every variable studied was met. Variables entered into 
multivariable analysis were those significant at a 0.20 level of significance in a univariate 
analysis.  
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The study sample therefore had to include a minimum of 180 people from the study sites. 
As outlined in the table below, 302 subjects were enrolled and interviewed. 
Table 3.1 Study sample 
Sample PHRU Weilers Tintswalo 
Nthabiseng 
Bara Gen 
Nthabiseng 
Bara ARV Total 
Target sample 90 30 30 30  180 
Actual Sample 111 41 30 60 60 302 
 
3.4 Preparatory work 
3.4.1 Planning the questionnaire 
Initial planning work was done in collaboration with Professor Melvyn Freeman of the 
Human Sciences Research Council, who was engaging in a similar study. The two 
researchers developed an initial questionnaire exploring risk and mitigating factors 
together. The research assistant for this study, a trained psychiatric nurse with extensive 
experience, conducted interviews for Professor Melvyn Freeman prior to the initiation of 
this study. From this work, it was possible to revise the questionnaire used in this study in 
terms of the way in which questions were asked and the content of some of the questions. 
During this phase significant issues in relation to the quality of pre-test counseling were 
raised. As a result, an additional interview schedule was developed, which was 
administered to a sub-sample of study subjects. This interview explored various aspects of 
pre-test counseling.  
 
Professor Melvyn Freeman also conducted individual semi-structured interviews with/of a 
number of HIV-positive individuals who were involved with an NGO in Grahamstown. A 
review of the information obtained from these interviews confirmed that the most 
significant issues raised had been included in the questionnaire for this study. 
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In addition, a focus group discussion with staff working in the wellness clinic at the PHRU 
at Chris Hani Baragwanath Hospital was facilitated by the investigator and research 
assistant. The aim this discussion was to inform staff of the purpose and methodology of 
the study, and to obtain information regarding their perceptions of the prevalence of 
psychiatric disorder in their clinic, the possible presenting symptoms and risk and 
mitigating factors. The information obtained from this discussion confirmed that relevant 
factors were to be explored. The discussion also highlighted the fact that the practitioners 
working in this service are very aware of the mental health issues related to HIV, but are 
often at a loss about to how to deal with these issues. The information obtained from this 
discussion was presented in poster form at the International AIDS Impact conference in 
Cape Town in April 2005. 
 
3.4.2 The diagnostic interview  
Considerable time was spent in exploring issues surrounding psychiatric diagnosis and 
research methodology in psychiatry. Various psychiatric diagnostic instruments were 
considered before the SCID was selected as the most appropriate for the purposes of this 
study.  
 
In a research setting, the presence or absence of a mental disorder needs to be established 
according to internationally agreed-upon criteria. It should also be possible to make 
comparisons between various studies of the same disorder. Therefore, a structured 
approach, using standardised criteria for particular disorders, needs to be applied.  
 
As evident from the literature review, considerable confusion exists regarding psychiatric 
diagnoses in research, and conclusions are sometimes drawn regarding psychiatric 
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diagnoses from studies that use screening instruments or rating scales. In a research 
context, when being particular about standardised diagnoses is required, it is necessary to 
consider the difference between screening tools, diagnostic instruments and rating scales. 
 
Screening tools are used to identify/elicit disorders in a large population. They need to be 
easy and quick to administer and they need to detect all possible cases of disorder. They 
therefore need to be highly sensitive to the possible presence of disorder, but there should 
also be a number of “false positives” detected (not very specific). Examples of screening 
tools for depression are the Self-Reporting Questionnaire (SRQ) (Cherian, Peltzer & 
Cherian, 1998), the General Health Questionnaire (GHQ) (Schmitz, Kruse & Heckrath, 
1999), the Centre for Epidemiological Studies – Depression subscale (CES-D) (Radlof, 
1977; Cheng & Chan, 2005), and the Prime-D (Fisher & Copenhaver, 2006). 
A consideration of the CES-D highlights some of the difficulties involved in using 
screening tools in research studies. The original screening tool is a 20-item self-report 
measure, which includes screening for cognitive and affective symptoms as well as 
somatic symptoms of depressive disorder. Somatic symptoms are confounders in the 
presence of physical illness. Therefore, an alternative CES-D 10-item scale which excluded 
these symptoms was subsequently developed. The CES-D reports current symptomatology 
for the past seven days.  
 
That the duration diagnostic criterion for DSM1VR Major Depressive Disorder is the 
presence of symptoms for at least two weeks already indicates the problems intrinsic to 
using this instrument to make a diagnosis. In a 1985 validation study (Breslau, 1985) 
comparing diagnoses made with the Diagnostic Interview Schedule (DIS), which at the 
time was considered the “gold standard” psychiatric interview schedule determining 
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Research Diagnostic Criteria and Feighner Criteria (equivalent to DSM111 diagnostic 
criteria), it was found that the CES-D did not discriminate adequately between major 
depression and generalized anxiety disorder. It was also found that it had high sensitivity 
but low specificity (in keeping with the purposes of a screening tool) and “high” scores on 
the CES-D should be considered a reflection of depressive symptomatology, which cannot 
be equated with a clinical diagnosis of major depressive episode (MDE). The CES-D has 
been used in a number of studies on depression in HIV. Both the 20-item and the 10-item 
scales have been used. A significant problem when comparing studies in this field using 
this tool is the variation in cut-off scores and their definitions: some researchers use a cut-
off of 16 or more as equivalent to a major depressive disorder, whereas others have defined 
this as “probable depression” and others use a cutoff of 23 or more for MDE for the 20-
item scale. One study by Cheng suggested a cutoff of 12 for the 10-item scale (Cheng, et 
al., 2005). Of note is that the 20-item CES-D has been validated in South Africa (Pretorius, 
1993) and used in a recent study in HIV-positive mothers to assess depressive 
symptomatology (Swartz, Brandt & Dawes, 2005). 
 
Rating scales: once a diagnosis has been made, these are used to determine the severity of 
the disorder in question, and to track response or progression longitudinally. Examples of 
rating scales include the Beck Depression Inventory (Storch, Roberti & Roth, 2004), the 
Hamilton Anxiety and Depression Rating Scales (Bagby, Ryder & Schuller, 2004), and the 
Montgomery-Asperg Depression Rating Scale (Montgomery, et al., 1979). 
 
Diagnostic instruments make a diagnosis of a mental disorder. These are usually structured 
clinical interviews. Examples include the Diagnostic Interview Schedule (DIS) (Robins, 
Helzer & Croughan, 1981), the Structured Clinical Interview for DSM (SCID) (Segal, 
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Hersen & Van Hasselt, 1994), the Composite International Diagnostic Interview (CIDI) 
(Kessler & Ustün, 2004; Haro, Arbabzadeh-Bouchez & Brugha, 2006), the Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN) (Wing, Babor & Brugha, 1990) and the 
Mini International Neuropsychiatric Interview (MINI) (Sheehan, Lecrubier & Hairnet-
Sheehan, 1998). Some of the differences between these instruments are outlined in the 
table below. 
Table 3.2 Diagnostic instruments used in psychiatric epidemiological studies 
Diagnostic 
instrument 
Administered 
by: 
Training Diagnoses Analysis 
SCID Clinician Self-guided with 
user’s guide and 
videos 
Current and 
lifetime (DSM) 
Computerised 
or manual 
CIDI Lay person Structured 
training 
1-month, 12-
month and 
lifetime 
versions (ICD) 
Computerised 
only 
MINI Clinician Self-guided Current (DSM) Manual 
SCAN Clinician Structured  ICD Comp/manual 
The SCAN developed from the Present State Examination (PSE) (Wing, Cooper & 
Sartorius, 1974), which the investigator had used in previous epidemiological research. 
However, this instrument only produces diagnoses of the subject’s current mental state and 
not life-time diagnoses. Since a key question in the research was the relationship between 
the stage of HIV infection, knowledge of diagnosis and psychiatric disorder, it was 
important to be able to make diagnoses across the subject’s lifetime. In addition, the SCAN 
now requires intensive training by an accredited SCAN trainer. There are none in South 
Africa. Analysis of data is by a computer programme, which involves considerable 
expense. The SCAN was therefore not suitable for the purposes of this study. 
 
The CIDI is an interview schedule that can be administered by trained non-clinicians. It is 
recognized by the WHO as a user-friendly and appropriate interview schedule that can be 
used in a range of settings in order to conduct epidemiological research on mental 
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disorders. It has been used in a number of epidemiological research studies conducted 
recently by the WHO, including one such study in South Africa, the SASH study 
(Williams, et al., 2004). However, no-one is not allowed to use this instrument without 
training by the developers of the CIDI at the University of Michigan. Again, the results are 
analysed by a computer programme. The difficulties around obtaining permission to use 
the CIDI and the training and expense involved resulted in a decision not to use it. It is to 
be noted that the SCID was used in the South African SASH study to validate the CIDI. 
 
The Mini International Neuropsychiatric Interview (MINI) is a shortened mental state 
examination that takes a trained clinician 15 minutes to administer. It is user-friendly and 
available in the public domain and does not require any additional training in order to be 
able to administer it. However, it also does not test for lifetime depressive disorders (only 
for recurrent major depressive disorder if there is a current major depressive episode), 
lifetime anxiety or substance use disorders. It also lacks a category for depressive disorders 
that do not meet criteria for a Major Depressive Episode, or for adjustment disorders.  
 
The Structured Clinical Interview for DSM-1V-TR Axis 1 Disorders (SCID)  
The SCID (First, et al., 2002) is a structured clinical interview that can be used to assess 
mental disorders and provide diagnoses according to the definitions and criteria of the 
fourth edition (revised) of the American Psychiatric Association’s Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV-TR) (American Psychiatric Association, 
2000). The SCID has been used in a variety of countries, cultures and settings (Wilson & 
Young, 1988; Buntting & Wessels, 1991; Williams, Spitzer & Gibbon, 1992). It is 
administered by a clinician or trained mental health professional who is familiar with the 
DSM-IV classification and diagnostic criteria (American Psychiatric Association, 2000). 
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The SCID has a research version and a clinical version. It consists of an overview section 
that allows the participant or patient to describe current and past psychiatric symptoms, and 
the researcher/clinician to explore the significance of such symptoms. The remainder of the 
SCID has a modular design which enables the researcher or clinician to eliminate 
consideration of major diagnostic classes that are irrelevant to their purposes. 
 
The research version of the SCID is more comprehensive than the clinician version, but is 
designed to be used flexibly, depending on the circumstances of the individual study. The 
SCID is considered the gold standard in terms of making DSM research diagnoses and has 
been validated for use in both community and clinical populations in a range of countries 
and contexts (Segal, et al., 1994). Most other diagnostic instruments are validated by 
comparing them to the SCID (Haro, et al., 2006). Using the SCID, it is possible to obtain 
current and lifetime diagnoses. [Lifetime diagnoses include the diagnosis of a mental 
disorder at any time up to one month before the administration of the interview.] 
 
The schedule is available from the developers, together with an 11-hour training 
programme on video. While a computer programme is available for analysis of results, this 
can also be done by the researcher, using a simple spreadsheet and statistical package.  
 
Of the versions of the SCID, that chosen for this study was the primary care version, which 
is used in non-psychiatric (primary care) treatment settings. It includes a screen for 
psychotic disorders. The SCID was considered to be the most suitable diagnostic 
instrument as it is an appropriate instrument for experienced clinicians to use, training is 
accessible and not too expensive; it is available without undue regulation, has been well-
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tested in many settings and is considered to be the gold standard in terms of psychiatric 
research interviews. 
 
V-codes: 
The SCID also generates V-codes as listed in the DSM classification. These are conditions 
that are not psychiatric disorders, but they are significant in that they often nevertheless 
require a mental health intervention. Examples of V-codes include bereavement and 
problems in interpersonal relationships (partner relational problem, parent-child relational 
problems. 
 
3.4.3 The International HIV Dementia Scale 
The SCID does not include any assessment of cognitive functioning. However, none of the 
other interview schedules listed above do this either. In order to cover this area, the 
International HIV Dementia Scale was used to screen for possible dementia due to HIV 
disease. This screening instrument has been found to have good sensitivity and adequate 
specificity in study populations in both the United States of America and Uganda in Africa 
(Sacktor, Wong & Nakasujja, 2005). See Appendix 2. 
 
3.5 Logistics 
3.5.1 Responsibilities of investigator 
Training and preparation for data collection 
The principal investigator and the study coordinator/research assistant were trained in 
administration of the SCID. The principal investigator also familiarised the research 
assistant with the complete interview schedule (semi-structured and diagnostic interviews), 
so that the interviews could run smoothly when translated/assisted by the professional 
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nurse/study coordinator. The research assistant also received training in GCP principles, 
recruitment procedures and collection of clinical data from the clinical records. The 
investigator supervised the research assistant throughout the study.  
 
Information and training regarding the study was also provided for the clinicians/health 
workers at the study sites, as well as appropriate interventions (and referral resources) for 
patients who were identified to be in need of mental health intervention. 
 
Preparation for data collection 
The investigator prepared the case-report form (CRF) and the interview schedules in 
liaison with staff involved in data management at the PHRU. The CRF was prepared in a 
way that allowed scanning of the forms into a database. Quality control checks were then 
routinely completed to ensure that data entered was correct. 
Data collection  
The investigator and the study coordinator/research assistant were responsible for 
obtaining informed consent from each subject, for conducting the interviews and 
completing the case report form (CRF). 
 
Data management and analysis 
The data management department at the PHRU entered CRFs into a database and provided 
quality control over the data. Assistance with analysis of the data was obtained from the 
Epidemiology Data Centre of the Faculty of Health Sciences, University of the 
Witwatersrand, and the Biostatistics Unit of the Medical Research Council of South Africa.  
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3.5.2 Responsibilities of staff 
A research assistant/study co-ordinator, Ms Dumi Masondo, was appointed to assist with 
the study. She is a trained professional nurse with a qualification in psychiatric nursing. 
The study co-ordinator was responsible for co-ordinating the study, liaising with clinical 
staff at the various study sites, recruiting study subjects according to the randomization 
strategy, assisting in obtaining informed consent for the study, collecting clinical 
information from the subjects’ clinical records and for assisting with translation for the 
principal investigator during interviews. She also assisted with the keeping of the study 
records, together with the data management department, and ensured proper data control 
procedures. Clinical staff working in the study sites worked closely with the investigator 
and the study co-ordinator.  
 
3.6 Time schedule 
1. The research protocol was submitted to the Postgraduate Committee in September 
2003. Revisions were required, which included changing the psychiatric screening 
and diagnostic interview, improving the randomisation strategy and clarifying the 
rating scale for depression, which was to be used in the study. The committee 
finally approved the protocol on 20 October 2004.  
2. The research protocol was submitted to the Committee for Research on Human 
Subjects (medical) in September 2003 and the committee approved the study. 
Amendments to the protocol were submitted to the committee in August 2004 and 
these were approved by the chairperson of the committee on 24 August 2004.  
3. Approval from authorities at the various institutions was obtained. This included 
approval from the hospital management of Chris Hani Baragwanath Hospital, 
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Tintswalo Hospital, the Johannesburg Metro District Health Service, and the 
provincial health departments of Gauteng and Limpopo/Mpumalanga.  
4. Preliminary exploratory work was conducted from September 2003 to September 
2004.  
5. Preparation of research instruments took from February 2004 to September 2004. 
6. Preparation of protocols and referral resources for clinical staff and orientation of 
clinical staff to the study took place from July to October 2004. 
7. Data collection was done from November 2004 to November 2005 
8. Results were analysed and the thesis was written up between January 2006 and 
January 2008. 
 
3.7 Data management and analysis 
Data capture was carried out by data management staff of the Peri-Natal HIV Research 
Unit at Chris Hani Baragwanath Hospital. Analysis was done by the investigator, with 
assistance from Dr Piet Becker from the Medical Research Council and Mr. Eustacius 
Musenge from the Epidemiology Data Centre at the Faculty of Health Sciences. The 
Enterprise Guide for SAS Version 3 (SAS Version 9.1) (SAS institute inc., 2007) and 
STATA (Statacorp, 2007) were both used for the statistical analysis of the data. Univariate 
logistic regression analysis to identify significant risk and mitigating factors for mental 
disorders was carried out. Further multivariate analysis was undertaken only on those 
variables that were significant at a < 0.2 level of significance. 
 
3.8 Resources 
This study was conducted with financial support from the Division of Psychiatry of the 
University of the Witwatersrand, USAID (through its funding of the Perinatal HIV 
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Research Unit of the University of the Witwatersrand and the Human Sciences Research 
Council (Social Aspects of HIV/AIDS). Additional funding was obtained from the 
National Research Foundation (NRF) (through a Thutuka Grant to the investigator) in 2005 
and 2006. The Biostatistics Unit of the Medical Research Council and the Epidemiology 
Data Centre of the Faculty of Health Sciences, University of the Witwatersrand provided 
assistance with statistical analysis of the research. 
 
3.9 Ethical and legal considerations 
The study was introduced at all the study sites by clinicians working at these sites. In order 
to ensure confidentiality of HIV status, clinical staff advised patients of the study before 
they were approached by the researchers. Only patients who agreed to be approached were 
included in the recruitment process. All participants were clearly informed about the 
purpose of the research. Furthermore, they were provided with an opportunity to decide 
whether or not they wanted to participate in the study.  
 
3.9.1 Risks and benefits 
There were no risks associated with the study. The benefit was that early intervention and 
treatment was offered to individuals with a positive psychiatric diagnosis. 
 
3.9.2 Privacy and confidentiality  
Every effort was made to keep all patient information private and confidential. Participants 
were assigned study numbers to identify them in the study, and were not identifiable by 
name on the data collection forms. All source data remains in secure sites at the Peri-Natal 
HIV Research Unit or at the study sites. All staff involved in the research followed 
standard procedures (both in operation at the sites, and in relation to mental disorders) to 
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ensure confidentiality. These were described to the staff in the information sessions held 
before the study commenced.  
 
3.9.3 Compensation 
Participants did not receive any financial compensation for taking part in the study. 
However, their transport and refreshment costs were reimbursed. Each participant at the 
study sites in Gauteng received R30. The issue of this payment at Tintswalo generated 
some concern amongst the staff and directors of the service. Thirty rand in a poverty-
stricken rural context was considered a perverse incentive and the staff there was opposed 
to our providing the participants with this amount of money. They felt that it could create 
conflict within the patients, particularly those who were not selected in the randomisation 
process. It was finally agreed that the money allocated for payment to the study subjects 
each day would be pooled and a meal for all the patients attending the clinic that day was 
provided out of this fund. It was felt that all the patients contributed to the study, either by 
participating directly or by waiting longer than usual for service as a result of staff 
involvement in the research.  
 
3.9.4 Conflicts of interest 
There were no conflicts of interest in this study. 
 
3.9.5 Informed consent 
Written informed consent was obtained for all aspects of this study. This included consent 
to access the participants’ clinical records, and also included consent from all staff 
participating in the focus group discussion.  
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The information letter and consent form was read, explained and given to individual 
participants. The investigator ensured that the participant understood the information, the 
potential risks and benefits, confidentiality and privacy issues.  
 
If a potential participant was unable to give informed consent, s/he was to be included only 
if a responsible escort was in a position to give proxy consent. This did not happen with 
any of the participants who were interviewed. A number of participants were unable to 
read or write. In these cases, with the participants’ agreement, their consent was witnessed 
by an independent person.  
 
3.9.6 Follow-up for mental disorders 
All study subjects were informed of the availability of treatment for psychiatric disorders. 
The staff working at the study sites received some training and information regarding the 
management of common mental disorders. Study subjects were encouraged to discuss any 
concerns with their treating clinicians. Possible treatments included medication, 
psychotherapy, counselling or involvement in a support group and/or referral to a 
specialised mental health service. These were offered singly or in combination. Protocols 
for the use of anti-depressant medications available on the primary level Essential Drugs 
List (EDL) in Gauteng and Limpopo were provided at the study sites. Criteria for referral 
to a psychiatrist/mental health service were also provided. 
 
Participants identified as needing a mental health intervention, (or who needed attention 
for a physical disorder, including possible HIV dementia) were referred to the clinician 
who was primarily responsible for their treatment. If this clinician could manage the 
problem, no further action was taken. However, where the researcher felt that the 
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participant needed a specialist mental health referral, this was discussed with the 
responsible clinician and the researcher made a referral to the nearest mental health 
service. A copy of the referral letter was inserted into the participant’s clinical record. 
 
Contingency plans were discussed beforehand with regard to a possible situation where the 
investigator might be urgently concerned about the mental condition of a study subject. It 
was agreed that she would ask the subject if she could inform the treating clinician of her 
concern and ensure that the subject was seen by a clinician who could take over the 
management of the mental disorder. If the study subject refused such referral or treatment 
and the investigator remained concerned, the investigator would then inform the head of 
the HIV service, or the delegated responsible person, immediately and a joint decision 
would be made regarding the management of the individual. It could have become 
necessary in such a case for the principal investigator/head of the HIV-service to identify 
the subject in order to ensure that the subject received the necessary intervention and for 
procedures in terms of mental health legislation to be followed. The training of the study 
co-ordinator and the input provided to the clinical staff working at the study sites covered 
these aspects, and they were given information regarding management of common mental 
disorders, indications for referral to a mental health service and a list of referral resources. 
The mental health service, in the district health service and at the hospitals, was also 
informed of the study, and the possibility of referrals for emergency management. 
However, no subject required urgent psychiatric intervention and no-one refused referral to 
a mental health service when this was suggested.  
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3.9.7 Ethical approval 
This study was approved by the University of the Witwatersrand Human Research Ethics 
Committee (Medical) on 26 September 2003, with a further approval of an amendment to 
the protocol on 24 August 2004 (Protocol Number: 03-09-51; ref R14/49 Thom) 
 
3.10 Critique of study methodology  
Because this was a cross-sectional descriptive analytic study, it was able to provide a 
picture of participants’ lives at a particular point in time. For collecting data on current 
mental status, this is adequate, but a richer and probably more accurate picture would have 
been obtained in a prospective longitudinal study. The recent report by Swartz et al. 
(2005), which (amongst other things) explored the mental health of young HIV-
seropositive mothers, exemplifies how such research could be done. In terms of exploring 
risk and protective factors, again, a more comprehensive assessment would have been 
obtained using a longitudinal study design, with more qualitative research methods. These 
are, however, labour- and time-intensive, so the methodology was chosen as above. These 
factors must, however, be borne in mind when considering the results of the study. 
 
Much of the literature in the area of HIV and mental disorders reports on psychiatric 
symptomatology as well as disorders. For example in the WHO study (Maj et al, 1994)), in 
addition to using the CIDI to make a diagnosis of a depressive disorder, the MADRS was 
administered to all participants to generate rates of depressive symptomatology. In this 
study the MADRS was completed only for those participants who were identified as 
having a depressive disorder. This gave an indication of the range of severity of these 
depressive disorders. Using the MADRS in all participants gives an indication of the extent 
of depressive symptomatology in all participants. It is not clear how useful assessing 
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symptomatology is. On the one hand, it can identify individuals who are distressed but who 
do not meet criteria for a depressive disorder. On the other hand, one would expect that 
there should be an association between depressive disorder and higher scores on a rating 
scale, so that outlining the extent of depressive symptomatology is not likely to add much 
information about the participants. In addition, rating symptomatology in this manner gives 
a result at a particular point in time, i.e. at the time of the interview, and is dependent on 
the individual’s feelings at that particular point in time, which may be transitory. How 
useful this is in terms of assessing an individual’s need for intervention is debatable. 
 
There has been considerable research examining the influence of language and culture on 
the diagnosis of disorders; particularly, depressive and anxiety disorders (Swartz, 1998). 
While understanding of these disorders has advanced from biological, psychological and 
social perspectives, the question remains as to whether mental disorders and diagnostic 
criteria are standard across cultures. Both quantitative epidemiological studies and 
qualitative ethnographic research can contribute to our understanding of these disorders 
across cultures. This research is based on the premise that depressive and anxiety disorders 
(and other mental disorders) do exist in all cultures and can be diagnosed through using 
standardised diagnostic instruments. Recent ethnographic research in Africa has provided 
interesting evidence of this in the area of depressive disorders and the HIV epidemic 
(Wilk, et al., 2002). While there are valid concerns about using a categorical approach to 
diagnose mental disorders in people who are individuals, in differing cultural contexts, the 
DSM or ICD systems, imperfect as they are, provide the best approach available thus far, 
in terms of comparing disorders across studies. 
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CHAPTER 4 
 
RESULTS 
 
Three hundred and two interviews were conducted as set out in the table below. 
Table 4.1: Breakdown of participants by site 
Site name Site number Number of 
interviews  
Wellness PHRU  1 111 
Wellness Tintswalo 2 30 
Nthabiseng General clinic CHB 3 60 
Nthabiseng ARV clinic CHB 4 60 
Wellness Weiler’s Farm 5 41 
Total  302 
 
4.1 Demographic characteristics of study sample 
Just over seventy percent (70.2%) of the participants were female and 29.8% were male. 
The mean age of the study sample was 36.3 years, with a range from 19 to 63 years. Just 
over sixty percent (60.6%) of the participants described themselves as currently single, 
divorced or widowed and 39.4%, as married or in a long-term relationship. Most (83.11%) 
of the participants had children, with a mean number of children (alive) of 1.92. 
 
Only 17% of the study sample had completed secondary education. Unemployment in the 
study sample was high: almost seventy percent (69.87%) of the participants were 
unemployed; 19.87% were in part-time employment, self-employed or had “piece jobs” 
and 10.26% were in full-time employment. Forty percent (40%) of the participants felt that 
they had insufficient financial income to provide for even the most basic needs (food and 
clothing), while 47% of the participants felt they had just enough funds to provide for basic 
needs alone. Only 13% felt they were able to afford most of the important things in their 
households. While there may have been some reporting bias in this subjective reporting, 
 Results 
 86 
the findings did indicate that the study population came from a socially deprived and 
disadvantaged sector of the population.  
 
4.2 Clinical characteristics of the study sample 
Clinical stage 
At the time of their interviews, seventy-two percent of the participants were in WHO 
Clinical Stage 1 or 2, and 28% were in Stage 3 or 4.  
 
CD4 count 
Two hundred and seventy-three participants had at least one CD4 count recorded in their 
clinical files. The mean for the most recent CD4 count of these participants was 243 
cells/ml. One hundred and fifty-four (51% of the total sample) and 56.4% of those who had 
a CD4 count (n=273) had a count of <200 cells/ml. This indicates the minimum number of 
participants who qualified for HAART at the time of the study. (Participants who did not 
yet have a CD4 count result may also have had a count < 200 cells/ml.) 
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Figure 4.1: Percentage of participants in each CD4 count category 
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Viral load 
Ninety-nine participants had a recorded viral load. Ninety-four of these participants were 
patients at the HIV clinic at Chris Hani Baragwanath Hospital. The mean viral load was 
1,128,938 copies/ml, with a range from 25 copies/ml to 50 million copies/ml. 
 
Anti-retroviral therapy 
Seventy participants (23.18%) of the total sample had started anti-retroviral therapy at the 
time of their interview. This is in contrast to the 154 (51%) of participants who qualified 
for anti-retroviral therapy at the time of their interview. Ninety percent of the participants 
receiving ART were attending the HIV clinic at Chris Hani Baragwanath Hospital. 
 
 
 
 
 
 
 
 
. 
Figure 4.2: Number of participants on ART by CD4 count category 
From the table above, it can be seen that only about a third of participants with a CD4 
count of < 200/ml were on HAART at the time of their interview. Many of these were 
waiting to start treatment. From the table it can be seen that a number of individuals were 
on HAART and had CD4 counts > 200 cells/ml. These were individuals who had been on 
treatment for some time, and is probably an indication of their response to treatment.  
CD4 count vs ART
0
20
40
60
80
100
120
> 500 351-500 201-350 <200
CD4 count
N
o 
of
 p
ar
tic
ip
an
ts
ART
No ART
 Results 
 88 
Table 4.2: Viral load by ART 
ART N Mean viral load 
(copies/ml) 
Range (copies/ml) 
Not on ART 43 1 420 026 4 000 to 50 million 
On ART 56 905 425  25 to 22 million 
 
The difference in mean viral load between those on ART and those not on ART was not 
statistically significant. This was to be expected, since many participants had only recently 
commenced ART and data on duration of ART treatment was not obtained. 
This information may not be that useful, since there may be a number of reasons for a high 
viral load. It would have been more useful to identify those on HAART with an 
undetectable viral load as a measure of the success of treatment. 
 
Medical conditions in addition to HIV infection 
Over 40% of the study sample (n=127; 42.05%) had, in addition to HIV infection, at least 
one other medical condition. Almost 75% (74.02%) of these could be directly related to 
HIV infection. The most common opportunistic condition was tuberculosis.  
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4.3 Demographic and clinical characteristics of participants by site 
Table 4.3: Summary of demographic and clinical characteristics by site 
 Site 1 
PHRU 
Site 2 
Tintswalo 
RADAR 
Site 3 HIV 
CHB General 
(Wed) 
Site 4 
HIV 
CHB 
ART 
Site 5 
Weiler’s 
Farm 
Total 
Participants (n) 111 30 60 60 41 302 
Gender M:F (%) 15: 85 30: 70 37: 63 48: 52 32: 68 30: 
70** 
Mean Age (yrs) 32.8 39.7 38.7 39.1 35.8 36.3** 
Relationship status 
single: in relationship 
(%) 
60: 40 60: 40 58: 42 57: 43 71: 29 61: 39 
Mean No of children 
(n) 
1.8 2.9 2.0 1.5 2.0 1.9 
Household situation: 
Cannot afford basics 
(%) 
34 50 30 32 76 40** 
Employment status: 
Unemployed (%) 
60 80 77 68 80 70** 
Part-time 
employment (%) 
30 17 8 18 15 20 
Full-time 
employment (%) 
10 3 15 13 5 10 
Level of education 
Completed secondary 
education (%) 
28 7 13 13 7 17** 
Clinical stage 1 (%) 55 13 18 23 51 37** 
Clinical stage 2 35 20 37 45 27 35** 
Clinical stage 3 10 64 33 20 20 23** 
Clinical stage 4 0 3 12 12 2 5** 
Mean CD4 
(cells/mm3) 
356 285 140 132 260 243** 
CD4 < 200 (%) 26 40 80 82 39 51** 
Number on ART (%) 1 13 27 78 5 23** 
Medical condition 
(%) 
28 20 63 52 51 42** 
** Statistically significant difference between sites (p<0.05) 
* Some significance (p<0.2) 
Notes: 
1. Overall, there was a statistically significant difference in gender ratio, mean age, level of education, 
employment status and household situation between sites (p<0.05). There was no significant difference 
in relationship status or in the mean number of children between sites.  
2. There was a statistically significant difference in clinical stages at the different sites with more people 
being in Stage 1 at the PHRU and Weiler’s Farm sites (p<0.05).  
3. There was also a statistically significant difference in mean CD4 count at the different sites (p<0.05). 
Participants at the Nthabiseng HIV clinics at Chris Hani Baragwanath Hospital had significantly lower 
mean CD4 counts than those at the other three sites.  
4. Significantly more participants at the Nthabiseng sites and at Weiler’s Farm had concurrent medical 
conditions than those at PHRU or Tintswalo. The Nthabiseng general HIV clinic had the most 
participants with a medical condition.  
 
 Results 
 90 
In general, participants attending PHRU Wellness clinic were more likely to be female, 
and in the earlier stages of HIV infection, with a higher mean CD4 count and fewer 
associated medical conditions.  
 
Participants at Tintswalo hospital were older than those at the other sites, were 
predominantly female, were less educated, had more children and were predominantly in 
the later clinical stages of HIV infection, although they had an intermediate mean CD4 
count.  
 
Participants at both the Nthabiseng clinics at Chris Hani Baragwanath Hospital were also 
generally older and there were more males attending at this site than at any of the other 
sites. In general, more participants had a higher level of education, were employed (either 
full-time or part-time) and were better-off financially than those at the other sites. They 
were, however, more medically ill, with more associated medical conditions and the lowest 
mean CD4 counts, although fewer participants were in Stages 3 and 4 than at the Tintswalo 
Hospital site. 
 
The Weiler’s Farm site had the most participants with low levels of education, who were 
single and considered themselves the worst off in terms of financial status. Gender ratio 
and clinical indicators were intermediate between the Nthabiseng clinics and Tintswalo 
Hospital.   
 
4.4 Demographic and clinical characteristics by gender 
Females were in the majority in the sample. There were statistically significant gender 
differences in age, levels of education and relationship status (p<0.05). Females were 
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generally younger (mean age 34.9 years vs. males mean age 39.5 years; p<0.0001), better 
educated and more likely to be in a relationship than males in the sample. 
 
There was also a statistically significant gender difference in clinical stage (p=0.0155): 
females were more likely to be in Stage 1 or 2 of HIV infection. The difference in mean 
CD4 count between genders was also statistically significant (p=0.0003). The mean CD4 
count in males was 167 cells/ml and in females it was 274 cells/ml.  
 
4.5 Occurrence of mental disorders in the study sample 
Although the primary focus of this study was on depressive and anxiety disorders, other 
mental disorders were found in the participants, which could have been confounders or 
contributors to the occurrence of depression and anxiety. For example, substance use 
disorders are commonly associated with mood and anxiety disorders, and medical 
conditions can also produce organic mood and anxiety disorders. The sample was therefore 
analysed for the presence or absence of a current and lifetime mental disorder or a V-code. 
 
The mental disorders included in the analysis were: 
1. Mood disorders 
2. Anxiety disorders 
3. Substance use disorders 
4. Adjustment disorders 
5. Mental disorders secondary to a general medical condition (including HIV/AIDS) 
or substance use 
6. Psychotic disorders (screen on SCID) 
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7. Possible Dementia due to HIV disease (screen with International HIV Dementia 
Scale and make a clinical diagnosis) 
Although diagnosed separately, adjustment disorders were regarded as depressive disorders 
and are included in the discussion about these disorders.  
 
4.5.1 Current mental disorders 
Almost one third (94) of participants (31.13%) had at least one current mental disorder and 
fifty-five (18.21%) had a V-code only. Forty-three participants had two current mental 
disorders, and 3 participants had three current mental disorders.  
 
4.5.2 Lifetime mental disorders 
One hundred and twenty-one (40.07%) participants had evidence of at least one mental 
disorder at some stage in their lives (up to one month prior to interview). Forty participants 
had a second lifetime disorder and six participants had a history of three lifetime disorders. 
Thirteen (4.3%) participants had a lifetime history of a V-code. 
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Figure 4.3: Current mental disorder and V-codes 
 
 
Figure 4.4: Lifetime mental disorders and V-codes 
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Table 4.4: Breakdown of mental disorders (current and lifetime) by diagnostic 
groupings 
 Current mental 
disorders 
Lifetime mental 
disorders 
Diagnostic grouping No Percentage of 
total participants 
(n=302) 
No Percentage of total 
participants 
(n=302) 
Mood disorder 34 11.26% 48 15.89% 
Anxiety disorder 12 3.97% 11 3.64% 
Adjustment disorder 20 6.62% 0 0% 
Substance use disorder2 23 7.62% 56 18.87% 
Dementia (HIV) 11 3.64% 11 3.64% 
Organic mental disorder – 
other (delirium, dementia, 
mental disorder secondary to 
general medical condition or 
substance use) 
3 9.93% 5 1.66% 
Psychotic disorder 14 4.64% 12 3.97% 
Other mental disorder 0 0% 1 0.33% 
V-code 76 25.17% 21 6.95% 
 
4.5.3 Relationship of lifetime mental disorders to diagnosis of HIV infection: 
Of the 121 participants with at least one lifetime mental disorder, 86 (28.48% of the total 
sample) had the onset of at least one mental disorder prior to knowledge of their HIV 
status. 
Table 4.5: Relationship of lifetime mental disorder to HIV diagnosis 
Relation to HIV diagnosis Frequency Percent Cumulative 
Frequency 
Cumulative 
Percent 
No mental disorder3 181 59.93 181 59.93 
Lifetime mental disorder prior to 
HIV diagnosis 
86 28.48 267 88.41 
Lifetime mental disorder since 
HIV diagnosis 
35 11.59 302 100.00 
                                            
2 Many participants had more than one comorbid substance use disorder. See section on substance use disorders 
3 Participants may have had a V-code 
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The remaining 35 participants with a lifetime mental disorder had no history of a mental 
disorder prior to receiving their diagnosis of their HIV status. This constituted 11.59% of 
the total sample, and consisted of participants primarily with dementia due to HIV disease 
and depressive disorders.  
 
Table 4.6: Breakdown of primary lifetime mental disorder into categories 
Primary lifetime 
mental disorder 
Total  Percent Pre-
HIV 
diagn. 
Percent Post-
HIV 
diagn. 
Percent 
Dementia due to HIV 
disease 
7 5.8% 0 0% 7 20% 
Mood disorder 48 39.7% 22 25.6% 26 74.2% 
Psychotic disorder 9 7.4% 8 9.3% 1 2.9% 
Anxiety disorder 7 5.8% 6 7.0% 1 2.9% 
Substance use disorder 45 37.2% 45 52.3% 0 0% 
Organic mental disorder 
– other 
5 4.1% 5 5.8% 0 0% 
Total 121 100.00% 86 100.00% 35 100.00% 
 
This does not include the substantial number of V-code diagnoses that were related to the 
knowledge of a positive diagnosis of HIV infection. The most common mental disorder 
prior to diagnosis of HIV infection was a substance use disorder. The most common 
mental disorder after diagnosis of HIV infection was a mood disorder 
 
4.5.4 Individual groups of disorders 
4.5.4.1 Mood disorders 
Current depressive disorder 
A total of 34 participants had a diagnosis of a current mood disorder. One was diagnosed 
with a Bipolar Disorder in remission. The remaining 33 (10.92%) had a depressive 
disorder. In addition, 18 (5.96%) participants received a diagnosis of an adjustment 
disorder with mixed anxiety and depressed mood or depressed mood. (One participant 
received a diagnosis of adjustment disorder with disturbance of conduct, and one had an 
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adjustment disorder with anxiety only.) Thus, 16.88% of the participants had a current 
depressive disorder. Twenty-five (8.28%) participants were suffering from depressive 
symptoms related to a recent bereavement. (None of these participants met criteria for a 
depressive disorder.) Incorporation of all these diagnoses gives a total of 25.16% of 
participants who had depressive symptomatology that met criteria for a mental disorder or 
a V-code. (Participants diagnosed with schizoaffective disorder were classified as 
primarily having a psychotic disorder and were not included in the analysis of mood 
disorders.) 
 
Fifteen participants (4.96%) met criteria for a diagnosis of a current Major Depressive 
Episode. Four of these had evidence of a general medical condition that could have 
contributed to their mood disorder. In one of these cases, the episode appeared to be related 
to antiretroviral medication (efavirenz). Sixteen participants (5.29%) had depressive 
symptoms that did not meet criteria for a Major Depressive Episode, but could be 
classified as depressive disorder Not Otherwise Specified (NOS). Three of these had 
evidence of a co-morbid medical condition that could have contributed to the mood 
disorder and in another three there was evidence of a substance use disorder that could 
have contributed to the mood disorder. Two participants met criteria for a current 
dysthymic disorder. 
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Table 4.7: Current depressive disorders 
Current Diagnosis Freq % Cum Freq Cum % 
Major depressive episode 11 3.64 11 3.64 
MDE secondary to GMC 4 1.32 15 4.96 
Dysthymic disorder 2 0.66 17 5.62 
Depressive disorder NOS 10 3.31 27 8.93 
Mood disorder secondary to GMC 
(not MDE) 3 0.99 30 9.92 
Substance-induced mood disorder 3 0.99 33 10.92 
Adjustment disorder with depressed 
mood or mixed anxiety and 
depression 18 5.96 51 16.87 
Total depressive disorders 50 16.87   
Bereavement symptoms 25 8.28   
Total depressive syndromes 75 25.16  
Bipolar disorder in remission 1    
 
Severity of depressive disorders  
MADRS scores were obtained only for those participants who met DSM1V criteria for a 
depressive disorder (including adjustment disorder with depressed mood). The mean 
MADRS score for these participants was 31, with a range from 11 to 57. 
 
Lifetime depressive disorders 
Forty-eight participants (15.89%) had a lifetime history of a depressive disorder. Thirty-
one (10.26%) of these had a lifetime history of at least one major depressive episode. In 19 
(61.3%) of these participants, the onset of the first major depressive episode occurred after 
the diagnosis of HIV infection was made. Fifteen participants had a lifetime history of at 
least one depressive episode that did not meet full criteria for a major depressive episode 
(Depressive Disorder NOS). Seven (46.67%) of these participants had their first depressive 
episode after the diagnosis of HIV infection was made. Overall, there is no statistically 
significant difference in the number of participants who developed a lifetime depressive 
disorder before or after the diagnosis of HIV infection. More participants with a lifetime 
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major depressive disorder developed this after diagnosis of HIV infection compared to 
before the diagnosis, but the difference is not statistically significant.  
 
Table 4.8: Lifetime depressive disorders 
Lifetime Diagnosis 
Total 
No. % 
Pre-HIV 
diagnosis 
%  Post-HIV 
diagnosis % 
Major depressive 
episode 31 10.26% 
12 3.97% 
19 6.29% 
Depressive disorder 
NOS 15 4.97% 
8 2.65% 
7 2.32% 
Dysthymic disorder 2 0.66% 2 0.66% 0 0 
Total 48 15.89% 22 7.28% 26 8.61% 
Bipolar disorder  1  1  0  
 
4.5.4.2 Anxiety disorders 
Twelve participants received a diagnosis of a current anxiety disorder (including one 
participant with a diagnosis of adjustment disorder with anxiety). In three of these 
participants there was a co-morbid mood disorder. The following anxiety disorders were 
diagnosed: 
Table 4. 9: Current anxiety disorders 
DIAGNOSIS NO. % 
POSTTRAUMATIC STRESS DISORDER 3 0.99% 
GENERALISED ANXIETY DISORDER 3 0.99% 
SOCIAL PHOBIA 2 0.66% 
PANIC DISORDER 1 0.33% 
ANXIETY DISORDER NOS 2 0.66% 
ADJUSTMENT DISORDER WITH ANXIETY 1 0.33% 
TOTAL 12 3.96% 
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Eleven participants had a lifetime diagnosis of an anxiety disorder. The following anxiety 
disorders were diagnosed: 
 
Table 4.10: Lifetime anxiety disorders 
DIAGNOSIS NO. % 
POST-TRAUMATIC STRESS DISORDER 7 2.31% 
GENERALISED ANXIETY DISORDER 0 0% 
SOCIAL PHOBIA 2 0.66% 
PANIC DISORDER 2 0.66% 
TOTAL 11 3.63% 
 
The only lifetime anxiety disorder that occurred after the diagnosis of HIV infection, was 
in one participant who developed a panic disorder without agoraphobia after the diagnosis 
of HIV infection was made. Another participant, with a lifetime history of panic disorder, 
did not meet criteria for a current panic disorder, but did have a current major depressive 
episode.  
 
4.5.4.3 Adjustment disorders (see under depressive and anxiety disorders) 
As outlined in the section on depressive disorders above, most participants with adjustment 
disorders had mixed mood and anxiety symptoms. A strong relationship was found 
between severity of psychosocial stressors and the presence of an adjustment disorder but 
there was no relationship between recent diagnosis of HIV and the presence of an 
adjustment disorder (p=0.3). It appears that other psychosocial stressors (besides 
knowledge of HIV status) were largely responsible for the development of adjustment 
disorders. 
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4.5.4.4 Substance use disorders 
Fifty-seven participants (18.87% of the total sample) met criteria for a lifetime substance 
use disorder, while only 23 (7.62%) of these participants were diagnosed with a current 
substance use disorder. Presuming that reporting on current substance use disorders is 
accurate, this indicates a significant reduction in the occurrence of substance use disorders 
(two sample test of proportion; p<0.0001).  
 
Table 4.11: Breakdown of current substance use disorders 
Substance use disorder No. Percentage 
Alcohol abuse and dependence only 17 73.91% 
Cannabis only 2 8.70% 
Alcohol and cannabis 3 13.04% 
Other substances only 1 4.35% 
Total participants with current substance use 
disorder 
23 100.00% 
 
Table 4.12: Breakdown of lifetime substance use disorders 
Substance use disorder No. Percentage 
Alcohol abuse only 27 47.39% 
Alcohol abuse and dependence only 18 31.58% 
Alcohol and cannabis 7 12.27% 
Cannabis abuse only 1 1.75% 
Polysubstance abuse or dependence 4 7.01% 
Total participants with lifetime substance use 
disorder 
57 100.00% 
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4.5.4.5 Dementia due to HIV disease 
The International HIV Dementia Scale has been validated as a screening tool for HIV 
dementia across cultures (Sacktor, et al., 2005). Using this scale, 57 (18.87%) participants 
scored 10 or less on the IHDS, which has been suggested as the cut-off score for possible 
HIV dementia. Eleven of these (3.64%) participants received a clinical diagnosis of HIV 
dementia (based on a clinical assessment of neurocognitive impairment in keeping with a 
subcortical dementia, using a brief “bedside” neuropsychological and clinical 
examination). The SCID does not contain a module for assessing dementia. No 
neuropsychological testing was done. Participants who scored 10 or less on the IHDS 
should have had a more thorough neurological and neuropsychological assessment but this 
was not part of the scope of this study. It is possible that a more comprehensive clinical 
assessment and formal neuropsychological testing in these participants may have found 
evidence of dementia or less severe neurocognitive impairment in these participants. Some 
of these participants were already on HAART, while others were to due to start treatment 
soon as a result of their low CD4 counts.  
 
4.5.4.6 Psychotic disorders 
Fourteen (4.64%) of the participants had evidence of a current psychotic disorder. Six of 
these participants had a history and evidence of a primary psychotic disorder 
(schizophrenia or schizo-affective disorder), with onset prior to diagnosis of HIV infection. 
The other participants had clinical presentations in keeping with substance-induced 
psychotic disorders and/or psychotic disorders due to a general medical condition. The 
general medical conditions involved included: HIV (Stage 3 or 4, or low CD4 count), 
tuberculosis and temporal lobe epilepsy.  
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Twelve participants had a history of a past psychotic episode. Six of these were the 
participants noted above, who had a chronic primary psychotic illness. The other 
participants had presentations in keeping with substance-induced psychotic disorders 
and/or psychotic disorders due to a general medical condition.  
 
4.5.4.7 V-codes 
Seventy-two participants (25.49% of the total study sample) had one or more V-code 
diagnosis made. Of these, fifty-five (18.21%) only had a V-code diagnosis (i.e. no 
additional mental disorder), while 17 had a mental disorder and one or more V-code 
diagnosis.  
 
Table 4.13: The breakdown of V-code diagnoses 
Diagnosis No.  % of total sample (n=302) 
Bereavement symptoms 29 9.60% 
Parent-child relational problem 6 1.99% 
Partner relational problem 29 9.60% 
Relational problem NOS 2 0.66% 
Sibling relational problem 7 2.32% 
Other 4 1.32% 
Total 77 25.49% 
 
4.5.5 Relationship between mental disorders and site 
Despite significant demographic and clinical differences between sites, there were no 
statistically significant differences in current or lifetime mental disorder, current or lifetime 
depressive disorder, and current or lifetime substance use disorders between sites.  
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Table 4.14: Occurrence of mental disorders by site 
 Site 1 
PHRU 
Site 2 
Tintswalo 
RADAR 
Site 3 HIV 
CHB 
General 
(Wed) 
Site 4 
HIV 
CHB 
ART 
Site 5 
Weiler’s 
Farm 
Total 
Current mental 
disorder (%) 
27 37 37 25 39 31 
Current 
depressive 
disorder (%) 
18 13 17 17 15 17 
Current 
substance use 
disorder (%) 
7 7 7 7 20* 9* 
Lifetime mental 
disorder (%) 
35 43 50 40 37 40 
Lifetime mental 
disorder onset 
after HIV 
diagnosis (%) 
11 17 22 5 5 12 
Lifetime 
depressive 
disorder (%) 
19 13 20 12 7 16 
Lifetime 
depressive 
disorder onset 
after HIV 
diagnosis (%) 
9 7 15 5 5 9 
 
Although not statistically significant, the following was noted: 
1. Current mental disorder, current substance use disorder and lifetime substance use 
disorder were highest at Weiler’s Farm.  
2. The general Nthabiseng clinic had the most lifetime mental disorders and the most 
lifetime depressive disorders. 
 
There were also no statistically significant differences between sites in terms of the cut-off 
score for dementia on the IHDS although there was a marginally significant trend to there 
being fewer participants at the PHRU site who screened positive for a possible dementia 
(p=0.0948).  
 
4.5.6 Relationship between mental disorders and gender 
The association between gender and mental disorder was explored in some detail.  
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Current mental disorders by gender 
Although not statistically significant, males were found to have more current mental 
disorders than females had in this study (males: 35.56% vs. females: 29.25%). There were 
also slightly more current depressive disorders in males (16.98% vs. 15.56%). 
Significantly more males than females had a current substance use disorder (16.67% vs. 
5.19%) (p=0.0011).  
 
Lifetime mental disorders by gender 
No significant gender difference was found in the rates of lifetime mental disorder. There 
were significant gender differences in the rates of lifetime depressive disorder (p<0.0005). 
As expected from general prevalence studies, depressive disorders were more common in 
females than in males. Also, as expected, there were statistically significant gender 
differences in lifetime substance use disorders (males > females) (p<0.0001) 
 
4.6 Suicidal ideation or behaviour 
Current suicidal ideation or behaviour 
Twenty-six participants (8.61% of the study sample) had suicidal ideation when 
interviewed. Of these, 19 reported thoughts of suicide but no serious plan to attempt it, and 
7 reported that they had a plan for attempting suicide. These participants were all referred 
to the nearest mental health service for assessment and intervention. None were considered 
to be at immediate risk of attempting suicide.  
 
Relationship between current suicidal ideation and current mental disorder  
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There was a statistically significant relationship between the presence of suicidal ideation 
and the presence of a current mental disorder (p=0.0008) and a current depressive disorder 
(p<0.0001). Participants with a current mental disorder were 4 times more likely to express 
suicidal ideation and those with a current depressive disorder were 5 times more likely to 
express suicidal ideation than those without a current mental or depressive disorder (p < 
0.0001). There was also a statistically significant relationship between current and past 
suicidal ideation (p=0.0181). Participants with past suicidal ideation were twice as likely to 
express current suicidal ideation as those without past suicidal ideation.  
 
Past suicidal ideation or behaviour 
Sixty-eight participants (22.52% of the study sample) reported previous suicidal ideation or 
behaviour on one or more occasion (total 90 episodes). Of these, 44 participants had 
experienced suicidal thoughts only, 16 had developed plans to attempt suicide, but had not 
carried them out, and 8 had attempted suicide at least once in the past. In total there were 
10 suicide attempts in these 8 participants. Five participants had made a serious suicide 
attempt, while the other three had made what were considered to be 5 para-suicide 
attempts.  
 
From the table below it can be seen that more than two-thirds (69%) of past episodes of 
suicidal ideation were related to HIV diagnosis.  
Table 4.15: Reasons given for past suicidal ideation or behaviour 
REASON No. % (of all episodes of past 
suicidal ideation) 
At time of HIV diagnosis 34 37.78% 
Change in stage of HIV illness 7 7.78% 
Other related to HIV diagnosis or 
infection 
21 23.33% 
68.89% (due 
to HIV 
diagnosis 
Unrelated to HIV diagnosis or infection 28 31.11% 
Total episodes 90 100% 
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Relationship between past suicidal ideation, lifetime mental disorder and lifetime 
depressive disorder 
A statistically significant association was found between past suicidal ideation and lifetime 
depressive disorder. Lifetime mental disorder and lifetime substance use disorder were not 
significantly associated with past suicidal ideation, although there was a trend for lifetime 
mental disorder to be associated with past suicidal ideation. When adjusted for mental 
disorder and substance use disorder, participants with lifetime depressive disorder were 
seven times more likely to have had past suicidal ideation (adjusted odds ratio = 7.3).  
 
4.7 Postulated risk and mitigating factors in the study sample 
Besides demographic and clinical variables, the following factors were hypothesized to be 
potential risk or mitigating factors in the development of current depressive or anxiety 
disorders. A description of the study population in terms of these factors follows.  
 
Time since informed of HIV status 
More than half the participants (56.95%) had known their HIV status for a year or more at 
the time of their interview.  
 
Mode of transmission 
Most (91.06%) of the participants reported that they had become infected with HIV 
through consensual sexual intercourse with a regular or a casual partner.  
 
Why an HIV test was done 
The most common reasons for having an HIV test were: as a result of falling ill with a 
condition likely to be related to HIV-seropositive status (58.8%); receiving antenatal care 
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(17.61%); concern regarding HIV status (14.62%). As expected, the majority of 
participants at PHRU were tested while receiving antenatal care, while the most common 
reason for having an HIV test at the other sites was a result of having a medical illness. 
While Tintswalo and Weiler’s Farm are Wellness clinics, they were then the only HIV 
treatment sites available to the population in those areas, so people who were medically ill 
made use of these sites.  
 
Voluntary counselling and testing 
Fifty (16.56%) participants stated that they had received neither pre- nor post-test 
counselling. 
 
Pre-test counselling 
Seventy-five (24.85%) participants stated that they had not received pre-test counselling 
before having an HIV-test. Of the 227 participants who did receive pre-test counselling, 
184 (81.06%) considered the pre-test counselling helpful in terms of coping with receiving 
a positive HIV diagnosis.  
Post-test counselling 
One hundred and fourteen (37.42%) participants stated that they had not received any post-
test counselling. Of the 188 who did, 159 (84.57%) considered the post-test counselling to 
be helpful in terms of coping with receiving a positive HIV diagnosis.  
 
Use of support groups 
One hundred and twenty-four participants (41.06% of the total sample) had been in a 
support group with other HIV-seropositive individuals since being diagnosed with HIV 
infection. Seventy-one (23.5% of the total sample) participants were still in a support 
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group at the time of their interview. One hundred and nineteen (95.97%) of the 124 
participants attended a support group more than once, and 106 (85.48%) attended a support 
group for more than a month. Eighty-three (66.94%) of the participants who attended a 
support group found being in the group very helpful in terms of coping with their 
diagnosis. 
 
There was a statistically significant association between helpfulness of support groups and 
the number of times (p<0.0001) and length of time (p=0.01) an individual attended a 
support group. 
 
Disclosure 
Two-hundred and seventy (89.70%) of the participants had disclosed their HIV-status to 
someone outside the health service. They were most likely to disclose their status to their 
partners, siblings, relatives, friends, mothers and other people whom participants knew to 
be HIV positive. Most participants found it helpful to disclose their status to someone.  
 
Two-hundred and thirty six participants (78.15%) were in a relationship when they were 
informed of their HIV status. One-hundred and seventy-six (74.58%) of these informed 
their partners of their HIV status. In 28 (15.91%) cases the disclosure caused that 
relationship to break up. 
 
Being open regarding HIV status 
Of note is the response to the question about being totally open about HIV status. Of the 
participants, 256 (84.77%) indicated that they were not totally open about their status, but 
chose carefully to whom to disclose their status. However, all of the 46 (15.23%) 
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participants who indicated that they were totally open about their status felt that this helped 
them cope with their status. 
 
Involvement in organisations for people living with HIV/AIDS 
Only 16 participants reported that they were involved in such organisations. Examples 
were the TAC, PLWA and community-based self-help and support groups. All but two felt 
that their involvement helped them cope with their diagnosis/infection.  
 
Role of religion/faith in coping with HIV status 
More than half the participants described themselves as being very religious and almost 
two-thirds stated that their faith was very helpful to them in terms of coping with their HIV 
status.  
 
Experience of discrimination as a result of HIV status 
Almost a quarter of the participants (75 participants or 24.83% of the study sample) 
claimed that they had been discriminated against as a result of their HIV status. The types 
of discrimination experienced included labelling, avoidance and verbal abuse. Of those 
who had experienced discrimination, 58.66% felt that this had had considerable negative 
effects on their ability to cope.  
 
Feelings of isolation 
A small number of participants (38, or 12.58% of the sample) described feeling isolated 
from other people as a result of their HIV status. Almost equal numbers of participants (43 
to 44% each) felt that the diagnosis had made no difference or that they had become closer 
to others. There were problems related to the way in which this question was interpreted. 
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In many cases the researcher felt that when participants said they were closer to others, 
what they actually meant was that they preferred to spend time with people because it 
made them feel less alone, and that they were able to forget their HIV status while in the 
company of others. It is possible that these individuals still had internal feelings of 
isolation, and used the company of others to alleviate this feeling. However, those who 
answered that they had become isolated did describe internal feelings and behaviours of 
isolation and confirmed that this change had happened since they had been informed of 
their HIV status.  
 
Duration of attendance at current clinic 
The mean duration of attendance at the current clinic was 12 months, with a range from 0 
to 99 months.  
 
Antiretroviral therapy 
One-hundred and fifty-four (56.41%) of those who had a recent CD4 count (n=273) had a 
count of <200 cells/ml. This indicates the minimum number of participants who should 
have been on HAART at the time of the study.  
 
Seventy participants (23.18%) were on anti-retroviral treatment. The mean CD4 count in 
participants on HAART was 146, with a range from 2 to 484 cells/mm3, and 53 (75.71%) 
had a CD4 count < 200cells/ml.  
 
Ninety-seven participants had a CD4 count < 200 cells/ml and were not on ART at the time 
of interview. Of these, 89 (91.75%) said they would take ART if it was offered to them.  
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Reactions to not being on ART  
It was possible to give more than one response to this question. Sixteen participants gave 
two responses. It should be noted that in response to this question more participants said 
that they had joined an activist or advocacy group, than in the prior question related to 
having joined an activist organisation.  
 
Table 4.16: Reactions of participants who were not on ART and who qualified for 
treatment  
Reaction Frequency Percentage 
Angry 9 8% 
Depressed/ anxious 23 20.4% 
Activist 24 21.2% 
No effect  37 32.7% 
Other 20 17.7% 
Total 113 100.00% 
 
Almost half the participants who responded to this question were unhappy about their lack 
of access to ART, while the other half had no problem with their current lack of access. 
This included those who responded “other” to the question. Eighteen of these participants 
were due to start ART within the next month, and 2 participants had only recently been 
diagnosed HIV positive and were happy to wait a while before starting ART. From this it 
can be concluded that most of the participants thought that ART would help in managing 
their disease.  
 
Eight participants, who should have been on ART according to their CD4 counts, stated 
that they would not take ART at that stage. The reasons given were: a lack of information 
about the medications, fear of side effects, feeling healthy at the time, and concern 
regarding the commitment to taking medication for the rest of their lives once started on 
treatment.  
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Death of others as a result of AIDS 
Almost half the sample, 141 (46.36%) participants, had experienced the death due to AIDS 
of at least one person who was close to them.  
 
Effect of deaths due to AIDS 
Of the participants who had experienced AIDS-related bereavements, 102 (72.86%) felt 
that these deaths had had a major impact on their ability to cope with their own illness.  
 
Other losses in the past year 
Sixty-nine participants (22.85%) had experienced bereavement (the death of a close 
relative or friend) in the past year, and 14 had been bereaved more than once in that period. 
Forty-four (63.76%) felt that this had had a major impact on their ability to cope. These 
deaths were not AIDS-related, as far as could be ascertained.  
 
Levels of psychosocial stress 
Levels of psychosocial stress were determined in each participant and an estimation of 
severity was made. This was dependent on the type and number of stressors. Thirty percent 
of participants had no additional stress besides knowledge of HIV status. Fifty-five percent 
had what was considered to be mild additional stress, and 8% had moderate or severe 
additional stress.  
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Figure 4.5: Levels of psychosocial stress in participants 
 
4.7.1 Site differences between psychosocial variables 
There were no significant differences between sites in terms of the following psychosocial 
variables: time since diagnosis, being open regarding HIV status, experiencing 
discrimination, experiencing losses in the past year (excluding AIDS-related deaths).  
 
There were significant differences in the following variables: 
1. Why HIV test done (p<0.0001): most participants at PHRU were tested during 
antenatal care;  
2. Pre-test counselling (p<0.001): at Tintswalo Hospital 43% did not have pre-test 
counselling;  
3. Post-test counselling (p=0.02): at Weiler’s Farm (56%) and at Nthabiseng ART 
(43%) did not have post-test counselling; 
4. No pre- or post-test counselling (p=0.003): Tintswalo Hospital and Nthabiseng 
ART had the most participants who claimed they had had neither pre- nor post-test 
counselling at the time that they were informed of their HIV test results; 
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5. Support groups – yes (p<0.0001): Tintswalo Hospital had most support group 
members. This probably reflects selection bias, since interviews were conducted on 
days that support groups met and more than half the participants at PHRU had 
been, or were, in support groups;  
6. Disclosure (p<0.0001): all (100%) participants at Nthabiseng ART had disclosed 
their status to someone (This probably also reflects selection bias) and the lowest 
levels of disclosure were at Weiler’s Farm;  
7. Disclosure to partner at time of diagnosis (p=0.03): the lowest levels of disclosure 
were at Tintswalo Hospital and the highest were at PHRU; 
8. Religious belief (p=0.0012): more participants at Weiler’s Farm described 
themselves as not at all religious (34%) than at the other sites; 
9. Experiencing AIDS-related deaths (p=0.05): participants at Weiler’s Farm had 
experienced the smallest number of such deaths (24%) in close family or friends 
(At all the other sites, between 40% and 50% of participants had experienced such 
deaths); 
10. Psychosocial stress (p<0.0001): Nthabiseng general clinic had the most participants 
with no additional psychosocial stress (52%) and PHRU had the most participants 
with moderate to severe stress (34%). 
 
4.7.2 Analysis of variables related to current mental disorder and current 
depressive disorder 
Analysis of possible risk and protective factors was carried out for current mental disorders 
in general and for current depressive disorders in particular. Since the occurrence of 
anxiety disorders was so low, it was unlikely that anything of significance would be found. 
Therefore, analysis of risk and mitigating factors was not carried out for anxiety disorders.  
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Appendix 1 outlines the univariate analysis of postulated risk or mitigating factors 
outlining the odds ratios and tests of statistical significance for current mental disorder and 
current depressive disorder. 
 
Univariate analysis 
On univariate analysis, the following variables were found to be statistically significantly 
associated with a current mental disorder (with a p value of <  0.05): 
1. Clinical stage of HIV disease; 
2. Presence of a medical condition  
3. Lack of a strong religious belief 
4. Psychosocial stress (mild or severe) 
5. A lifetime mental disorder at any time up to one month prior to interview 
6. A lifetime mental disorder before the diagnosis of HIV infection was made 
7. A lifetime depressive disorder at any time up to one month prior to interview 
8. A lifetime substance use disorder at any time up to one month prior to interview 
 
There was a marginally statistically significant (p<0.10) association between current 
mental disorder and an individual feeling that they had experienced discrimination as a 
result of their HIV-status, and feeling that this discrimination had made coping very 
difficult for them. 
 
On univariate analysis, the following variables were found to be significantly associated 
with a current depressive disorder: 
 
1. Feelings of isolation  
2. Increased levels of psychosocial stress (mild, moderate or severe) 
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3. A lifetime mental disorder at any time up to one month prior to interview 
4. A lifetime mental disorder before the diagnosis of HIV infection was made 
5. A lifetime depressive disorder at any time up to one month prior to interview 
6. A lifetime depressive disorder before the diagnosis of HIV infection was made 
 
There was also a marginally statistically significant (p<0.10) association between the 
number of AID-related bereavements the individual had experienced and the presence of a 
current depressive disorder.  
 
Multivariate analysis 
Variables that reached a level of statistical significance of p<0.20 were entered into a 
backward step-wise multivariate logistic regression and an attempt was made to develop a 
predictive model for the risk of mental disorder or depressive disorder in the study 
population based on the postulated risk and protective factors.  
 
The following variables were entered into the multivariate analysis for current mental 
disorder: 
· Clinical stage 
· Presence of a medical condition 
· Time since diagnosis of HIV status 
· Disclosure of HIV status 
· Impact of discrimination 
· Lack of a strong religious belief 
· Impact of faith on coping 
· Impact of AIDS-related bereavements 
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· Number of AIDS-related bereavements 
· Presence of lifetime depressive disorder at any time up to one month prior to 
interview 
· Presence of a lifetime depressive disorder before the diagnosis of HIV infection was 
made 
· Lifetime history of substance abuse 
 
Although the presence of a lifetime mental disorder at any time up to one month prior to 
interview, and the presence of a lifetime mental disorder before the diagnosis of HIV 
infection was made, were statistically significantly associated with a current mental 
disorder on univariate analysis, these variables were not entered into the logistic 
regression, as they were considered to be too broad to give a useful result. In addition, the 
variables of lifetime depressive disorder and lifetime substance use disorder were already 
entered into the regression analysis, and these specific categories were also subsumed into 
the category “lifetime mental disorder”.   
 
The results of the logistic regression analysis showed a statistically significant association 
(p<0.05) between the following variables and the presence of a current mental disorder: 
· Clinical stage 3 and 4 (OR = 2.16; p=0.025) 
· Presence of additional psychosocial stress (OR = 2.2: p=0.023)  
· Feeling that one’s faith was marginally helpful or not at all helpful in coping with 
HIV status (OR= 2.3: p=0.044) 
· The presence of a lifetime history of a depressive disorder (OR= 2.37: p=0.022) 
· The presence of a lifetime history of a substance use disorder (OR= 4.3: p<0.0001)   
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Of note is that a lifetime history of depressive disorder prior to the diagnosis of HIV 
infection was not found to be statistically significantly associated with a current mental 
disorder.  
 
Disclosure of HIV status was found to be statistically significantly protective of having a 
current mental disorder (OR=0.42; p=0.044) 
 
It was not possible to build a sufficiently robust predictive model using the variables which 
were identified in this study. 
 
The following variables (p <0.2) were entered into the multivariate analysis for current 
depressive disorder: 
· Level of education 
· Attending a support group 
· Reported experience of discrimination 
· Feelings of isolation 
· Number of AIDS-related bereavements 
· Psychosocial stress 
· Lifetime depressive disorder 
· Lifetime depressive disorder pre-HIV diagnosis 
 
Although there seemed to be some statistically significant association between 
employment status and current depressive disorder on univariate analysis, this variable was 
not entered into the multivariate logistic regression due to the large number of unemployed 
participants, which would have resulted in skewing of the results of the regression analysis. 
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Recent viral load was also excluded from the logistic regression due to the small number of 
participants with a documented viral load, as this again would have had a confounding 
effect on the regression analysis.  
 
The results of the multivariate analysis showed a statistically significant association 
(p<0.05) between the following variables and the presence of a current depressive disorder: 
· Moderate or severe levels of psychosocial stress (OR=5.5; p=0.001  
· Lifetime depressive disorder (OR=4.0; p=<0.0001 (again, of note is that a lifetime 
history of a depressive disorder prior to the diagnosis of HIV-infection was not found 
to be statistically significantly associated with a current depressive disorder 
· Feelings of isolation (OR=3.05;p=0.016)  
Being in a support group was found to be protective of the presence of a current depressive 
disorder (OR=0.48; p=0.043). 
 
Again, it was not possible to build a useful predictive model using the variables which 
were identified in this study. 
 Results 
 120 
4.8 Quality of pre-test counselling 
Nineteen participants who had received pre-test counselling were asked additional 
questions regarding their experience of pre-test counselling. Most pre-test counselling was 
done by lay counsellors in the patients’ home language. Most people received counselling 
in a private setting, but some reported interruptions and feeling that other people might 
overhear what was being said. Half felt that the counsellors did not really understand how 
they were feeling, and that the counsellors were either in a hurry, not listening or not 
interested and only seeing the job as a routine task. Some felt that too much emphasis was 
placed on the negative aspects of a positive diagnosis. Again, half felt that they were not 
given a chance to ask questions because the counsellors were in a hurry. Most felt that the 
counsellors did address issues of positive living, but some felt that they only focused on 
safe sex issues. Interestingly, more participants felt more anxious than less anxious after 
the pre-test counselling. Although these interviews were too few to provide any 
meaningful results, they did indicate some of the issues of importance related to pre-test 
counselling; particularly, the need for counsellors to demonstrate that they have sufficient 
time available for their clients and regard their task as important and not just a routine job. 
Increased anxiety after counselling may have been inevitable, as having an HIV test is a 
stressful experience. It may be more important to ensure that post-test counselling is 
always available, and that the feelings raised by a positive result are adequately dealt with. 
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CHAPTER 5 
 
DISCUSSION 
 
This research investigated:  
1. The occurrence of depressive and anxiety disorders in HIV-infected individuals 
attending certain treatment sites in South Africa  
2. Whether the results of this study are comparable with those of other studies 
conducted in South Africa, Africa and internationally  
3. Whether there is an increased occurrence of depressive and anxiety disorders in this 
population of HIV infected individuals compared to the prevalence of these 
disorders in the general population in South Africa.  
4. Whether any aetiological/risk factors or protective/mitigating factors could be 
identified for mental disorders (and specifically for depressive and anxiety 
disorders) in the study population  
 
5.1 Important findings 
This study was conducted in both primary and tertiary HIV-treatment sites. All previously 
published studies of HIV-infected individuals in South Africa were conducted at tertiary 
level outpatient services. The Wellness clinics established under the auspices of PHRU are 
primarily intended to treat newly diagnosed asymptomatic individuals and maintain their 
health for as long as possible through primary health care, education, psychosocial support 
and treatment of sexually transmitted infections and opportunistic conditions. While the 
clinic population at the Soweto/CHB Wellness site matches this profile, those at Tintswalo 
and Weiler’s Farm had a considerable number of patients with symptomatic HIV disease. 
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They were intermediate between PHRU and the Nthabiseng clinics in this regard. It is 
possible that this was related to access to healthcare in these areas.  
 
5.2 The occurrence of depressive and anxiety disorders in HIV-
infected individuals in this study 
This study found a considerable burden of mental disorder in the study population. In 
terms of current mental disorders, the most common disorders were depressive disorders 
(including adjustment disorders), followed by substance use disorders, psychotic disorders, 
and equal numbers of anxiety disorders and dementia due to HIV disease. With regard to 
lifetime mental disorders, substance use disorders were the most common, followed by 
depressive disorders.  
 
The occurrence of current depressive disorders in this study was 16.87% and that of 
lifetime depressive disorders was 15.89%. Current anxiety disorders and lifetime anxiety 
disorders were found in 3.96% and 3.63% of the study population respectively. Therefore, 
about 20.83% of the participants suffered from current or lifetime depressive and anxiety 
disorders.  
 
Major depressive disorder was present in just under 5% of the participants at the time of 
interview, and just over 10% of participants had a lifetime history of a major depressive 
disorder. Of note is that almost two-thirds of these had their first major depressive episode 
after diagnosis of their HIV status.  
 
Generally, anxiety disorders were not common. There was a range of anxiety disorders, 
none of which predominated.  
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5.2.1 Comparison with similar studies in Sub-Saharan Africa, including South 
Africa 
5.2.1.1 Depressive disorders 
Other studies conducted in Sub-Saharan Africa, including South Africa, have produced 
results for current major depressive episode only. 
Table 5.1: Studies of depressive disorders in HIV-infected individuals conducted in 
Sub-Saharan Africa  
Researcher Country Year 
published 
Methodology Results 
Maj et al. 
(1994) 
Zaire 
(DRC) and 
Kenya 
1994 Diagnostic 
interview (CIDI)  
HIV-negative 
controls 
No statistically significant increase 
in depressive disorders; generally 
low prevalence of depressive 
disorder (0 to5.5%) 
Sebit et al. 
(2003) 
Zimbabwe 2003 Diagnostic 
interview (MINI) 
HIV-negative 
controls 
Statistically significant difference 
in prevalence of psychiatric 
disorder between HIV-positive and 
HIV-negative (71.3% vs. 44.3%). 
(No separate information on 
depressive disorder) 
Stranix-
Chibanda, 
Chibanda and 
Chingono 
(2005) 
Zimbabwe 2005 Screening 
instrument (Shona 
SSQ) 
HIV-negative 
controls 
17% of all women attending a VCT 
clinic had psychological morbidity. 
No statistically significant 
difference between those who were 
HIV-positive and those who were 
HIV-negative 
Kahazura et al. 
(2006) 
Uganda 2006 Screening 
instrument (CES-D) 
No control group 
47% of 1017 HIV-infected 
individuals had a CES-D score 
>=23 (significant depression). 
Bganya (1999)  South 
Africa 
(Gauteng) 
1999 
(MMed) 
Screening (BDI) + 
unstructured clinical 
interview. No 
control group 
38% major depressive disorder  
Els et al. 
(1999) (Free 
State) 
South 
Africa 
1999 MINI 
No control group 
35% major depressive disorder 
Olley et al. 
(2003) 
(Western 
Cape) 
South 
Africa 
2003 MINI (baseline of 
cohort; within 6 
months of HIV-
diagnosis). No 
control group 
35% major depressive disorder 
Olley et al. 
(2006) 
(Western 
Cape) 
South 
Africa 
2006 MINI (6-month 
follow-up of 
cohort). No control 
group. 
26% major depressive disorder 
Thom 
(Gauteng, 
Mpumalanga) 
South 
Africa 
Current 
study 
SCID MDE. No 
control group. 
5% major depressive disorder 
Thom 
(Gauteng, 
Mpumalanga) 
South 
Africa 
Current 
study 
SCID all depressive 
disorders. No 
control group. 
16.87% all depressive disorders 
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The WHO study by Maj et al. in 1994, found prevalence rates of between 0 and 5.5% in 
HIV-seropositive individuals (asymptomatic and symptomatic) at the two African study 
sites. The difference between these groups and HIV-negative controls was not statistically 
significant. The only other African study conducted with a diagnostic interview and with 
HIV-negative controls was carried out by Sebit in Zimbabwe in 2003. This study reported 
on psychiatric disorders in general, and not specifically on depressive disorders. This study 
did, however, find high rates of disorder, and a statistically significant difference between 
HIV-positive and HIV-negative individuals.  
 
Generally, all the other studies (including all those from South Africa) show much higher 
rates of MDE than the current study does (26 to 38% vs. 5%). Possible reasons include the 
use of differing methodologies, different study populations or the existence of other as yet 
unknown reasons for the variation in results.  
 
Some studies used screening instruments rather than diagnostic interviews, which would 
result in inflated results. All the studies conducted in South Africa used a diagnostic 
interview, although Bganya used the Beck Depression Inventory to screen for major 
depressive disorder and confirmed the diagnosis with an unstructured clinical interview. 
The other studies in South Africa used the MINI. As was discussed in Chapter 3, while the 
MINI has been validated against the SCID (Sheehan, Lecrubier, & Hairnet-Sheehan, 
1998), it does not provide the range of diagnoses that the SCID does. It also usually takes a 
trained clinician an average of 15 minutes to administer, whereas the SCID usually takes, 
on average, an hour to administer. The MINI does not code for sub-syndromal depressive 
disorders (Depressive disorder NOS), nor for adjustment disorder. This might lead to an 
expectation that these diagnoses would be excluded when the MINI is used. However, it is 
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possible that for this very reason the criteria are applied more liberally than with the SCID. 
It is therefore possible that sub-syndromal depressive disorders were included as major 
depressive disorder in these studies. 
 
As noted previously, it is difficult to differentiate depressive disorders from early signs of 
cognitive impairment in HIV-infected individuals. The other studies did not give results for 
levels of cognitive impairment and no diagnoses of dementia were made. As reported by 
Ciesla & Roberts (2001), the overlap in symptoms between cognitive impairment, physical 
illness and depressive disorder in HIV disease makes accurate diagnosis very difficult, 
particularly within a limited period of 15 minutes. This may, again, have led to over-
diagnosis of major depressive episode in these studies. Again, of note, is that these studies 
were conducted in tertiary infectious diseases clinics, where the levels of confounding 
cognitive impairment could be expected to be quite high. 
 
Another consideration relates to who conducted the interviews in these research projects. 
The interviewers in all the studies, except that by Els et al (1999), were trained mental 
health clinicians. Els used final year medical students trained and supervised in 
administering the MINI and other instruments used in the research. Interviewers are 
instructed to use their clinical judgement in administering both the MINI and the SCID. It 
is possible that the criteria for major depressive disorder were more liberally applied in the 
studies using the MINI than in the study under discussion, particularly in those using 
interviewers with less clinical experience, especially considering that there was no other 
category of depressive disorder allocated for participants with less severe depressive 
disorders.  
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Another methodological argument may relate to cultural and linguistic difficulties in 
making diagnoses of mental disorders in a cross-cultural context. The other studies 
conducted in South Africa did not comment on this aspect. All these studies, including the 
current one, were conducted in similar cultural populations. Therefore, the cultural 
concepts and understandings of depression and anxiety are likely to have been similar 
across the studies.  
 
With regard to language: in the current study, interviews were conducted by the researcher 
in English if the participant was fluent in English. However, the research assistant was 
present during all interviews, which were jointly conducted in the participant’s home 
language where that person lacked fluency in English. Since the research assistant was also 
a trained in administering the SCID and was an experienced mental health clinician, the 
researcher and assistant were able to reach consensus in terms of diagnosis in all cases. It is 
therefore unlikely that language difficulties affected the accuracy of diagnoses in the 
current study. There was no comment on this aspect in the other studies.  
 
In terms of the study populations: all the other South African studies were conducted at 
infectious diseases clinics in tertiary hospitals. The study populations were largely similar 
in socio-demographic profile to those in the current study. Clinical indicators were also 
similar, although most of the participants in Bganya’s study were in Stages 3 and 4 of HIV 
disease. The study population in Olley et al.’s baseline study were recently diagnosed 
(mean of 5.8 months since diagnosis). However, their 6-month follow-up study 
nevertheless showed significantly more major depressive disorder than the study under 
discussion did. All these studies had fewer than 150 participants.  
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Sixty percent of participants in the current study were attending primary care sites. The 
Nthabiseng clinic at Chris Hani Baragwanath Hospital is a tertiary level infectious diseases 
clinic, similar to the sites in the other South African studies. Patients attending the tertiary 
care sites are likely to be more medically ill or to have significant cognitive impairment, 
and there were significant differences in demographic and clinical variables between sites 
in the current study. However, no significant difference was found in the occurrence of 
depressive disorders and major depressive disorders between the sites in the current study. 
Therefore, while the primary and tertiary level populations may have been different, this is 
likely to account only partially for the differences in findings between this and other South 
African studies.  
 
The other studies were conducted before antiretroviral treatment was made available in the 
public sector, while the current study was conducted during the initiation of this treatment. 
Very few of the participants in the other studies were on anti-retroviral treatment, whereas 
almost one quarter of participants in the current study were on anti-retroviral medication. 
However, univariate and multivariate logistic regression did not find that being on anti-
retroviral medication had any significant impact on rates of depressive disorder. Many of 
the participants had only recently commenced anti-retroviral therapy and it is therefore 
unlikely that this had yet had an effect. It is possible that participants in the current study 
had an increased level of hope, which was not present in the previous studies and this may 
explain to some extent the lower levels of depressive disorder in the current study. 
However, this is unlikely to completely explain the difference; particularly the difference 
in occurrence of a serious mental illness like major depressive disorder.  
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It is therefore possible that some or all of these methodological and contextual issues may 
have contributed to the differences in the findings between this study and other South 
African studies. On the other hand, the rates of depressive disorder may simply be different 
in the populations studied.  
 
5.2.1.2 Anxiety disorders 
As stated above, anxiety disorders were not common in the study sample. Less than 4% of 
the sample had a current and/or a lifetime anxiety disorder. While this result is in keeping 
with the findings of the WHO study sites in Africa (Maj et al., 1994), this again is in 
contrast with other studies conducted in similar settings in South Africa. In particular, Els 
et al. found panic disorder in 37% of their study sample, and generalised anxiety disorder 
in 21%, while Olley et al. found PTSD in 14.8% at baseline and 20% at 6-month follow-
up. Disparities may, again, be due to methodological or study population differences, true 
differences in rates of the disorders, perceptions of distress or the psychological effects of 
the anti-retroviral roll-out.  
Table 5.2: Prevalence of anxiety disorders in HIV-infected individuals in Africa 
Prevalence AUTHOR Country 
of study 
Methodology 
HIV+ve HIV-ve  
Maj et al. (1994) Multi-
national 
control group: CIDI (all anxiety disorders) 1-2% 1-2% 
Carson et al. 
(1998) 
Kenya control group: CIS 
worry symptoms (no anxiety disorders) 
13% 12% 
Els et al. (1999) South 
Africa 
no control group; MINI 
Panic disorder 
Agoraphobia 
Social phobia 
GAD 
PTSD 
 
37% 
9% 
15%  
21% 
6% 
 
Olley et al. (2005) South 
Africa  
no control group; MINI 
PTSD (Baseline) 
 
14.8% 
 
Olley et al. (2006) South 
Africa 
cohort study; MINI at 6 month follow-up 
PTSD 
 
20% 
 
Thom (current 
study) 
South 
Africa 
No control group; SCID (all anxiety 
disorders) 
3.96%  
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5.2.2 Occurrence of mood and anxiety disorders compared to general prevalence 
studies 
Table 5.3: Prevalence rates for mood and anxiety disorders in the general population 
in South Africa 
Study name Year Site Methodology Result 
Thom et al. 
(Thom, Zwi & 
Reinach, 
1993) 
1993 Urban Primary 
Care clinic 
SRQ + PSE 10% (anxiety and 
depression) 
Rumble et al. 
(Rumble, 
Swartz & 
Parry, 1996)  
1996 Rural community 
in Western Cape 
SRQ + PSE 27.1% (most anxiety and 
depression 
Bhagwanjee et 
al. 
(Bhagwanjee, 
Parekh & 
Paruk, 1998) 
1998 Rural community 
in KwaZulu-Natal 
SRQ + clinical 
interview 
23.9% (anxiety and 
depression) 
Pillay et al. 
(Pillay & 
Kriel, 2006) 
2006 District-level 
services – hospital 
and CHC 
Screening 
instrument 
21% depression 
10% anxiety 
SASH Study 
(Stein et al, 
2007) 
2007 Country wide 
community 
prevalence study 
CIDI (12-
month and 
lifetime) 
4.8%  mood disorder (12- 
month) 
9.8% mood disorder 
(lifetime) 
8.1% anxiety disorder (12-
month) 
15.8% anxiety disorder 
(lifetime) 
12.9% mood and anxiety 
disorder (12-month) 
25.6% mood and anxiety 
disorder (lifetime) 
 
Prevalence rates in studies of depressive and anxiety disorders in the general population in 
South Africa range from 9% to 27%. The most recent estimate of 12-month prevalence 
rates in South Africa is from the SASH study (Stein, Seedat & Herman, 2007), which 
reported a prevalence of 12.9% in the general population. While not entirely comparable, 
the 1-month occurrence rate in this study for the same two disorders was 20.83%.  
Study n affected percentage 
SASH 4351 561 12.90% 
Thom 
HIV 302 63 20.83% 
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There is a statistically significant difference in the rates of mood and anxiety disorders 
between these two studies (p<0.0001). The SASH study did not take account of HIV 
status, and there would certainly have been some HIV+seropositive individuals who 
participated in this study. It should thus be noted that comparing these two studies is not 
the same as comparing the current study with an HIV-seronegative control group.  
 
The findings of this current study, in comparison with those in a study conducted by the 
same researcher using a similar methodology in a very similar study population (a primary 
care clinic in Soweto) (Thom, Zwi & Reinach, 1993), show a difference in prevalence of 
depressive and anxiety disorders of 10% vs. 20%. Again this is a statistically significant 
difference (p<0.0001). However, this general prevalence study was conducted in 1991, 
some 14 years prior to the current study and prevalence levels of depression and anxiety 
may have changed in that time independent of the HIV epidemic.  
Study N affected percentage 
Thom 
PHC 300 30 10% 
Thom 
HIV 302 63 20.83% 
    
 
5.2.3 Occurrence of other mental disorders in the study 
While other mental disorders were not the primary concern of this study, significant 
findings were also noted with regard to substance use disorders, and to a lesser extent, 
organic mental disorders, including HIV dementia and psychotic disorders.  
 
Substance use disorders are common in South Africa. Data from the SASH study show a 
12-month community prevalence of substance use disorders of 5.8% and a lifetime 
prevalence of 13.3%. Other data on the prevalence of alcohol abuse and abuse of other 
substances show that 9.9% of females and 27.6% of males in South Africa can be 
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considered to be alcohol dependent (National Department of Health, 1998), while the point 
prevalence of abuse of other substances (cannabis, cocaine, amphetamines, ecstasy and 
opiates) in South Africa was estimated to be just over 10% (United Nations Office on 
Drugs and Crime, 2006). 
 
Lifetime occurrence of substance use disorders in the current study was 18.87% and 
current occurrence was 7.72%. Almost all of this was alcohol abuse and/or dependence, 
with some cannabis abuse and a very small occurrence of abuse of other substances. These 
findings are in keeping with the general prevalence rates in South Africa as noted above.  
 
The breakdown of substance use (current and lifetime) is outlined by gender in the table 
below.  
Table 5.6  Current and lifetime substance use  
Gender Lifetime SUD Current SUD 
 Lifetime 
SUD** 
No lifetime 
SUD 
Current 
SUD* 
No current 
SUD 
Male 36.67% 63.33% 16.67% 83.33% 
Female 11.32% 88.68% 5.19% 94.81% 
**p<0.0001 
*p=0.0011 
 
It can be seen that significantly higher levels of substance use disorder were found in males 
than in females, in the study population. Again, this is in keeping with findings in the 
general population. However, there was a significant decline in current substance use 
disorders compared to lifetime rates in both genders. This could have been due to under-
reporting of current substance abuse or it could have been due to a genuine decrease in 
substance use disorders.  
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This finding may have implications for HIV-treatment services. It suggests that individuals 
attending HIV-treatment sites may reduce their use of harmful substances once they know 
that they are HIV-positive. Alcohol was the most common substance abused in this study. 
While some individuals on HAART may experience disulfiram-like effects when using 
alcohol, this is considered rare and not likely to be clinically significant (McDowell, 
Chittick & Pilati-Stevens et al, 2000). The reduction in substance abuse may have been due 
to under-reporting of current abuse, or it may have been as a result of knowledge of HIV 
status alone, as a result of unpleasant side-effects, due to psychosocial interventions that 
took place at these sites or it may have resulted from a combination of all these factors. 
This is an area that needs further exploration.  
 
The considerable numbers of participants who screened positive for a possible dementia 
according to the International HIV Dementia Scale is a cause for concern. While most of 
these participants had a low CD4 count, which would render them eligible for ART (the 
treatment of choice for Dementia due to HIV disease), some had CD4 counts > 200 
cells/ml. While the treatment guidelines in South Africa indicate treatment for any HIV-
positive person with an AIDS-defining condition, (of which HIV-associated dementia is 
one), irrespective of CD4 count, it is unclear whether HIV-practitioners are always aware 
of this. Dementia due to HIV disease is also difficult to diagnose unless specific 
assessments are carried out.  
 
One of the difficulties affecting access to appropriate treatment may involve the diagnosis 
of HIV-associated dementia. The IHDS is a screening tool for HIV dementia, and not a 
diagnostic instrument. The cut-off suggested by the developers for possible HIV dementia 
is 10 or less in patients without psychotic or affective symptoms. The mean IHDS score for 
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the total research population in this study was 11, while the mean score for those who were 
given a clinical diagnosis was 8.  
 
The diagnosis of HIV-associated dementia is made by thorough clinical assessment. 
Laboratory and other special investigations may be needed to exclude other causes of 
cognitive impairment. Sometimes neuropsychological testing may be necessary to confirm 
the diagnosis. This can be difficult in a resource-constrained environment such as exists in 
public sector health services in South Africa. However, with judicious use of bedside 
neuropsychological testing, together with neurological and psychiatric examination, it 
should be possible to reach a firm diagnosis in most cases.  
 
In 2007, the National Department of Health, Directorate: Mental Health and Substance 
Abuse invited a task team of public sector psychiatrists to develop recommendations on the 
prevention, screening and treatment of HIV Associated Dementia (HAD) and related 
conditions. A draft document was submitted to the National Department of Health SMT 
working group on the comprehensive HIV and AIDS plan. The recommendation of the 
task team in terms of diagnosis of HAD as well as other common mental disorders was to 
use the IHDS as a screening tool, and the modified MINI screen as a screening tool for 
depression and alcohol use disorders. Dr John Joska of the task team developed an 
assessment tool for HIV Dementia Case Definition. It was recommended that further 
research in this area be commissioned by the National Department of Health to ensure that 
the most effective assessment methods are used in the diagnosis of HIV Associated 
Dementia.   
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In terms of psychotic disorders noted in this study, a number of participants had chronic 
psychiatric illnesses that had been present prior to diagnosis of HIV infection. Most of the 
participants with psychotic disorders had a CD4 count of <200 cells/ml and had associated 
substance use disorders or medical conditions. Only one of these participants was on ART. 
 
 
Whether any of the psychotic disorders presenting after diagnosis of HIV status were true 
“new-onset” psychoses related to HIV CNS infection, psychotic disorders related to other 
general medical conditions or primary psychotic disorders is not clear. As with depressive 
disorders, the natural history of schizophrenia and other chronic psychotic disorders is 
onset in early adulthood, also the age at which HIV infection is most commonly incurred. 
This makes it difficult to identify which psychotic disorders require treatment for HIV 
CNS infection. Nevertheless, the fact that only one of these participants was receiving 
ART at the time of interview and that most of these participants had CD4 counts less than 
200 cells/ml is a matter for concern. It may be that these participants were part of the group 
of participants waiting to start on HAART. It would however, be important to track 
patients with psychotic disorders in an HIV-treatment setting to ensure that they are not 
unnecessarily deprived of HAART due to their mental state or psychiatric diagnosis. 
 
5.3 Risk and protective factors 
5.3.1 Risk and protective factors for current depressive disorders 
Statistically significant risk factors for current depressive disorder identified on 
multivariate analysis in this study were a lifetime history of a depressive disorder (OR: 
4.0), experiencing moderate or severe levels of psychosocial stress (OR: 5.5) and 
experiencing feelings of isolation (OR: 3.05).   
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A history of depressive disorder is one of the most important risk factors for developing 
depressive disorders, so this was not an unexpected finding. When associations with other 
mental disorders were explored, although there was a significant risk overall, no specific 
association between current or lifetime substance use disorders and current depressive 
disorder was found. This is unusual, since the literature indicates an association between 
substance use disorders and depressive disorders. It is possible that the size of the sample 
was insufficient to show this relationship, or that more detailed exploration of this 
relationship that was not within the scope of this study might have shown such a 
relationship.  
 
The fact that over 50% of lifetime depressive disorders (and 60% of major depressive 
disorders) occurred for the first time after diagnosis of HIV infection is of interest. These 
may possibly have been related to HIV infection or to general medical conditions. They 
could also have been related to the psychosocial stress of receiving a diagnosis of HIV 
infection. However, they could also have been unrelated.  
 
Age could have been a possible confounding factor here. As mentioned earlier, the mean 
age of onset for major depressive disorder is about 40 years, and onset in 50% of all 
patients occurs between the ages of 20 and 50 years (Kaplan, et al., 1997). Therefore, some 
individuals who developed a major depressive episode after the diagnosis of HIV infection 
was made might have developed a major depressive episode without this particular 
stressor. Moreover, psychosocial stressors other than knowledge of HIV status could have 
played a role in the onset of these depressive disorders.  
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A closer analysis of the relationship between current depressive disorder and the time of 
onset of lifetime mental or depressive disorder revealed that a past history of a depressive 
disorder prior to diagnosis of HIV infection did not significantly increase the risk of having 
a current depressive disorder. A mental disorder with onset prior to HIV diagnosis was not 
statistically significantly associated with a current one. However, with onset after diagnosis 
of HIV, both mental disorders in general, and depressive disorders in particular, 
significantly increased the risk of a current depressive disorder. (Odds ratios: 7.180 and 
6.166 respectively on univariate analysis). These odds ratios were higher than for lifetime 
diagnoses pre-HIV diagnosis. This suggests that while a strong association with past 
psychiatric disorder exists, there appears to be a greater risk once the diagnosis has been 
made. The reasons for this are not clear but it suggests that knowing one’s status and/or 
having HIV infection increases the risk of depressive disorder.  
 
The strong relationship between psychosocial stressors and depressive disorder is also in 
keeping with general findings in the literature on depressive disorders. This study showed 
an increasing risk of depressive disorder with increasing severity of stress, such that those 
experiencing moderate or severe levels of psychosocial stress resulted in a five-times 
greater risk of having a current depressive disorder than those with no additional or mild 
additional psychosocial stress.  
 
As discussed in the results section, the question probing feelings of isolation was 
problematic in terms of the interpretation. However, there does appear to be a relationship 
between feelings of isolation and depressive disorder. Whether being, or feeling, isolated is 
a cause of depressive disorder or whether these feelings are a symptom of such a disorder 
is not clear. However, reporting these feelings resulted in a threefold increase in the risk of 
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having a depressive disorder, and this could be an important indicator of depressive 
disorder to be monitored in clinical practice. 
 
The negative findings in this study, of the relationship between various demographic, 
clinical and psychosocial variables and the presence of depressive disorder, also require 
consideration. Clinical stage and CD4 count did not appear to influence the risk of 
developing a depressive disorder. This is contrary to findings of studies of depressive 
disorders in general, and to those of some studies of depressive disorder in HIV-infected 
individuals. Gender and age may have been confounding factors in this study. Seventy 
percent of the study population was female. Risk of depressive disorders is thought to be 
twice as high in females as it is in males in the general population, and it was expected that 
this would apply in this study. Females in this study also had significantly higher levels of 
lifetime depressive disorders. Therefore, expectation of higher rates of current depressive 
disorder in female participants would be usual.  
 
However, no gender differences were found in the occurrence of current depressive 
disorders in this study. In fact, the occurrence of current depressive disorders was slightly 
greater in male participants overall. The male participants in the study were generally older 
than the females. In addition, males in the study were in later stages of HIV disease and 
had significantly lower CD4 counts than females. Males were also significantly more 
likely to have lifetime and current substance use disorders than females. Therefore it is 
possible that older age, clinical factors related to HIV infection and/or substance use may 
have explained the higher rates of depressive disorders in males than females in this study.  
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The lack of a significant relationship between clinical indicators and depressive disorder 
may also be due to the study design. Most of the studies exploring the relationship between 
depression and disease progression have been prospective cohort studies. The cross-
sectional design of this study may have lacked the capacity to show such relationships at a 
single point in time. 
 
It was hoped that factors that could protect HIV-infected individuals from depression 
would be identified in this study. The factors that were explored in the study included the 
impact of pre- and post-test counselling, the use of support groups, disclosure to others, the 
role of religious faith and the impact of antiretroviral treatment.  Of these factors, being or 
having been in a support group was the only factor that was found to be protective of the 
presence of a current depressive disorder (OR=0.48; p=0.049) on multivariate analysis.  
 
This study design was again probably not the most appropriate for exploring this area, and 
a closer examination of these factors in a prospective structured intervention study using 
qualitative research methods would probably be more useful.  
 
It should not be concluded from these findings that counselling and other psycho-social 
interventions are not useful in this context. There is clear evidence from this study that the 
participants felt that these interventions were helpful in terms of enabling them to cope 
with their illness. 
 
Certain critical protective factors, particularly other forms of social support, were not 
explored. Data were obtained on people with whom participants lived, but there was no 
exploration of those whom participants relied upon for support. During interviews it was 
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clear that many participants found relationships with particular family members or friends 
to be helpful, and it is possible that these relationships played a part in preventing 
depressive disorders. This would have been an important area to explore, and again is 
probably best studied over a longer period, using a combination of quantitative and 
qualitative research methods. 
 
Given the reported high levels of stigma related to HIV-infection in South Africa, the 
investigator expected that levels of disclosure in the study population would be low. This 
was not the case. Most participants had disclosed their status to at least one other person 
outside the health services, and most felt that this was important in terms of helping them 
to cope with the diagnosis. On the other hand, most participants were careful to whom they 
disclosed their status, and only a small percentage of participants were completely open 
about their status.  
 
This was a selected sample of HIV-infected individuals who were attending treatment 
sites. It is possible that levels of disclosure in community samples of HIV-infected 
individuals could be quite different. In particular individuals who are attending treatment 
sites with the intention of accessing antiretroviral treatment would be much more likely to 
disclose their status to at least one person. Many HAART treatment programmes require 
the patient to have a “buddy”/ person to support them in their treatment. 
 
Several studies have found a decrease in depressive disorders with antiretroviral therapy.  
This was not found in this study, again largely because of the cross-sectional study design 
and the fact that most participants had only recently started HAART when the ART roll-
out was initiated.  
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5.3.2 Risk and protective factors for current mental disorders 
The results of the logistic regression analysis showed a statistically significant association 
(p<0.05) between the following variables and the presence of a current mental disorder: 
· Clinical stage 3 and 4 (OR = 2.16; p=0.025) 
· Presence of any additional psychosocial stress (OR = 2.2: p=0.023  
· Feeling that one’s faith was marginally helpful or not at all helpful in coping with 
HIV status (OR= 2.3: p=0.044) 
· The presence of a lifetime history of a depressive disorder (OR= 2.37: p=0.022) 
· The presence of a lifetime history of a substance use disorder (OR= 4.3: p<0.0001)   
Of note again is that a lifetime history of depressive disorder prior to the diagnosis of HIV 
infection was not found to be statistically significantly associated with a current mental 
disorder.  
 
Whereas clinical stage and medical condition did not influence depressive disorders, these 
factors played a significant role in current mental disorders overall. Participants in clinical 
Stages 3 and 4 were twice as likely to have a current mental disorder as those in Stages 1 
and 2.  
 
It might also be expected that a low CD4 count would be associated with a current mental 
disorder. However, the only significant association between mean CD4 count and a current 
mental disorder was in participants who screened positive for possible HIV-associated 
dementia on the IHDS (cut-off score of 10 or less). Participants with a current substance 
use disorder had a lower mean CD4 count than those without, but this was not statistically 
significant. 
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The presence of psychosocial stressors was again found to be a significant risk factor (OR: 
2.2), although this factor appears to have had a greater impact in relation to depressive 
disorders in particular.  
 
While disclosure of HIV status was not found to be statistically significantly protective in 
terms of current depressive disorders in particular, it was found to be protective in terms of 
current mental disorders as a whole (OR=0.42; p=0.044). It is not clear why this should be 
so.  
 
Religious belief and the use of religious faith as a coping mechanism was explored in this 
study and it was found that more than half of the participants described themselves as 
religious and almost two-thirds of these found their faith very helpful in coping with their 
HIV-status. Both having a religious faith and finding it helpful in coping were significantly 
protective against current mental disorder on univariate analysis. However, on multivariate 
analysis it appears that it is the impact that the participants’ faith has in terms of coping 
that is protective against current mental disorder.   
 
It is not clear from this study how religious faith and the way people use it to cope, 
influences mental disorder. There is some evidence to show that prayer decreases 
depressive symptoms in HIV-infected individuals (Desai, Desai & Naik, 2004). Therefore, 
there may be a direct effect. However, in this study no association between religious faith 
and depressive disorder was identified. Therefore, the reduction in mental disorder as a 
result of religious faith may be due to its impact on mental disorders other than depression. 
A possibility may be that individuals who use their faith to cope use fewer maladaptive 
coping mechanisms, such as abusing substances.  
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Another factor which may partially express disease progression is time since diagnosis of 
HIV status. Although there was no statistically significant association between this factor 
and current mental disorder, there was a trend towards the period of 4 months to 3 years 
being a period of lower risk of mental disorder (p=0.05 to 0.09). This may suggest that the 
first few months after diagnosis are a period of high risk as a result of the psychosocial 
stress of receiving bad news, and that as individuals live for longer periods with the 
disease, their risk of disease progression increases, and with that there may be an increased 
risk of mental disorder. This study also found an increased risk of mental disorder in 
Clinical Stages 3 and 4. The finding by Lyketsos et al (1996a) of an increased risk in the 
18 months prior to development of AIDS also suggests an increased risk later in the course 
of HIV-infection. This would be an interesting area to explore in a follow-up longitudinal 
cohort study in South Africa. 
 
Another factor explored that was found to be marginally statistically significant on 
univariate analysis was the experience of discrimination, and in particular, the impact of 
this on the individual. Those who felt that discrimination made coping very difficult 
appeared to possibly be at increased risk of having a mental disorder (p=0.0989). However, 
this did not reach statistical significance on the multivariate analysis. It is again likely that 
this is a complex issue that would be better explored in a qualitative study, since the 
perception of discrimination may be a reflection of an individual’s mental state as much as 
a contributing factor to developing a mental disorder. 
 
Antiretroviral therapy was also not found to decrease the risk of having a current mental 
disorder, probably again because of the short duration of time that most participants had 
been on treatment.  
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Of the postulated protective factors (pre- and post-counselling, support groups and other 
psychosocial support interventions), being in or having been in a support group showed a 
significant association with a decreased risk of current depressive disorder. Because of the 
study design it was only possible to explore these issues in a very superficial manner, 
however, this is an area that merits further study. 
 
Another area of interest was the reduction in substance use disorders, from lifetime to 
current levels; previously mentioned as an important finding. Further research in terms of 
confirming and exploring the reasons for this could be useful.  
 
5.4 Limitations of the study 
This was a cross-sectional descriptive-analytic study of occurrence of depressive and 
anxiety disorders in an HIV-seropositive population. It was a selected sample, in that only 
people attending particular HIV-treatment sites were included in the study. Therefore, no 
conclusions can be drawn on the prevalence of depressive and anxiety disorders in HIV-
seropositive individuals in the community who may not be accessing treatment. It is 
possible that individuals who attend HIV-treatment sites are more mentally healthy 
because they have the energy and motivation to access treatment. On the other hand, the 
opposite could be true and they might use HIV-treatment sites in help-seeking behaviour. 
From this study it is not possible to draw conclusions on this issue.  
 
There were, moreover, no HIV-seronegative controls in this study, so it was not possible to 
make comparisons between HIV-seropositive and HIV-seronegative individuals at the 
sites. However, the comparison with general population prevalence studies does appear to 
indicate some increased risk of depressive and anxiety disorders in this study population. 
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As already mentioned, the exploration of risk and mitigating factors was not ideally done 
in a cross-sectional study. The questionnaire used to probe for risk and protective factors 
was, furthermore, problematic in terms of exploring complex interventions and experiences 
in a closed-ended questionnaire. A prospective cohort study, possibly also with randomised 
controlled interventions, would give a more accurate understanding of risk and mitigating 
factors for mental disorders, including depressive and anxiety disorders. It would be better 
able to track disease progression and determine the interaction between clinical indicators 
and mental disorders, including depressive and anxiety disorder. A more qualitative 
approach to the exploration of some of these factors would also add to understanding of 
their influence. 
 
Another limitation to consider is the particular time when this study was done, which was 
just before and during the implementation of the public-sector roll-out of ART, when 
people with HIV infection may have been feeling generally more optimistic about their 
disease status. However, the period was too soon after the roll-out for the effects of ART 
on mental disorders to have manifested themselves.  
 
5.5 Conclusions 
Despite these limitations, while the estimates are more conservative than those of other 
similar studies in South Africa, the results of this study confirm previous research that 
depressive and anxiety disorders are common in HIV-infected individuals in South Africa. 
This study also shows that current mental disorders, in general, are common in individuals 
attending HIV-treatment sites. The high background prevalence of these disorders in the 
general population, the methodology of the study and the small sample size made it 
impossible to demonstrate a statistically significant difference between HIV-infected 
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individuals and non-HIV-infected individuals in similar populations. There is a need for 
this kind of study to be conducted on a larger scale, with matched HIV-seronegative 
controls. However, the results suggest that more attention needs to be paid to these 
disorders, particularly in the light of literature demonstrating the impact of mental 
disorders, especially depression and anxiety, on disease progression and adherence to 
antiretroviral medication.  
 
Other mental disorders found in this study, besides depressive and anxiety disorders, also 
constitute a significant burden. In particular, mental disorders resulting from general 
medical illness and substance abuse are common. These need appropriate treatment 
(sometimes including antiretroviral treatment). Substance use disorders in themselves are 
also common, and are a significant factor to consider in the treatment of HIV disease, as 
they also impact on disease progression and adherence and may result in untoward side-
effects and drug-substance interactions.  
 
Risk factors that were identified for the development of depressive disorders are: a lifetime 
history of a depressive disorder, particularly after diagnosis of HIV infection is made, 
increased levels of psychosocial stress and feelings of isolation in the individual. Being or 
having been in a support group was protective against the development of a current 
depressive disorder.  
 
Regarding mental disorders in general, being in clinical stages 3 or 4, a lifetime history of 
depressive or substance use disorder and experiencing feelings of discrimination increased 
the risk of having a current mental disorder.  Finding one’s faith helpful in terms of coping 
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with the diagnosis and disclosing one’s status were found to be significant protective 
factors against having a current mental disorder.  
 
 Recommendations 
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CHAPTER 6 
 
RECOMMENDATIONS 
 
6.1 Introduction 
The research conducted in this project shows the extent of depressive and anxiety disorders 
as well as other mental disorders in HIV-infected individuals attending treatment sites in 
Gauteng and a rural area in Mpumalanga. The results show that there are significant mental 
health problems that need attention in this population. They also show that a number of 
factors could either increase or decrease the risk of individuals with HIV infection 
developing co-morbid mental disorders. The burden of mental disease and the likely 
contributors to such disease have implications for health services in South Africa. 
 
The aim of this research was primarily to study depressive and anxiety disorders. Other 
disorders that were found in the research to be significant problems were substance use 
disorder and organic mental disorders. These too have implications for health services.  
 
6.2 Implications 
As outlined in Chapter 2, depressive and anxiety disorders cause considerable suffering, 
increase the risk of suicidal behaviour and may impact on HIV disease progression and 
adherence to antiretroviral treatment. As a result, there are considerable implications 
associated with the high levels of these disorders in this population (one in five participants 
in this study). It is important to increase awareness of these conditions in health workers 
and service users, and to develop ways of identifying and managing these disorders as 
early as possible.  
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Substance abuse is a common and serious problem in South Africa. The findings of this 
research indicate that the occurrence of substance use disorders decreased in the study 
participants (lifetime rates compared to current rates), suggesting that knowing their HIV 
status may have made participants more aware of the need to reduce intake of alcohol and 
recreational drugs. Whether this outcome was simply a result of this awareness, due to 
unpleasant drug-substance interactions, or a result of psycho-education and support to 
individuals who attend these HIV-treatment sites, is unclear. Caution should be exercised 
in generalising these findings to other sites, and this area should be explored further.  
 
While considerable organic mental disorder was found in this study, it is important to 
remember the context of the study; that it covered November 2004 to November 2005. 
During this period the public-sector antiretroviral roll-out was implemented. Many of the 
participants who were not on antiretroviral treatment at the time of interview will have 
begun antiretroviral treatment since then. This is likely to have had an impact on the 
occurrence of organic mental disorders in this population. There is concern, however, in 
mental health services (Phakathi, 2007) about the difficulty in accessing ART for people 
who present with neuropsychiatric conditions resulting from HIV CNS infection, 
particularly since this treatment has been shown to be effective in treating these conditions. 
 
6.3 Recommendations 
1. Findings from this research should be disseminated to public sector health service 
managers, mental healthcare professionals, HIV-physicians, other health workers, 
HIV-infected individuals and their families. 
Providing information to health services and to those affected by the HIV epidemic, on the 
relationships between HIV infection and mental disorders, in particular depression and 
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anxiety, would be an important first step in developing responses to the problems 
highlighted in this study. Both health workers and individuals accessing services could act 
on this information. This might result in further learning and development of locally 
appropriate interventions. It has been shown, particularly in the field of HIV, that self-help 
or consumer-driven initiatives can be successful (Treatment Action Campaign, 2007; 
Stephen Lewis Foundation, 2007). Some mental health not-for-profit organisations are also 
well-positioned to provide support (The South African Depression and Anxiety Group, 
2007). 
 
2. Management of mental disorders, including depressive and anxiety disorders, in 
HIV-infected individuals should be improved: health systems issues. 
It has been suggested that the best way of providing comprehensive care for people with 
HIV-infection is for HIV-treatment sites to provide mental healthcare together with the 
physical healthcare needed for the condition (Green, et al., 2004; The Nucleus Consulting 
Group, 2005). This should include management of substance use disorders. An example of 
such a service in Denver, Colorado is described by Kobayashi and Standridge (2000) in 
their chapter on comprehensive HIV care, in Cournos and Forstein’s book: “What Mental 
Health Practitioners Need to Know about HIV and AIDS”. They argue that members of an 
HIV-treatment team should include HIV-physicians, psychiatrists, HIV- and mental health-
trained nursing staff, pharmacists, lay counselors, social workers, psychologists and 
specialists in other areas of physical care. In such a setting, there would be cross-
pollination of knowledge and skills. Support for staff should also be provided, considering 
the nature of the work involved in caring for people with serious conditions and the 
considerable psychosocial ramifications. 
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While the above model may work in well-resourced settings, it is a pipe-dream for the 
countries most affected by the HIV/AIDS epidemic. These countries have very poor 
healthcare resources and mental healthcare, in particular, is generally very limited (WHO, 
2001). South Africa is a middle-income country, with wide disparities between rich and 
poor. The majority of people with HIV infection are poor and their only access to 
healthcare (including mental healthcare) is through public sector health services and not-
for-profit healthcare organisations.  
 
At present HIV-treatment and ART roll-out sites are somewhat “specialised” but the aim is 
to make this service accessible throughout the primary healthcare system. Mental health 
services are also largely “specialised” but South African mental health policy is to 
integrate these services to make them accessible throughout the primary healthcare system 
and to deliver mental health services in the community/ district health service as far as 
possible. 
 
The issue of mental healthcare for people with HIV infection highlights the existing 
difficulties in implementing mental health policy in South Africa. Mental health service 
provision is inadequate and inequitably distributed across the country (Lund & Flisher, 
2006). While many people make use of traditional healers for both physical and mental 
healthcare, and this could be considered an additional resource, the roles and functions of 
such practitioners are not clearly defined. It is unlikely that the traditional healthcare 
system would ever be able to fill the gap in mental health service provision. Mental health 
professionals currently working in the public sector would argue that they do not have the 
capacity to expand into HIV-treatment services. On the other hand it can be argued that, 
since the prevalence of HIV infection is so high and many infected people will come for 
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treatment, this is an opportunity for more people to access mental health services and for 
these services to be integrated into general health services (Thom, 2007). 
 
The question remains as to how comprehensive HIV care (including mental healthcare) can 
best be provided in developing countries such as South Africa. Freeman, Patel and Collins 
(2005) addressed this issue in their article “Integrating mental health in global initiatives 
for HIV/AIDS”. They described the World Health Organisation’s initiative to integrate 
mental healthcare into HIV care through its “3 by 5” programme. While this initiative was 
not wholly successful, various training materials developed in this process could be used in 
South Africa. These include clinical training materials as well as suggestions for 
organisational restructuring. 
 
Freeman et al.’s primary recommendation was based on the fact there are insufficient 
trained mental health service providers in developing countries to offer additional mental 
health services in HIV/AIDS treatment programmes. Therefore, primary care providers 
(including lay counsellors) in HIV treatment settings should be trained to provide as much 
primary mental healthcare as possible. They did caution, however, against overloading 
these front-line workers. The need to support primary care workers once they have been 
trained and to provide easily accessible referral sources was also highlighted.  
 
The disparities in resources and organisation between South African provinces need to be 
recognised in developing models of HIV care that include mental healthcare. In provinces 
with poor mental health resources (such as Mpumalanga) it is likely that the best approach 
to delivering comprehensive HIV care would be through strengthening the knowledge and 
skills of primary care practitioners. Existing training material could be used to achieve this. 
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As emphasised above, experience with training of primary care practitioners has shown 
that it is very difficult to implement training without adequate support and supervision. 
Mpumalanga currently has one psychiatrist employed in the public sector, who is based at 
Witbank Hospital. The community mental health service is provided by primary healthcare 
nurses, trained mental health nurses and generalist doctors who do outreach from general 
hospitals. It is important that mental health professionals in these settings also be trained in 
the field of HIV psychiatry. Increased support and encouragement should, moreover, be 
given for primary care doctors to obtain the Diploma in Mental Health. In addition, 
provinces with very poor resources could consider the use of telemedicine, regular in-
service training, collaboration with NGOs and visiting experts to support primary care 
practitioners in their work.  
 
Provinces with more resources may be able to adapt existing systems of mental healthcare 
and physical healthcare resulting in restructuring along the lines suggested in the South 
African mental health policy. For example; Gauteng is fortunate to have a secondary level 
community mental health service in the district health service but it is currently 
inappropriately utilised. A small number of highly trained mental health professionals 
spend most of their time managing people with chronic serious mental illness in the 
community, many of whom are stable most of the time and could be managed at primary 
care level. As a result of this and other obstacles, development of a comprehensive mental 
health service has not occurred.  
 
A recent development in the district health service in Gauteng which could make a 
significant difference in improving primary healthcare services is the decision to establish 
Family Medicine as a discipline in the district health service (Gauteng Provincial 
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Government, Department of health, 2007). It is likely that this will improve the quality of 
care provided in the district health service, by improvements in staffing levels, increased 
training and ensuring that standards of care are adequate in training sites that are to be 
accredited by professional councils. 
 
The family medicine approach is well-suited to deliver comprehensive health services, 
including primary mental healthcare. Through training of family medicine practitioners, 
much of the service load currently inappropriately carried by the secondary level service 
could be devolved to primary care services. This would free the specialist professionals in 
the secondary level service to do what they are supposed to do: to be a referral resource for 
primary care practitioners, provide training and supervision to primary care practitioners 
and continue to develop comprehensive mental health services in the community.  
 
Family medicine practitioners are likely to be managing the ART programme in the district 
health service. They need to be convinced of the importance of identifying and treating 
mental disorders in HIV-infected individuals whom they treat. This research and further 
local research can be used to do this. Training of these practitioners in management of 
mental disorders in conjunction with HAART is important. Mental health professionals 
and family medicine practitioners should work together to ensure that mental healthcare 
services are accessible through this programme, and eventually throughout the primary 
healthcare service.  
 
At secondary and tertiary hospitals physicians and mental healthcare professionals need to 
come together to determine how best to ensure that both HIV-treatment and mental 
healthcare treatment are available to all at these levels of care. Again, this is likely to 
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involve training of HIV-practitioners in mental healthcare as well as training of mental 
healthcare practitioners in HIV-care. Good communication and good working relationships 
are probably more important in the successful provision of these services than merely 
having both services at the same site.  
 
Even without additional staffing and/or training in HIV mental healthcare, an essential 
organisational strategy is to expand psychosocial services at HIV-treatment sites across all 
levels of care. The current services at these sites, in particular support groups, have been 
shown to be helpful. Most of these services are provided by non-professionals (lay 
counsellors) with limited knowledge of healthcare, particularly, mental healthcare. It is 
necessary to increase awareness of mental health issues in these individuals and to assist 
them in identifying individuals who may be at risk of depressive or anxiety disorders. 
However, providing these counsellors with support, supervision and easily accessible 
referral resources is then also necessary.  
 
Besides lay counsellors, mental healthcare professionals such as social workers and 
psychologists can play a crucial role in the provision of psychosocial support. A good 
network of social services is critical, as this study has shown the extent of social 
disadvantage in individuals at public sector HIV-treatment sites. Both social workers and 
psychologists can play an important role in training and supervising lay counsellors and 
being the primary referral resource for these counsellors (Clacherty & Kistner, no date). 
 
One key issue in HIV care is the provision of psycho-social support to ensure adherence. 
Here it is even more important to identify those individuals who are at risk of depressive or 
anxiety disorders, since there is strong evidence that these disorders impact on adherence. 
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Numerous organisations have already developed programmes to assist in this aspect of 
adherence work (Saloner, 2005). This needs to be expanded to become a routine part of 
management at ART treatment sites. 
 
Much funding is being channelled into AIDS care and a strong argument can be made in 
favour of using some of this on mental healthcare in HIV-treatment settings. Even if this 
were to be done on a short-term basis and attempting to attract mental health professionals 
currently working outside the public sector, it would be an effective way of providing 
training in the mental healthcare aspects of managing HIV disease to staff who are 
primarily involved in the physical care of such patients.  
 
In order to improve mental healthcare to people living with HIV/AIDS, all involved in 
their care need to improve their awareness, knowledge and skills. Mental health 
professionals also need to improve their knowledge of HIV psychiatry. Currently the 
Department of Psychiatry at the University of Toronto is involved in a grant-funded project 
to determine the learning needs of African psychiatrists in HIV psychiatry (Maggi and 
Halman, 2006). The South African Society of Psychiatrists has an HIV psychiatry special 
interest group, which can facilitate the improvement in mental healthcare for people living 
with HIV/AIDS in South Africa through the dissemination of research findings, advocacy, 
the development of management guidelines and input into training (South African Society 
of Psychiatrists, 2006).  
 
3. HIV practitioners should be assisted to identify depressive and anxiety disorders.  
A range of screening instruments are available that can be used by HIV practitioners to 
identify patients with possible depressive and anxiety disorders. These include the SRQ 
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(Cherian, Peltzer and Peltzer, 1998), the CES-D (Cheng, Chan & Fung, 2006) and the 
Modified MINI Screen(Sheehan, Lecrubier & Hairnet-Sheehan, 1998). Some have been 
used in South African research studies and validated as satisfactory screening tools for 
these disorders in our population (Brandt, Dawes & Bray, 2006). Further work may need to 
be done to ensure that these are the most appropriate tools to use in our country (Parry, 
1996). Enquiry on past psychiatric history is not included in most of these instruments and 
should be included in any screening for mental disorder. The immediate period after 
diagnosis of HIV status should be considered a period of elevated risk of developing a 
depressive or anxiety disorder, but those in the later stages of HIV disease are also likely to 
be at risk.  
4. The treatment of HIV-infected individuals with depressive and anxiety 
disorders should be improved. 
Treatment for depressive disorders in HIV-infected individuals 
Because patients on HAART take large amounts of medication, clinicians are often 
reluctant to add yet another medication to treat a depressive disorder, especially those with 
the potential to interact with HAART medications. However, there is strong evidence that 
depressive disorders in HIV-infected individuals can be effectively treated, with both 
pharmacological and psychotherapeutic interventions (Olatunji, Mimiaga & O’Cleirigh, 
2006). The SSRI’s are the treatment of choice as first-line agents; in particular, citalopram, 
which has a different metabolic pathway from the antiretrovirals’, and does not have active 
metabolites. Mirtazepine, Buproprion and Venlafaxine have also been found to be effective 
with minimal side-effects (Stolar, et al., 2005), but these medications are not readily 
available in the public sector. Fluoxetine, with its long half-life, active metabolites, and 
metabolism by the cytochrome p450 system, may accumulate and result in a serotonin 
syndrome (De Silva, Le Flore & Marston, 2001). Amitryptaline is commonly used in South 
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Africa as a treatment for painful peripheral neuropathy in doses of 25 mg nocte but this 
may be insufficient to treat severe depressive disorders. Tricyclic antidepressants are 
effective agents (Markowitz, Kocsis & Fishman, 1998), and Amitryptaline is readily 
available and inexpensive in South Africa, but should be used with caution, owing to the 
high risk of drug-drug interactions resulting in toxicity. Nortryptaline and desipramine are 
preferred tricyclic drugs because of their low anti-cholinergic burden and lack of active 
metabolites (Kaplan & Sadock, 1998:524-580). Methylphenidate and testosterone have 
also been used in the treatment of depressive disorders in HIV, particularly when there are 
severe difficulties with energy levels and hypogonadism (Wagner, Rabkin & Rabkin, 
1996; Martin, et al., 2002). Research on newer pharmacological treatments is ongoing, 
both in depression per se, and in depression in HIV-infected individuals (Ho & Douglas, 
2004).  
 
There is good evidence that psychotherapy interventions are effective in treating depressive 
disorders, particularly those of mild to moderate severity. Interpersonal psychotherapy and 
cognitive behavioural therapy have both been found to be effective in randomised 
controlled trials (Kelly, et al., 1993b; Markowitz, Klerman & Clougherty, 1995). 
 
Treatment of anxiety disorders in HIV-infected individuals 
The management of anxiety disorders in HIV-infected individuals should follow the 
principles of management in the general population and in other medically ill populations 
(Martin, et al., 2002:139). A primary focus should be exploration of psychosocial stressors 
and psychotherapeutic interventions. Medication should be considered secondarily if these 
interventions are insufficient or ineffective, or if the disorder is severe and acute, causing 
significant distress or impairment. Benzodiazepines and other tranquillising medication 
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should be used for short periods only to assist the individual over the crisis period, and 
with due regard for drug-drug interactions with anti-retroviral medication and for the 
presence of comorbid substance use disorders, which are common. Should the need for 
longer term medication arise, the treatment of choice is SSRIs. These have been shown to 
be effective and safe for the treatment of chronic anxiety disorders in HIV-infected 
individuals. 
 
From this study it is suggested that the use of support groups should be encouraged, and 
while the study was not able to show statistically significant effects of counselling, the 
study does confirm that participants find these interventions useful in coping. Identifying 
individuals who feel isolated, and encouraging those with strong religious faith to use it as 
a coping mechanism can also be important interventions. 
 
5. Interventions that can assist HIV-infected individuals to reduce substance use 
disorders should be developed.  
As stated before, this study did not clearly identify the cause of the reduction in substance 
use disorder from lifetime to current levels. This requires further exploration. It is clear 
from the literature that substance use disorders may share common neurobiological 
pathways with HIV CNS infection (Hauser, El-Hage & Stiene-Martin, 2007), that they 
may accelerate disease progression (Kapadia, Vlahov & Donahoe, 2005), and that they 
impact on adherence (Tucker, et al., 2003). Screening for substance use disorders is critical 
in HIV-infected individuals. The two most commonly used screening tools for alcohol 
abuse, the CAGE and the AUDIT, have both been used in South African studies (Danson 
& Peden, 1999, Betancourt & Herrera, 2006). Motivational interviewing is a skill that can 
be learnt by primary care workers, and probably by lay counsellors as well (Beckham, 
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2007). Counselling to reduce substance abuse is a critical component of adherence 
counselling and support (Saloner, 2005). Individuals with co-morbid substance use 
disorders, mental disorders, and HIV infection (particularly those on HAART) may require 
specialised care, and should be referred to mental health services if interventions at the 
HIV-treatment site are insufficient to manage the patient.  
 
6. Appropriate treatment guidelines for the management of organic mental 
disorders related to HIV infection should be developed and widely distributed 
within health services, to HIV practitioners and mental health practitioners. 
This study, using the International HIV Dementia Scale, revealed that almost 19% of the 
participants screened positive for possible HIV-associated dementia. International evidence 
shows that antiretroviral medication is effective in preventing further progression of HIV 
associated dementia and, possibly, even in reversing some of the damage due to HIV CNS 
infection (Sacktor, Nakasujja & Skolasky, 2006). In developed countries, treatment with 
ART is now initiated at higher CD4 counts than the current South African or World Health 
Organisation recommendations suggest, and HIV-associated dementia is seen less 
commonly as a presenting clinical feature of HIV disease (Halman, 2007; personal 
communication). As South Africa reviews the outcomes of anti-retroviral treatment, it is 
possible that local ART treatment guidelines may also change.  
 
The national treatment policy for HIV infection is to initiate Highly Active Antiretroviral 
Treatment at a CD4 count of </= 200 cells/mm3 or in the presence of an AIDS-defining 
condition. HIV-associated dementia is such a condition, and HAART should be initiated in 
patients with HIV-associated dementia, irrespective of CD4 count (National Department of 
Health, 2004:2). As discussed in Chapter 5 (Section 5.2.3), in 2007 the National 
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Department of Health reviewed treatment practices in relation to HIV-associated dementia 
and requested the Mental Health and Substance Abuse Directorate to develop treatment 
guidelines with an estimation of the likely numbers of people who require treatment and 
the costs involved. A draft document with suggested assessment tools and treatment 
guidelines was developed (National Department of Health, 2007). It remains for this draft 
document to be finalised and implemented as a national guideline with the appropriate 
monitoring, evaluation and revision as necessary.  
 
Among the major impediments to initiating antiretroviral treatment in individuals with 
cognitive impairment is their capacity to consent to treatment and to adhere to it. While 
these issues may raise ethical and logistic dilemmas, these are not sufficient to deprive  
individuals with cognitive impairment related to HIV infection, the right to treatment for 
their condition. Legislation (South Africa, 2003) and guidelines are in place that can 
inform clinicians in terms of managing these patients.  
 
An essential aspect of treating HIV-infected individuals with cognitive impairment is the 
provision of support to ensure adequate adherence. This may involve ensuring that each 
such patient has a “buddy” to monitor their treatment or even, in some cases providing 
residential care during the period of initiation of therapy until the individual has recovered 
sufficiently to manage their own medication. An interesting model in this regard evolved 
from AIDS hospice care in Toronto (Casey House Hospice, 2007), where this hospice now 
provides care to HIV-infected individuals with neuropsychiatric complications (and often 
comorbid mood and substance use disorders). Patients who need this kind of assistance are 
admitted to the hospice and provided with both antiretroviral and psychiatric treatment. 
Usually, after 6 months the individuals are able to be discharged back to their homes and 
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they are followed up in the community by HIV-trained nurses. It is possible that this kind 
of model could be adapted in South Africa, using existing resources and expanding them as 
they are demonstrated to be successful.  
 
6.4 Suggestions for further research 
1. Ongoing epidemiological studies of mental disorders in the community and in 
primary care settings are needed.  
The lack of accurate information on the burden of mental disorders in South Africa makes 
it very difficult to plan services. There is likely to be always a shortage of mental 
healthcare resources. Therefore, basing prioritisation of service needs and services on 
accurate information is critical. This will also help to focus resources and reduce fruitless 
expenditure which can ill be afforded.  
 
2. Community-based studies of mental disorder in HIV-infected individuals should 
be conducted. 
Very little information is available on the burden of mental disorder in HIV-infected 
individuals in community settings in South Africa. These would include people who are 
not accessing treatment, and in this setting the extent of mental disorder may well differ 
from that in treatment sites. While the 2005 HIV Household Survey (Shisana, et al., 2005) 
by the HSRC included some screening questions for mental disorder and found significant 
levels of symptoms, a need exists for more comprehensive assessment of the number of 
people requiring intervention. Controlled prevalence studies with HIV-seronegative 
controls are needed to compare, more accurately, the prevalence in those who are infected 
with HIV with the prevalence of mental disorders in general. 
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3. Follow-up and intervention studies are needed to assess the impact of identifying 
and treating mental disorders related to HIV infection. 
In order to best utilise scarce resources, local interventions studies are needed to identify 
cost-effective and time-limited interventions that can make a difference to people’s lives 
and to the extent of distress, morbidity and mortality that results from untreated depression 
and anxiety. 
4. Prospective cohort studies of HIV-infected individuals are needed to identify more 
clearly, risk and protective factors for mental disorders in this group.  
While multivariate analysis of various factors in this study, did identify possible risk and 
mitigating factors, a cross-sectional study design is not the best method for identifying 
such factors, while prospective cohort studies and qualitative exploratory studies could add 
to our understanding of which factors are significant. 
5. Prospective cohort studies are needed to assess the impact of HAART on mental 
disorders in HIV-infected individuals.  
Most individuals who were on HAART in this study had recently commenced treatment. 
International studies show that, while there is substantial improvement in mental health 
status generally in individuals who take HAART, HIV-infected individuals continue to 
suffer a high burden of mental disorder. It is important to document the situation in South 
Africa and to suggest the type of ongoing interventions that may help to support such 
individuals.  
6. The impact of knowledge of HIV-status, psychosocial interventions in HIV-
positive individuals and HAART on substance use behaviour should be explored. 
Since substance use disorders play a significant role in risky behaviour, disease 
progression and adherence, this is an important area to explore. Intervention models are in 
place, but need to be evaluated for effectiveness. 
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7. Health systems research to develop appropriate models of comprehensive service 
delivery to HIV-infected individuals is needed.  
Research from developed countries suggests that integrated services provide the best 
model for comprehensive service delivery to HIV-infected individuals. It is also suggested 
that access to mental healthcare through general healthcare services is the most effective 
model in general. It was on the basis of this premise that the WHO mental health 
programme and the “3 by 5” programme developed mental health training packages to be 
included in training packages for health workers treating people with HIV infection 
(Freeman, et al., 2005). These training packages need to be used and evaluated in terms of 
their effectiveness in achieving comprehensive care. Any attempts to develop or change 
models of mental health service delivery to HIV-infected individuals should be evaluated, 
so that the best recommendations for such service delivery can be made.  
8. Research is needed into factors that increase resilience and coping in HIV-infected 
individuals. 
While much of the emphasis of this and other research is on risk factors for mental 
disorders in HIV-infected individuals, little work has been done on identifying protective 
factors, particularly in South Africa. From that which has been done, it is suggested that 
this is a very important area on which focus is needed, particularly in relation to the 
efficient utilisation of scarce resources. 
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Appendix 1:  
Postulated risk or mitigating factors: odds ratios and tests of statistical significance of the possible influencing variables for current 
mental disorder and current depressive disorder 
** statistically significant effect (p<0.05) 
* marginally statistically significant effect (p<0.10) 
 Current mental disorder  Current depressive disorder 
Variable Odds ratio 95% Confidence 
interval 
P value Odds ratio 95% confidence interval P value 
Site   0.3543   0.9727 
PHRU 0.579 0.272 to 1.231 0.1553 1.282 0.475 to 3.458 0.6236 
Tintswalo Hospital 0.905 0.342 to 2.391 0.8398 0.898 0.230 to 3.508 0.8765 
Nthabiseng HIV clinic CHB Hospital 0.905 0.399 to 2.050 0.8102 1.167 0.388 to 3.506 0.7837 
Nthabiseng ARV clinic CHB Hospital 0.521 0.221 to 1.228 0.1360 1.167 0.388 to 3.506 0.7837 
Weiler’s Farm 1.00   1.00   
Gender   0.2787   0.7605 
Male  0.749 0.444 to 1.264 0.2787 0.901 0.459 to 1.766 0.7605 
Female 1.00   1.00   
Age   0.9520   0.1491 
Mean age CMD Yes CDD Yes 1.001 0.973 to 1.029 0.9520 0.973 0.938 to 1.010 0.1500 
Mean age CMD No CDD No 1.00   1.00   
Age group   0.6959   0.4961 
18 to 24 0.618 0.188 to 2.030 0.4276 1.869 0.533 to 6.555 0.3288 
25 to 39 1.012 0.598 to 1.713 0.9645 1.419 0.709 to 2.842 0.3231 
40 + 1.00      
Relationship status   0.4705   0.9413 
Single 0.833 0.507 to 1.368 0.4705 0.977 0.526 to 1.816 0.9413 
In a relationship 1.00   1.00   
Level of Education   0.3857   0.1222 
No/some primary education 0.972 0.465 to 2.030 0.3118 0.717 0.280 to 1.832 0.4865 
Completed primary education 1.410 0.490 to 4.051 0.6474 2.352 0.733 to 7.543 0.1504 
Some secondary education 1.532 0.740 to 3.173 0.2448 1.283 0.526 to 3.130 0.5845 
Completed secondary education 1.00   1.00   
Employment   0.7523   0.1187 
Unemployed 0.774 0.350 to 1.710 0.5263 0.458 0.187 to 1.121 0.0873* 
Part-time employment 0.909 0.366 to 2.260 0.8375 0.795 0.289 to 2.188 0.6572 
Full-time employment 1.00      
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Household situation   0.8216   0.5501 
Not enough for basics  1.040 0.466 to 2.319 0.9245 0.613 0.241 to 1.558 0.3038 
Basics only 1.202 0.549 to 2.630 0.6456 0.794 0.326 to 1.937 0.6125 
Most of important things 1.00      
Clinical stage    0.0514**   0.6210 
Stage 1 1.00   1.00   
Stage 2 1.303 0.713 to 2.382 0.3896 1.147 0.546 to 2.408 0.7170 
Stage 3 2.074 1.088 to 3.955** 0.0268** 1.619 0.743 to 3.528 0.2251 
Stage 4 3.110 1.065 to 9.082** 0.0379** 0.848 0.176 to 4.091 0.8375 
CD4 count   0.9672   0.1636 
Mean CD4 Yes 1.000 0.999 to 1.001 0.9671 1.001 1.000 to 1.002 0.1668 
Mean CD4 No 1.00   1.00   
CD4 range    0.7165   0.3231 
>500 cells/ml 1.204 0.533 to 2.722 0.6552 2.071 0.823 to 5.210 0.1219 
350-499 cells/ml 1.101 0.459 to 2.643 0.8292 1.709 0.620 to 4.711 0.3005 
201-349 cells/ml 0.708 0.366 to 1.370 0.3054 0.949 0.413 to 2.184 0.9025 
<200 cells/ml 1.00   1.00   
Presence of a medical condition   0.0171**   0.7601 
Yes 1.815 1.109 to 2.970 0.0177** 1.100 0.597 to 2.028 0.7602 
No 1.00   1.00   
Time since diagnosis   0.1329   0.3727 
<4 months 0.993 0.454 to 2.171 0.9862 0.466 0.158 to 1.373 0.1658 
4 months to 1 year 0.573 0.296 to 1.110 0.0986* 0.574 0.258 to 1.276 0.1730 
1 to 3 years 0.531 0.277 to 1.019 0.0571* 0.606 0.280 to 1.311 0.2033 
> 3 years 1.00   1.00   
Duration of attendance  
(in months) 
  0.7720   0.4399 
Mean CMD Yes CDD Yes 1.003 0.984 to 1.021 0.7713 1.008 0.987 TO 1.030 0.4401 
Mean CMD No CDD No 1.00   1.00   
ART   0.7211   0.2108 
On ART 1.110 0.627 to 1.965 0.7211 1.536 0.782 to 3.015 0.2127 
Not on ART 1.00   1.00   
Impact of ART on coping   0.1220   P=0.1375 
Pretest counselling   0.4449   0.6166 
Yes 0.806 0.463 to 1.402 0.4454 1.207 0.584 to 2.496 0.6120 
No       
Appendix 1: Postulated risk or mitigating factors for current mental disorder and current depressive disorder 
 166 
Effect of pretest counselling   0.2303   0.3575 
Not helpful 1.533 0.572 to 4.110 0.3961 1.495 0.462 to 4.837 0.5018 
Marginally helpful 2.021 0.834 to 4.899 0.1192 2.453 0.925 to 6.503 0.0712* 
Helpful 1.00   1.00   
Posttest counselling   0.2150   0.6795 
Yes 0.730 0.444 to 1.201 0.2157 0.877 0.472 to 1.633 0.6796 
No    1.00   
Both pre- and post-test counselling   0.2504   0.9078 
Yes 0.691 0.368 to 1.300 0.2504 1.050 0.460 to 2.397 0.9078 
No 1.00   1.00   
Post-test counselling number of sessions   0.8244   0.6693 
Once 0.611 0.163 to 2.289 0.4649 0.526 0.124 to 2.231 0.3834 
2 to 3 0.789 0.210 to 2.964 0.7258 0.466 0.107 to 2.032 0.3092 
4 to 10 0.625 0.126 to 3.087 0.5641 0.314 0.043 to 2.265 0.2504 
> 10 1.00   1.00   
Effect of post-test counselling   0.4914   0.4238 
Not helpful 1.619 0.371 to 7.065 0.5217 1.971 0.375 to 10.368 0.4231 
Marginally helpful 1.660 0.644 to 4.283 0.2944 1.848 0.617 to 5.535 0.2727 
Helpful 1.00   1.00   
Support group   0.5119   0.1540 
Yes 0.846 0.514 to 1.394 0.5121 0.628 0.329 to 1.196 0.1565 
No 1.00   1.00   
Effect of support group   0.4729 Cant do  0.3738 
Not helpful 1.127 0.272 to 4.678 0.8692 <0.001 <0.001 to >999.999 0.9732 
Marginally helpful 1.973 0.626 to 6.214 0.2459 1.000 0.202 to 4.955 1.000 
Helpful 1.00      
Still in support group   0.5189   0.6497 
Yes  0.774 0.355 to 1.688 0.5189 1.284 0.436 to 3.786 0.6503 
No 1.00      
Duration of attendance at support group   0.6236   0.6158 
< 6 months 0.752 0.317 to 1.785 0.5188 0.458 0.142 to 1.483 0.1926 
7 to12 months 0.566 0.170 to 1.881 0.3527 0.699 0.161 to 3.035 0.6329 
> 12 months 1.00      
Number of times attended support group   0.8188   0.3581 
Once 1.055 0.444 to 2.508 0.9039 0.495 0.144 to 1.703 0.2644 
2 to 10 0.743 0.253 to 2.186 0.5896 0.409 0.083 to 2.020 0.2724 
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>10 1.00      
Disclosure   0.1744*   0.6648 
Yes 0.593 0.278 to 1.268 0.1799 0.811 0.314 to 2.093 0.6652 
No 1.00      
Open re status   0.4227   0.7907 
Yes 0.749 0.369 to 1.521 0.4239 0.889 0.373 to 2.119 0.7908 
No 1.00      
Belonging to activist organisation   0.2719   0.6537 
Yes 0.495 0.138 to 1.778 0.2808 0.709 0.156 to 3.219 0.6556 
No 1.00      
Discrimination   0.4449   0.1006 
Yes 1.241 0.713 to 2.159 0.4454 1.723 0.895 to 3.316 0.1032 
No 1.00      
Impact of discrimination   0.0773*   0.2779 
Made coping very difficult 3.500 0.791 to 15.495 0.0989* 3.542 0.674 to 18.623 0.1354 
Affected coping a lot 2.167 0.628 to 7.474 0.2210 1.971 0.454 to 8.551 0.3648 
Affected coping a little 0.300 0.030 to 2.966 0.3031 0.567 0.052 to 6.211 0.6422 
Has not affected ability to cope 1.00      
Feelings of isolation   0.2746   0.0192** 
Closer to others 1.108 0.653 to 1.881 0.7038 1.400 0.699 to 2.804 0.3430 
Isolated 1.828 0.865 to 3.863 0.1140 3.289** 1.390 to 7.781 0.0067** 
No change 1.00      
Religious belief   0.0302**   0.3220 
Not religious 2.193 1.123 to 4.281** 0.0215** 0.936 0.380 to 2.303 0.8853 
Just a little religious 1.739 0.875 to 3.459 0.1145 0.959 0.389 to 2.363 0.9280 
Somewhat religious 2.388 1.096 to 5.201** 0.0285** 2.145* 0.896 to 5.135 0.0867* 
Very religious 1.00      
Effect of faith on coping   0.0469**   0.7048 
Not helpful 2.406 1.278 to 4.531** 0.0065** 0.996 0.431 to 2.303 0.9924 
Marginally helpful 2.197 1.026 to 4.702** 0.0426** 1.465 0.588 to 3.648 0.4125 
Helpful 1.00      
AIDS deaths   0.6945   0.2355 
Yes 0.907 0.556 to 1.479 0.6945 1.444 0.785 to 2.655 0.2370 
No 1.00      
Effect of AIDS deaths   0.1953*   0.1004 
Severe impact 0.707 0.210 to 2.375 0.5750 0.152 0.018 to 1.269 0.0819* 
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Moderate impact 0.246 0.063 to 0.951** 0.0421** 0.361 0.092 to 1.420 0.1449 
Mild impact 0.622 0.272 to 1.425 0.2618 0.438 0.169 to 1.132 0.0883* 
No impact 1.00      
Number of AIDS deaths 1.094 0.833 to 1.438 0.5196 1.321 0.958 to 1.820 0.0870* 
Losses in past year   0.8769   0.5611 
Yes 1.047 0.588 to 1.865 0.8764 1.230 0.612 to 2.472 0.5615 
No 1.00      
Impact of losses   0.9986   0.5856 
Severe impact 0.918 0.181 to 4.655 0.9181 0.704 0.064 to 7.743 0.7740 
Moderate impact 1.071 0.264 to 4.341 0.9230 1.583 0.274 to 9.166 0.6080 
Mild impact 1.000 0.281 to 3.556 1.0000 2.375 0.511 to 11.047 0.2701 
No impact 1.00      
No of losses in past year 0.895 0.570 to 1.406 0.6315 1.086  0.638 to 1.849 0.7601 
Total number of bereavements 1.044 0.837 to 1.301 0.7048 1.235 0.952 to 1.602 0.1109 
Levels of psychosocial stress   0.0157**   0.0004** 
Severe additional stress 3.909 1.518 to 10.069** 0.0047** 7.809** 2.569 to 23.733 0.0003** 
Moderate additional stress 2.259 0.825 to 6.188 0.1130 5.124** 1.580 to 16.620 0.0065** 
Mild additional stress 2.235 1.205 to 4.148** 0.0108** 2.191 0.911 to 5.272 0.0800* 
No additional stress 1.00      
Lifetime mental disorder   <0.0001**   0.0005** 
Yes 11.587 6.470 to 20.752** <0.0001** 2.937** 1.570 to 5.495 0.0008** 
No 1.0   1.0   
Lifetime mental disorder pre-HIV diagnosis   <0.0001**   <0.0001** 
Mental disorder onset post-HIV diagnosis 14.603** 6.348 to 33.594** <0.0001** 7.180** 3.171 to 16.261** <0.0001** 
Mental disorder onset pre-HIV diagnosis 10.582** 5.665 to 19.767** <0.0001** 1.801 0.866 to 3.746 0.2598 
No mental disorder 1.0   1.0   
Lifetime depressive disorder   0.0289**   <0.0001** 
Yes 2.014 1.066 to 3.804** 0.0309** 4.903** 2.452 to 9.806 <0.0001** 
No 1.00   1.00   
Lifetime depressive disorder pre-HIV diagnosis      <.0001** 
Depressive disorder onset post-HIV diagnosis    6.166** 2.615 to 14.538** <.0001** 
Depressive disorder onset pre-HIV diagnosis    3.357** 1.269 to 8.879** 0.0147** 
No mental disorder       
Substance use disorder – current n/a n/a N/a    0.7011 
Yes    1.222 0.438 to 3.411 0.7015 
No    1.00   
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Substance use disorder – lifetime   <0.0001**   0.8238 
Yes 4.558 2.492 to 8.338** <0.0001** 1.090 0.509 to 2.336 0.8238 
No       
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Appendix 2: International HIV Dementia Scale 
 
Memory-Registration – Give four words to recall (dog, hat, bean, red) (in Luganda, 
kopo,engatto,doodo,myufo)– 1 second to say each. Then ask the patient all four words 
after you  have said  them. Repeat words if the patient does not recall them all 
immediately. Tell the patient you will ask for recall of the words again a bit later. 
 
1.  Motor Speed: Have the patient tap the first two fingers of the non-dominant hand as 
widely and as quickly as possible. 
 4 = ³ 15 in 5 seconds 
 3 = 11-14 in 5 seconds 
 2 = 7-10 in 5 seconds 
 1 = 3-6 in 5 seconds 
 0 = 0-2 in 5 seconds 
 
2.  Psychomotor Speed: Have the patient perform the following movements with the non-
dominant hand as quickly as possible: 
 1) Clench hand in fist on flat surface. 2) Put hand flat on surface with palm down. 3) Put 
hand perpendicular to flat surface on the side of the 5th digit. Demonstrate and have patient 
perform twice for practice.  
 4 = 4 sequences in 10 seconds 
 3 = 3 sequences in 10 seconds 
 2 = 2 sequences in 10 seconds 
 1 = 1 sequence in 10 seconds 
 0 = unable to perform 
 
3.  Memory-Recall: Ask the patient to recall the four words. For words not recalled, 
prompt with a semantic clue as follows:  
animal (dog); piece of clothing (hat); vegetable (bean); color (red). 
 Give 1 point for each word spontaneously recalled. 
 Give 0.5 points for each correct answer after prompting 
 Maximum – 4 points. 
 
Total International HIV Dementia Scale Score 
This is the sum of the scores on items 1-3. The maximum possible score is 12 points.  A 
patient with a score of <10 should 
 be evaluated further for possible dementia. 
 
(Sacktor et al.  Neurology 2003 60;1:A186-187) 
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